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4E-BP eIF4E - binding protein 
4-SU 4-thiouridine 
AdV Adenovirus 
ARNm Ácido ribonucleico mensajero 
ASF  African Swine Fever  
ASFV African Swine Fever Virus 
Ba71V Badajoz 71 ASFV strain addapted to grown on Vero cells 
cCL Conventional Crosslinking 
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CI Chloroform : isoamil alochol solution  
CLSM Confocal Laser Screening Microscopy 
CLSM Confocal Laser Scanner Microscopy 
CMV Cytomegalovirus 
D.S standard deviation 
Dcp1 Decapping enzyme 1 
Dcp2 Decapping enzyme 2 
DcpS Scavenger decapping enzyme 
Dhh1/DDX6 DEAD box Helicase Homolog 
DMEM Dulbecco´s Modified Eagle´s Medium 
DNA  Deoxyribonucleic Acid 
dsRNA double-stranded RNA 
DTT Dithiothreitol 
E glutamic acid 
E70  African Swine Fever virus España 70 strain 
E75 African Swine Fever Virus España 75 strain  
EBV Epstein-Barr virus  
Edc1 Enhancer of decapping protein 1  
Edc2 Enhancer of decapping protein 2 
Edc3 Enhancer of decapping protein 3 
Edc4 Enhancer of decapping protein 4 
EDTA Ethylenediaminetetraacetic acid 
eIF4A Eukaryotic translation initiation Factor 4A 
eIF4E Eukaryotic translation initiation factor 4E 
eIF4F Eukaryotic translation initiation factor 4F 
eIF4G Eukaryotic translation initiation factor 4G 
eIFs Eukaryotic translation initiation factors 
ELISA Enzime-linked ImunoSorbent Assay 
EMCV encephalomyocarditis virus 
EMSA Electrophoretic mobility shift assay 
ERS Enzyme Restriction Site 
F farads, electrical capacitance unit 
FACS Fluorescence-Activated Cell Sorting 
FBS Fetal Bovine Serum 
FRT Flp Recombination site 
FW forward sequence 
G glicine 
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g.o.i gene of interest 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GFP Green Fluorescente Protein 
HA Human influenza hemagglutinin 
HCV hepatitis C virus  
hpi hours post infection 
HSV-1 herpes simplex virus  
IgG Immunoglobulin G 
IRES internal ribosome entry site 
J joules, energy unit 
KDa Kilodalton 
KSHV Kaposi´s sarcoma-associated herpesvirus  
Lsm1-7 SM-like proteins 1-7 
M.O.I Multiplicity of infection 
m7GDP 7-methyl guanosine diphosphate 
m7GMP 7-methyl guanosine monophosphate 
m7GpppG cap analog 
Malawi LIL/21 African Swine Fever Virus Malawi strain 
MFI mean fluorescence intensity 
Mg2+ magnesium 
Mn2+ manganese 
mRNA messenger RNA 
mTOR mammalian Target of Rapamycin 
MW molecular weight 
NCLDV Nucleocytoplasmic Large DNA Viruses 
nm nanometers 
nsp1 nonstructural protein 1 
nt nucleotides 
Nudix domain Nucleoside diphosphate linked moiety X domain 
O/N Overnight 
ORF Open Reading Frame 
P0 / P1 / P2 Eukaryotic acidic ribosomal P proteins 
PABP Poly (A) Binding Proteins 
PABPC1 cytoplasmic Poly (A) Binding Protein 
PAR-CL Photoactivatable-ribonucleoside-enhanced Crosslinking 
Pat1 Protein Associated with Topoisomerase II  
PA-X Viral RNA-dependent RNA polymerase complex-X 
P-Bodies Processing Bodies 
PBS Phosphate Buffered Saline Solution 
PCI Phenol : chloroform : isoamil alochol solution  
PCR Polimerase Chain reaction 
pfu plate former unit 
PKR double stranded RNA-activated kinase  
PMSF phenylmethylsulfonyl fluoride 
PP1 protein phosphatase 1  
PPIA peptidylprolyl isomerase A 
Q glutamines 
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qPCR quantitative PCR 
R arginine 
RBP7 RNA-polymerase II subunit 7 
RIG-1 retinoic acid-inducible gene 1 
RNA Ribonucleic Acid 
RPL0 Ribosomal Protein LO 
rpm revolutions per minute 
RV reverse sequence 
S.E.M standard error mean 
SARS-CoV severe acute respiratory syndrome coronavirus  
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SG Stress Granules 
siRNA small interfering RNA 
TAE Tris Acetic EDTA solution 
TBS Tris Buffered Solution 
tet teracycline 
U  enzymatic Units 
U.V Ultraviolet Light 
UTR Untranslated region 
V volts 
VACV vaccinia virus 
vhs virion host shutoff protein 
VSV vesicular stomatitis virus  
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Xrn1 eXoRiboNuclease 
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El Virus de la Peste Porcina Africana (VPPA) es un virus ADN de gran tamaño que infecta distintas 
especies de suidos, y cuyas cepas virulentas causan una enfermedad altamente patógena y letal, que cursa 
con hemorragias generalizadas y para la cual no existe vacuna. La Peste Porcina Africana es endémica en 
África y Cerdeña, pero desde el 2007, un nuevo brote en la región del Cáucaso se ha extendido por Rusia, 
poniendo en peligro la cabaña porcina europea. El VPPA, único miembro de la familia Asfaviridae, es un virus 
icosaédrico con envuelta formado por varias capas concéntricas. En el interior se encuentra el nucleoide, 
que contiene el material genético del virus, una molécula de ADN de doble cadena que codifica para más de 
150 secuencias codificantes. La infección del VPPA se caracteriza por una progresiva disminución de la 
síntesis de proteínas celulares a la vez que se produce la síntesis de las proteínas virales. El mecanismo por el 
cual el virus logra éste fenómeno es aún desconocido, y ha sido el objeto de estudio de la presente Tesis 
Doctoral.  
Durante la infección por VPPA, hemos observado que se produce una degradación masiva de los 
ARN mensajeros celulares en el citoplasma de las células infectadas, lo que sugiere que la inhibición de las 
proteínas celulares es debida a la activa degradación de dichos mensajeros. A este respecto, el genoma del 
VPPA codifica para una proteína, g5Rp (pD250R en Ba71V), que posee un dominio Núdix hidrolasa y 
actividad decapping in vitro. En esta Tesis, hemos demostrado que g5Rp es capaz de interaccionar con el 
ARN poliadenilado en células que expresan establemente la proteína. Ésta interacción está mediada 
principalmente por el dominio N-terminal de g5Rp, y los amino ácidos conservados del dominio Núdix no 
son necesarios para dicha interacción. Ésta proteína viral también interacciona con los ARN mensajeros 
virales y celulares en el contexto de la infección, y la sobreexpresión de la misma en células infectadas 
provoca una disminución de ambas especies de mensajeros, así como de los niveles de ciertas proteínas 
virales tardías. g5R es un gen temprano e importante para la adecuada progresión de la infección. A tiempos 
tempranos de la infección, g5Rp presenta una localización subcelular típica de retículo endoplasmático y es 
capaz de interaccionar con los ribosomas y con PABPC, mientras que a tiempos tardíos, la proteína se 
acumula alrededor de la factoría viral, donde co-localiza con la estructura cap de los ARN mensajeros y con 
Dcp1, e interacciona tanto con los ribosomas como con las proteínas virales pp220, p10 y p72. Además, la 
infección por VPPA provoca la dispersión de los cuerpos citoplasmáticos o P-Bodies, así como la 
redistribución de los factores de iniciación de la traducción y los ribosomas a los sitios de replicación viral, 
donde también se localizan los ARN mensajeros virales tardíos. 
En conclusión, nuestro estudio indica que g5Rp es un factor viral implicado en la degradación del 
ARN celular y en la regulación temporal de la expresión génica del virus. Sin embargo, el VPPA utiliza más de 
un mecanismo para lograr la inhibición de la síntesis de proteínas celulares a la vez que lleva a cabo la 
síntesis de sus proteínas, como la relocalización de los factores de iniciación de la traducción o de los 
ribosomas a la factoría viral. 
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African Swine Fever Virus (ASFV) is a large DNA virus that infects different species of pig. ASFV 
virulent strains cause a highly infectious and deadly disease that produces generalized bleeding and for 
which there is no vaccine. African swine fever is endemic in Africa and Sardinia, but since 2007, a new 
outbreak in the Caucasus region has spread to Russia, jeopardizing the European pig population. ASFV, the 
only member of the Asfaviridae family, is an enveloped icosahedral virus formed by several concentric 
layers. The viral genetic material is a double-stranded DNA molecule located inside the nucleoid, which 
contain more than 150 coding sequences. ASFV infection is characterized by a progressive decrease in the 
cellular protein synthesis, concomitantly with an increase in the viral protein synthesis. The mechanism by 
which the virus achieves this phenomenon is still unknown, and has been the object of study of this Thesis. 
During ASFV infection, we observed that a massive degradation of cellular mRNA in the cytoplasm of 
infected cells occurs; suggesting that inhibition of cellular proteins is due to active degradation of mRNA. In 
this regard, ASFV genome encodes a protein, g5Rp (pD250R in Ba71V), which has a Nudix hydrolase domain 
and decapping activity in vitro. In this Thesis, we have shown that g5Rp is capable of interacting with poly(A) 
RNA in cells stably expressing the protein. We have determined that this interaction is mediated primarily by 
the g5Rp N-terminal domain, and that conserved amino acids of the Nudix domain are not required for this 
interaction. This viral protein also interacts with viral and cellular RNA in the context of infection, and its 
overexpression in infected cells results in decreased levels of both species of transcripts and of late viral 
protein levels. g5R is an early gene, which also play an important role in the proper progression of the 
infection. At early stages of infection, g5Rp presents subcellular localization typical of the endoplasmic 
reticulum and is able to interact with ribosomes and PABPC, while at later times, the protein accumulates 
around the viral factories, where it co-localizes with the mRNA cap structure and Dcp1, and interacts with 
ribosomes and with pp220, p10 and p72 viral proteins. Furthermore, ASFV infection causes scattering of the 
P-Bodies and a redistribution of translation initiation factors and ribosomes to the viral replication sites, 
where late viral mRNAs are also located. 
In conclusion, our study indicates that g5R protein is a factor involved in the cellular RNA 
degradation and in the temporal regulation of viral gene expression. Interestingly, ASFV uses more than one 
mechanism for the inhibition of cellular protein synthesis, as relocation of translation initiation factors and 
the ribosomes to the viral factories. 
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African Swine Fever Virus (ASFV) is a large, cytoplasmic, double-stranded DNA virus that infects 
different species of swine, including domestic pigs and wild suids (Costard et al., 2013; Vinuela, 1985). In 
wild suids, African Swine Fever (ASF) pathogenesis is usually subclinical (Montogomery, 1921), although in 
some cases the disease can be lethal. Warthogs are asymptomatic carriers of the disease and are considered 
the most important ASFV vertebrate reservoir in Africa (Costard et al., 2013; Kleiboeker and Scoles, 2001). In 
domestic pigs, ASF is characterized by an increase of vascular permeability, thrombocytopenia, petechial 
bleeding and haemorrhagic lesions, which normally lead the animal to death. However, clinical signs of ASF 
can vary depending on the virulence of the viral strain, being possible to distinguish among different forms 
of the disease: hyperacute, acute, subacute, chronic and subchronic (Blome et al., 2013). 
ASFV is the only member of the Asfaviridae family (Dixon et al., 2004; Dixon et al., 2012) and the 
single virus able to replicate in arthropods (ticks of the Ornithodoros genus), which act as biological vectors 
(Burrage, 2013; Kleiboeker and Scoles, 2001). In vertebrates, ASFV replicates in cells of the mononuclear 
phagocyte system, mainly monocytes and macrophages, although other cellular types can be infected, 
especially later during the infection. In fact, the activation of the secretory activity in macrophages by ASFV 
replication plays a key role on ASFV infection, being a modulating element of the pathogenesis (Carrasco et 
al., 1996a; Carrasco et al., 1996b; Gomez-Villamandos et al., 2013; Vinuela, 1985). The mechanism used by 
ASFV to entry in host cells has been a considerably discussed topic. Preliminary studies described it as a 
temperature, energy, cholesterol and low-pH dependent process, which requires receptor-mediate 
endocytosis (Alcami et al., 1989a; Alcami et al., 1989b; Carrascosa et al., 1999; Geraldes and Valdeira, 1985; 
Valdeira et al., 1998). Other studies described that ASFV entry requires dynamin and is a clathrin-dependent 
process (Galindo et al., 2015; Hernaez and Alonso, 2010). This subject has been widely studied on our 
laboratory. Combining pharmacological inhibitors, specific dominant-negative constructions and confocal 
and electron microscopy assays, we have demonstrated that ASFV entry in Vero and IPAM cells is 
predominantly taking place by micropinocytosis, in a process that requires sodium/proton exchangers 
(Na+/H+), activation of the epidermal growth factor receptor (EGFR) and the phosphatidylinositol-3-kinases 
(PI3K), phosphorylation of the Serine/threonine-protein kinase (Pak1) together with the activation of Rho-
GTPase Rac 1; and that relies on actin-dependent blebbing/ruffling formation (Sanchez et al., 2012). 
Traditionally, ASFV is widespread in Africa and in Sardinia, where it is endemic. However, in June 
2007, an outbreak in the Caucasus region of Georgia was confirmed (Rowlands et al., 2008). The virus rapidly 
spread to other neighbourhood regions of East Europe, as Russia, where it has not been controlled, to date. 
As there is no vaccine or treatment that effectively protect against ASFV infection, this outbreak supposes a 
real hazard for the world pig population. In this regard, several studies have been directed to decipher the 
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possible protection mechanism against ASFV infection (Escribano et al., 2013; King et al., 2011; Mulumba-
Mfumu et al., 2015; Wardley et al., 1985). First attempts used inactivated viral particles and irradiated 
lysates of infected cells, but they were unsuccessful (Escribano et al., 2013). Other studies have focused on 
studying the role of both cellular and humoral immune responses to generate a protective response to ASFV 
infection. Infection of pigs with the ASFV non-virulent strain OUR/T88/3 confers protection against challenge 
with the homologous virulent strain OUR/T88/1. However, infected pigs with OUR/T88/3 and then depleted 
of CD8+T leucocytes are no longer fully protect to the challenge, indicating that cellular immune response is 
essential to an effective protection against ASFV (Oura et al., 2005). On the other hand, the humoral 
immune response is also important and it has been deeply studied (Escribano et al., 2013). Passive transfer 
experiments in swine demonstrated that 85% of pigs inoculated with serum obtained from convalescent pigs 
previously immunized with the E75CV1-4 E75 strain (Spanish strain E75 adopt to grow in CV1 culture cells) 
were protected against ASFV isolate E75 infection (Onisk et al., 1994). Moreover, serum from pigs 
immunized with viral proteins p72, p30 and p54 neutralizes ASFV infection in vitro, although it does not 
protect against virulent strains infection in vivo (Gomez-Puertas et al., 1998; Gomez-Puertas et al., 1996). 
Further approaches have been directed to the use of DNA vaccines to enhance the immune response against 
ASFV in infected pigs. However, only a partial protection has been achieved using this technique, thus far 
(Argilaguet et al., 2011). 
 
ASFV virions are icosahedral structures of approximately 200 nm, which are constituted by different 
concentric layers: the internal core, the core shell, the inner membrane, the capsid and, in the extracellular 
virions, the external envelope (Andres et al., 1997; Breese and DeBoer, 1966; Carrascosa et al., 1984) (Figure 
1).  
 
 
Figure 1. Structure of the extracellular ASFV virion.  
Electron microscopy image of the extracellular ASFV particle. ASFV virion is composed by different concentric layers: the external envelope (red), the 
viral capsid (green), the inner envelope (yellow), the core shell (blue) and the nucleoid (purple). Examples of proteins present in each layer are shown 
in brackets (reviewed on (Salas and Andres, 2013)) 
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The internal core is formed by the nucleoid, and contains the viral genome and certain 
nucleoproteins such as the DNA-binding protein p10 (Andres et al., 2002b; Munoz et al., 1993). This layer is 
also supposed to encompass all the elements required to the synthesis of the early messenger RNAs 
(mRNAs): the transcriptional machinery, the poly(A) polymerase and the capping enzyme(Salas and Andres, 
2013). The core shell is a thick protein layer which surrounds the core and is mainly composed by the 
polyproteins pp220 and pp62. Both polyproteins are successively processed by a viral protease (S273R gene) 
and, together, they constitute 32 % of the total mass of the virion (Andres et al., 2002a; Andres et al., 2002b; 
Andres et al., 1997). The inner envelope is adjacent to the core shell and looks like a single lipid membrane 
by conventional electron microscopy (Salas and Andres, 2013). This membrane is derived from the 
endoplasmic reticulum (ER) (Andres et al., 1998) and viral proteins p54, p17 and p12 are constituents of this 
structure (Rodriguez et al., 2004; Salas and Andres, 2013; Suarez et al., 2010). The capsid is the outermost 
layer of the intracellular virions, and is composed by approximately 2000 hexagonal capsomers. p72 protein 
is the major module of the capsomers and constitutes one third of the total mass of the virion (Carrascosa et 
al., 1984; Garcia-Escudero et al., 1998). The external membrane or outer envelope of the extracellular viral 
particles is similar to the cellular plasma membrane, and is acquired during the budding process used by 
ASFV to exit from the cell (Breese and DeBoer, 1966; Carrascosa et al., 1984). This structure contains the 
viral protein p12, which has been identified as the viral factor needed for the attachment to the host cell 
(Carrascosa et al., 1991). Other protein suggested to be in the outer membrane is the virus homologue of 
cellular CD2 protein (CD2v), which mediates the hemadsorption of infected cells (Borca et al., 1994; 
Rodriguez et al., 1993).  
ASFV morphogenesis takes place in specialized areas of the cytoplasm, called viral factories, which 
are located near to the nucleus and the microtubule organization centre (MTOC). These structures 
essentially exclude host proteins, but are surrounded by ER membranes and enclosed in vimentin cages 
(Heath et al., 2001). In addition to ER membranes, mitochondria are also recruited to the periphery of viral 
factories (Rojo et al., 1998). 
 
1.1.3.1 ASFV replication 
ASFV genome is a linear double-stranded DNA molecule with variable length (from 170 to 193 kbp) 
among different viral strains (Dixon et al., 2013; Yanez et al., 1995). This variability is due to the gain and loss 
of Open Reading Frames (ORFs) in the multigene families and to the deviation of short tandem repeats in 
genes and intergenic regions (Dixon et al., 1990; Lubisi et al., 2007). ASFV genes are closely distributed, 
codified in both DNA strands and they do not present introns. Genome termini are hairpin-loops covalently 
cross-linked, being present in two possible forms inverted and complementary to each other (Dixon et al., 
2013). 
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ASFV replication predominantly takes place in the cytoplasm of infected cell, in the viral factories, 
and requires viral enzymes expressed immediately after virus entry. Due to this fact, and because of genome 
similarities, ASFV has been included in the nucleocytoplasmic large DNA viruses (NCLDV) superfamily (Dixon 
et al., 2013). However, an initial nuclear replication phase has also been described at early times post 
infection (Rojo et al., 1999). The exact function of this nuclear stage is not clear, but it has been described 
that nuclear organization is damaged as a consequence of ASFV infection, which includes nucleoli and 
nuclear envelope disorganization (Ballester et al., 2011). Both nucleoporin p62, a marker of the nuclear 
envelope; and B-23, a marker of the nucleolus, are found in the cytoplasm of ASFV infected cells at late 
times post infection, suggesting an important damage in nuclear functions.  
ASFV codifies for between 150 and 170 ORFs that express proteins with multiple functions: 
structural proteins, enzymes, transcription and replication factors, and proteins involved in modulation of 
ASFV-host cell interaction (Dixon et al., 2013). In this regard, ASFV encodes for several proteins that interfere 
with host defences, such as A179L, a viral homologous of the anti-apoptotic proteins of the Bcl-2 family 
(Revilla et al., 1997); EP153R, a homologous of the C-type lectin proteins (Hurtado et al., 2004), or A224L, a 
homologous of the IAP family of apoptosis inhibitors (Nogal et al., 2001). The viral protein A238L, a 
homologous of the IkB family that suppresses transcriptional activation of immunomodulatory genes, is 
especially important. Our laboratory has described that during ASFV infection, A238L protein reaches the 
nucleus and interacts with the transcriptional co-activator p300, preventing its phosphorylation by PKC-Ɵ. 
p300 phosphorylation is essential for the activation of the transcriptional factors NFAT, NFkB and c-jun. 
Using this mechanism, A238L inhibits the expression of the inflammatory regulator cyclooxygenase-2 (COX-
2), the tumour necrosis factor alpha (TNF-alpha) and the inducible nitric-oxide synthase (iNOS) (Granja et al., 
2006a; Granja et al., 2004; Granja et al., 2008; Granja et al., 2006b; Granja et al., 2009; Sanchez et al., 2013).  
1.1.3.2 ASFV transcription 
ASFV mRNAs are structurally similar to their cellular counterparts. In vitro transcribed viral mRNAs 
display no internal methylation, and possess a cap structure in its 5´UTR and a poly(A) tail of 33 nucleotides 
(nt) in average in its 3 ´UTR (Salas et al., 1981). The cap structure is predominantly the type m7G (5´) pppAm, 
which suggests that an enzymatic activity for RNA capping is required to occur. In this regard, ASFV encodes 
a guanylyltransferase (NP868R) able to exert triphosphatase and guanylyltransferase activities (Pena et al., 
1993; Yanez et al., 1995). In addition to the capping enzyme, ASFV genome codifies for a gene (C475L) that 
shares moderate similarity with the poly(A) polymerase of other NCLDV (Dixon et al., 2013; Rodriguez and 
Salas, 2013; Yutin et al., 2009), suggesting that the virus also possesses its own viral poly(A) polymerase. 
ASFV exhibits a notable independence from its host to carry out the transcriptional process. The 
virus uses approximately 20 % of its genome to encode 20 genes considered to be related to translation and 
mRNA modification (Rodriguez and Salas, 2013). Indeed, ASFV virion contains a DNA-dependent RNA 
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polymerase (Kuznar et al., 1980). In the presence of inhibitors of the cellular Pol II, the viral replication still 
takes place, indicating that all viral transcripts are transcribed by this viral polymerase (Salas et al., 1988). In 
addition to the RNA polymerase, ASFV genome also codifies for genes similar to the TFIIB and TFIIS RNA 
polymerase II transcription factors, and for genes analogous to early, intermediate and late poxvirus 
transcription factors. Due to the fact that ASFV genome encodes for its own complete transcription system, 
the virus is able to accurately control the expression of its genes, which occurs in a time-dependent manner. 
Genes expressed before the onset of viral DNA replication have been designated as prereplicative genes, 
while genes that are expressed after viral replication are referred as postreplicative genes (Rodriguez and 
Salas, 2013).  
Prereplicative genes have been described by their expression in ASFV-infected cells in the presence 
of DNA replication and/or protein synthesis inhibitors (Salas et al., 1986). Two classes of transcripts are 
expressed in the prereplicative stage of the infection, which exhibit different kinetics of accumulation at 
different times post infection in the presence of these inhibitors (Almazan et al., 1992). Early transcripts are 
easily detected by primer extension and nuclease S1 assays in the presence of both inhibitors, while 
immediately early transcripts accumulate in the presence of protein synthesis inhibitors, but are hardly 
detected when DNA replication inhibitors are present (Almazan et al., 1992). Both transcripts are expressed 
immediately after of virus entry: in the case of immediately early transcripts, expression is repressed before 
the onset of viral replication (4 - 5 hours post infection, hpi), while early transcripts expression is maintained 
until the initiation of viral replication, and rapidly decreases thereafter (8 - 10 hpi). Interestingly, a small 
amount of immediately early and early mRNAs are observed at late times post infection, due to a 
reactivation of its expression that takes place late during the infection (20 hpi). This phenomenon has been 
also observed in vaccinia infection (Masternak and Wittek, 1996) and it has been attributed to the presence 
of all the components of the transcription machinery and the DNA template during the viral morphogenesis 
(Rodriguez and Salas, 2013). The multigene family 110, which comprises a set of paralogous genes that are 
present in multiple copies at the left end of the genome, is expressed immediately after the virus entry 
(Almendral et al., 1990). For that reason, this family has been selected for the study of ASFV early 
transcription (Almazan et al., 1992). Transcriptional mapping of the multigene family 110 by primer 
extension show that early mRNAs possess a defined length. These mRNAs present a short sequence of 
nucleotides (8-70 nt) upstream of the translation initiation site, and terminate at one or more sites 
downstream of the termination codon. A conserved sequence motif of seven or more thymidylate residues 
(7T signal) is located at the 3 ´UTR region of these mRNAs, which has been described as the translational 
termination signal (Almazan et al., 1992). The majority of immediate early and early genes belong to the 
multigene families, which are believed to be involved in the control of host responses to the infection 
(Afonso et al., 2004) and in the viral DNA replication (Rodriguez and Salas, 2013). 
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Transcription of postreplicative genes takes place after viral replication and is dependent on this 
process: no postreplicative mRNAs are detectable in ASFV infected cells in the presence of inhibitors of the 
DNA replication (Almazan et al., 1993; Rodriguez et al., 1996). Two classes of transcripts are expressed on 
the postreplicative stage of the infection: the intermediate and the late mRNAs. Intermediate genes are 
differentiated of late genes because the first required transcription factors that are expressed before viral 
replication, thus they can be expressed ectopically in ASFV-infected cells in the presence of inhibitors of the 
DNA replication, and the exogenous mRNA can be detected by primer extension (Rodriguez et al., 1996). 
Expression of the intermediate genes directs the expression of the late genes. Both transcripts also present 
different kinetics of accumulation: intermediate mRNAs are expressed immediately after viral replication 
and are rapidly degraded before the accumulation of late transcripts, while the late mRNAs are expressed 
after the intermediate, accumulate approximately at 12 hpi and are slowly degraded thereafter (Rodriguez 
et al., 1996). In contrast to poxvirus, which possesses heterogeneous late transcripts with imprecise 
termination sites and a poly(A) leader sequence on its 5´UTR region (Yang et al., 2012), ASFV intermediate 
and late mRNAs retain an exact length (they initiate and terminate at fixed sites) and do not present poly(A) 
sequence at the 5´UTR. Indeed, their structure is similar to early transcripts, and they also present the T7 
termination signal at the 3 ´UTR sequence. In fact, the T7 motif is considered to be the termination signal for 
all the viral temporal transcripts, because a strong correlation between the presence of these motif and the 
transcript termination site in all the mapped ASFV transcripts has been observed (Garcia et al., 1995; 
Rodriguez and Salas, 2013). 
Despite these differences, the mechanism used by ASFV to temporally express its genes has been 
proposed to be similar to the cascade mechanism displayed by poxvirus (Broyles, 2003) : transcription 
factors necessary for the expression of the intermediate genes are codified by the early genes; transcription 
factors necessary for the expression of late genes are codified by the intermediate genes, and the 
transcriptional factors necessary for early gene expression are expressed at late times post infection and 
packaged into the viral particles (Rodriguez and Salas, 2013) (Figure 2). 
Few experimental analyses have been performed regarding ASFV promoter sequences. Alignment of 
the 50 nt sequence upstream of the initiation codon of mapped prereplicative genes shows that these 
regions are rich in A-T residues, but they do not present similarity of sequence (Rodriguez and Salas, 2013). 
Alignment of the upstream sequences from the initiation codon of both intermediate genes I226R and I243L 
revealed that these sequences are highly conserved at positions -25 to -15 and -9 to +9 (Rodriguez et al., 
1996). Regarding late cis-acting sequences, only the one that regulates the B646L gene (which encodes for 
the capsid protein, p72) has been characterized in detail (Garcia-Escudero and Vinuela, 2000). This promoter 
sequence covers 41 nt upstream of the ORF and presents two conserved regions: the first is located between 
the position -18 and -14 (TATTT), and the second is closer to the transcription start point, and it is located at 
position -4 to +2 (TATATA). Only the latter is moderately conserved among other intermediate and late 
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genes (Rodriguez and Salas, 2013). Mutational analysis of the TATATA region in the p72 promoter revealed 
that the -1 position is essential for the activity of the promoter, while changes in +1 and +2 positions 
considerably reduced its activity, but are not essential. Activity of other late promoters elements is also 
reduced when the TATA sequence is mutated, suggesting that this region can be a late promoter motif 
(Garcia-Escudero and Vinuela, 2000). 
 
Figure 2. Schematic representation of the transcriptional cascade mechanism proposed to ASFV.  
ASFV exerts a tight control of viral genes transcription. After viral entry and until the onset of the viral replication, immediate early and early genes 
are expressed, while after viral replication intermediate and late genes synthesis takes place. The mechanism used by ASFV to achieve this goal 
involves sequential expression of the different viral transcription factors: immediate and early transcription require transcriptional factors expressed 
at late times post infection and packaged into the viral particles, intermediate transcription needs the expression of the transcriptional factors 
encoded in early genes, and late transcription require transcription factors encoded in intermediate genes. AraC is an inhibitor of viral replication. 
 
As commented on the previous section, ASFV mRNAs are structurally similar to the cellular mRNAs, 
and the fact that ASFV mRNAs are capped suggests that they are translated by a canonical cap-dependent 
mechanism, as it happens with most of cellular mRNAs. 
The initiation of translation consists in the recruitment of the ribosome to the mRNA and it is one of 
most regulated steps in gene expression. The eukaryotic translation initiation factors (eIFs) play a central 
role in this process and are usually targets for fine viral regulation. The phosphorylation of eIF2 represents 
one of the most important steps in the regulation of the cellular translation since it allows rapid and 
reversible modulation of translation initiation. The phosphorylation of the α subunit inhibits eIF2 activity and 
is performed by several cellular protein kinases (Donnelly et al., 2013; Proud, 2005; Wek et al., 2006), and 
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among them, the double stranded RNA-activated kinase (PKR), the PKR-like endoplasmic reticulum (ER) 
kinase (PERK) and general control non-derepressible-2 (GCN2) play a major role in response to viral 
infections (Barber et al., 1993; Berlanga et al., 2006; Cheng et al., 2005; Garcia et al., 2007). 
Similarly to vaccinia virus (VACV) infection, during ASFV infection P-eIF2α levels decrease at early 
times post infection, and remain undetectable throughout the infection (Castello et al., 2009b). ASFV 
genome encodes a protein (DP71L) which possesses a characteristic binding protein phosphatase 1 motif 
(VxF) (Cohen, 2002) and that is able to interact with protein phosphatase 1 (PP1) in vitro and in vivo. In vitro, 
recombinant 6xHis-PP1 protein directly interacts with the recombinant protein GST-Dp71L, as demonstrated 
by pulldown assays (Rivera et al., 2007). In vivo, co-immunoprecipitation assays in cells transduced with a 
lentiviral vector expressing DP71L-V5 protein demonstrate that this viral protein can be detected in complex 
with the three forms of PP1. This result was further confirmed by yeast two-hybrid interaction assays (Zhang 
et al., 2010). Individual expression of DP71L induces a decrease of phosphorylated eIF2α and enhances the 
expression of co-transfected reporter genes. In these experiments, an increase in Beta-galactosidase (β-Gal) 
activity can be observed in cells transduced with the lentiviral vector expressing DP171L and cotransfected 
with the β-Gal reporter plasmid (Zhang et al., 2010). These results suggest that DP71L plays a role keeping 
the translation machinery active to allow viral protein synthesis. A schematic representation of this process 
is shown in Figure 3 A. However, the depletion of DP71L in the viral strains Malawi Lil 20/1 and E70 does not 
lead to an increase in the levels of P-eIF2α, suggesting that as VACV, ASFV possesses alternative mechanisms 
to avoid eIF2α phosphorylation (Zhang et al., 2010).  
The other key viral regulation point involves the recruitment of ribosomes and the eukaryotic 
translation initiation factor 4F (eIF4F) formation. eIF4F, as key component of the cap-dependent translation 
machinery, is accurately regulated in response to extracellular stimuli, stress and viral infections. eIF4F is a 
complex composed by three proteins: eukaryotic translation initiation factor 4A (eIF4A), eukaryotic 
translation initiation factor 4E (eIF4E) and eukaryotic translation initiation factor 4G (eIF4G) (Prevot et al., 
2003). eIF4A is a RNA helicase implicated in unwinding the secondary structure of the 5´end of the mRNA 
together with eIF4B; eIF4E binds the cap structure at the mRNA 5´terminus, and eIF4G is a scaffolding 
protein that forms a molecular bridge between the mRNA and the small ribosomal subunit 40 S. eIF4G 
coordinates the initiation of translation via protein-protein interactions: the N-terminus domain is involved 
in the recruitment of the mRNA by its interaction with the cap-binding factor eIF4E and the cytoplasmic 
Poly(A) Binding Protein (PABPC); and at the same time, the C-terminal domain recruits the small ribosomal 
subunit by its interaction with eIF3 (Jackson et al., 2010) (Figure 3 B). 
eIF4G has been reported to be a substrate for caspase-3 (Bushell et al., 1999; Prevot et al., 2003), 
being its proteolytic cleavage a potential cause of the shutoff during apoptosis (Marissen and Lloyd, 1998). 
At late times post infection, ASFV induces apoptotic response (Ramiro-Ibanez et al., 1996) and, 
consequently, caspase-3 activation (Granja et al., 2004). However, eIF4G is not affected by caspase-3 
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cleavage in ASFV-infected cells (Castello et al., 2009b) indicating some possibilities: that the cleavage sites 
are not accessible to the protease (perhaps protected by protein-protein interactions); that eIF4G is not at 
the same location than caspase-3; or that caspase-3 activity is abrogated. Regarding the last possibility, ASFV 
encodes for an inhibitor of the apoptosis (IAP)-like protein (A224L), which has been reported to be an 
inhibitor of caspase 3 (Nogal et al., 2001). The possibility that this factor protects translation machinery from 
caspase 3-mediated degradation has been not further studied, to date. On the other hand, ASVF induces 
mammalian target of rapamycin (mTOR)-mediated phosphorylation of eIF4G at Ser1108 (Castello et al., 
2009b), which has been associated to “translational activation” (Kimball et al., 2000; Raught et al., 2000), 
and in parallel, ASFV triggers the phosphorylation of eIF4E at Ser209 by Mnk-1 (Figure 3 B). Although the 
biological relevance of the eIF4E phosphorylation is controversial (Morley and Naegele, 2002), its 
importance for some viral infections has been demonstrated. In the case of influenza virus, vesicular 
stomatitis virus (VSV) and adenovirus (AdV), the dephosphorylation of eIF4E correlates with the inhibition of 
the cellular protein synthesis (Connor and Lyles, 2002; Cuesta et al., 2004; Feigenblum and Schneider, 1993). 
Whereas, for hepatitis C virus (HCV) or murine norovirus 1 eIF4E phosphorylation is important for virus 
translation and for the progression of the infection, respectively (Panda et al., 2014; Royall et al., 2015). 
During ASFV infection, eIF4E phosphorylation is related to an enhancement of the viral replication and 
protein synthesis (Castello et al., 2009b). eIF4E phosphorylation takes place after 8 hours post ASFV infection 
and reaches its maximum levels at 14 - 18 hpi. This phosphorylation in infected cells is avoided in the 
presence of the Mnk-1 inhibitor CGP57380, and correlates with the phosphorylation of this kinase, 
suggesting that it relies in Mnk1 activation, as reported before (Pyronnet, 2000; Pyronnet et al., 1999) 
(Figure 3 B). 
The eIF4E-binding proteins (4E-BPs) are well-known negative regulators of the cap-dependent 
translation (Sonenberg and Hinnebusch, 2009). In its hypo-phosphorylated state, 4E-BPs are able to 
associate with eIF4E and compete with eIF4G, impairing eIF4F assembly. On the other hand, 4E-BPs are 
inactivated by mTOR-mediated hyperphosphorylation, allowing cap-dependent translation (Bhandari et al., 
2001; Richter and Sonenberg, 2005). Similarly to VACV and other DNA viruses (Buchkovich et al., 2008), we 
have described that ASFV infection promotes 4E-BP1 phosphorylation at early times post infection, but in 
this case it is progressively hypo-phosphorylated at later times (from 14 hpi). eIF4G, eIF4E and 4E-BP1 
phosphorylations are concomitant with an increase of eIF4F assembly (Castello et al., 2009b). The hypo-
phosphorylation observed at late times post infection may be due to a viral mechanism to stop the viral 
protein synthesis when late morphogenesis stage is taking place (Figure 3B). 
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Figure 3. Regulation of translation in ASFV infection.  
A) ASFV infection prevents eIF2α phosphorylation. During ASFV infection, viral protein DP71L is able to interact with PP1 and promotes its activation, 
which leads to the dephosphorylation of eIF2α and allows cap-dependent translation. B) ASFV infection stimulates eIF4F assembly. During ASFV 
infection, eIF4E and eIF4G are phosphorylated by mTOR and Mnk1, respectively, which promote their interaction and the formation of eIF4F. 
Additionally, at early times post infection 4E-BP is hyper-phosphorylated, which inhibits 4E-BP and eIF4E interaction. At late times post infection, 4E-
BP is hypo-phosphorylated, which leads to its interaction with eIF4E and to an inhibition of the translation. The phenomenon observed at late times 
post infection may be due to a viral mechanism to stop the viral protein synthesis when late morphogenesis stage is going on. 
 
Nevertheless, phosphorylation of eIF4G, eIF4E and 4E-BP1 is important but not essential to the ASFV 
infection in cultured Vero cells, since the presence of inhibitors of Mnk-1 (CGP57380) and mTOR (rapamycin) 
affects moderately the viral protein synthesis and virus production. However, the activities of eIF4G and 
eIF4E per se are essential for ASFV, because depletion of those factors by specific small interfering RNAs 
(siRNAs) strongly abrogates viral protein synthesis, viral factory formation and virus production. In the case 
of the depletion of eIF4E, the viral factories detected in the cytoplasm of the infected cells are aberrant, 
while depletion of eIF4G promotes a reduction in size and number of the factories (Castello et al., 2009b). 
 
ASFV genome also encodes for proteins involved in mRNA metabolism. In this regard, ASFV D250R 
gene encodes a protein, g5Rp or pD250R (depending on the viral strain), that harbours a Nudix hydrolase 
motif, which is comparable to other Nudix hydrolases, such as the host decapping enzyme 2 (Dcp2) or the 
viral proteins D9 and D10 of VACV (McLennan, 2007). In viruses, presence of Nudix Hydrolases is almost 
exclusive of the members of the NCLDV (Rodriguez and Salas, 2013). It has been described that g5Rp exerts 
decapping activity in vitro (Parrish et al., 2009), although this protein can also degrade other substrates as 
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diphosphoinositol polyphosphates under these conditions (Cartwright et al., 2002). This protein, one of the 
targets of the present Thesis, is widely described in section 1.3.2.1.2.  
Additionally, ASFV genome encodes a protein called pD339L that contains a protein-protein 
interaction SHS2 domain similar to the SHS2 domain found in the RNA-polymerase II subunit 7 (RBP7) 
(Rodriguez and Salas, 2013). RBP7 is involved in numerous functions, including mediating both transcription 
and cytoplasmic mRNA decay pathways. In yeast, RBP7 travels from nucleus to cytoplasm, where stimulates 
the deadenylation process. RBP7 is a component of the Processing Bodies (P-Bodies) that interacts with the 
decapping activator protein associated with topoisomerase II (Pat1) and also stimulates 3´-5´ decay route 
(Lotan et al., 2007). Due to its similarity with this protein, pD339L could be embracing a similar role on ASFV 
infection. 
 
RNA decay mechanisms play a key role on mRNA physiology: not only control gene expression by 
determining RNA levels available for translation, but also is implicated in mRNA surveillance by removal of 
aberrant mRNAs (Garneau et al., 2007; Miller and Pearce, 2014). In eukaryotes, mRNAs are protected from 
degradation by two constructions: the cap structure at the 5´ end of the mRNA and the poly(A) tail at the 
3´end (Ross, 1995). Both structures have an essential function on RNA fate: depending on their interaction 
with different proteins, RNAs can be translated, repressed or degraded (Decker and Parker, 2012; Schwartz 
and Parker, 1999). For initiation of translation, the cap binding protein eIF4E and PABPC have to interact 
with both components. Through eIF4G, both proteins generate a closed mRNA loop that promotes 
translation and efficiently protects RNA from nucleases (Wells et al., 1998).  
In eukaryotic major decay pathways, the poly(A) tail interacts with the deadenylation complex, 
which shortens it targeting RNAs for degradation (Chen and Shyu, 2011; Decker and Parker, 1993). 
Deadenylation is a common rate-limiting step on RNA decay. Three major deadenylases have been described 
in eukaryotes: the Pan2-Pan3 complex, the CCR4-NOT complex, and the poly(A) ribonulease (PARN) (Parker 
and Song, 2004). After deadenylation, mRNAs could be eliminated by two general pathways depending on 
the degradation direction. In the 3´-5´decay pathway, RNAs are targeted by the exosome, a multi-protein 
complex of 3´-5´exonucleases that degrade RNA body. Resultant products are then decapped by the 
scavenger decapping enzyme, DcpS (Wang and Kiledjian, 2001). In the 5´-3 decay route, after deadenylation 
mRNAs are decapped by the decapping enzymes Dcp1 and Dcp2, leaving a 5´- monophosphate RNA (5´-P-
RNA) available for the action of the 5´-3´exonuclease Xrn1 (Garneau et al., 2007) (Figure 4).  
Additionally to the two major pathways, mRNA could also be degraded by other specific routes. In S. 
cerevisiae it has been described that certain mRNAs, as RPS28B and EDC1, can be degraded by a 
deadenylation-independent mechanism that does not require previous deadenylation process and directly 
decaps the mRNAs (Garneau et al., 2007). mRNAs could also be degraded by specialized endonucleolytic 
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pathways, which are initiated by the endonucleolytic cleavage of the RNA body. Resultant RNA fragments 
are then eliminated by Xrn1 and the exosome complex. These pathways are activated in response to certain 
physiological stimuli such as stress, viral infections or aberrant sequence and structural RNAs .This is the case 
of the RNA interference pathway (Eulalio et al., 2007). Other examples of endonucleolytic decay are the 
Nonsense-mediated decay (NMD) and the No-go decay (NGD). Both routes are cellular mRNA surveillance 
pathways that control the quality of the newly synthesise mRNA and avoid the accumulation of the 
potentially toxic aberrant proteins (Siwaszek et al., 2014). 
 
 
Figure 4. Major cellular mRNA decay pathways.  
The majority of the mRNAs are degraded by the deadenylation-dependent decay routes. Deadenylation is carried out by the CCRX/NOT complex of 
deadenylases that shorten the poly(A) tail at the 3’end of the mRNAs. After deadenylation, mRNAs can be targeted to decapping by the decapping 
activators Pat1-Lsm1 and Dhh1 and decapped by the Dcp2, entering in the 5´-3’ RNA decay route. Decapped mRNAs are degraded in 5´-3´orientation 
by the exonuclease Xrn1. Alternatively, after deadenylation mRNAs can be degraded by the 3´-5’ endonuclease complex, the exosome. The resultant 
cap structure is removed by DcpS. 
 
Decapping is an essential step in the 5´-3´RNA decay route because it induces RNAs to 5´-3´ 
degradation. In eukaryotes, this process is carried out by the decapping enzyme Dcp2, and it is a highly 
regulated phenomenon: numerous proteins, among which Dcp1 is described at the major activator, have 
been described to act as enhancers or inhibitors of decapping (Arribas-Layton et al., 2013; Ling et al., 2011; 
Meyer et al., 2004). 
The cap structure is an inverted 7-methylguanosine (m7G) bound by a 5´-5´triphosphate bridge to 
the first nucleotide of eukaryotic mRNAs. Different types of cap structure exist in nature. Cap 0 structure 
contains the guanosine methylated at the N7 position. Formation of the Cap 1 structure occurs by 2´O 
methylation on the ribose residue on the first adjacent nucleotide to the m7Gcap. Cap 1 structure can be 
converted to a Cap 2 by further 2´O methylation on the following nucleotide (Ghosh and Lima, 2010) (Figure 
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5). Capping is a process that mainly occurs at nucleus concomitant to transcription. In these conditions, it is 
carried out by three enzymes: a triphosphatase, a RNA guanylyltransferase and a methyltransferase (Ghosh 
and Lima, 2010). However, it also has been described to occur post-transcriptionally at cytoplasm by a 
capping enzyme complex that phosphorylates 5´-monophospahte RNA, which can function as a substrate for 
recapping (Otsuka et al., 2009). As commented above, the cap structure plays a critical role on mRNA 
stability and regulation. Due to its unique chemical properties, it is resistant to exonuclease activity and 
additionally, it can interact with multiple proteins, called cap binding proteins, which possess a determining 
role on mRNA fate. In the nucleus, cap interacts with the Cap Binding Complex (CBP), which stimulates 
splicing and export of RNA. In the cytoplasm, cap is recognised by eIF4E, which is essential for translation 
initiation (Topisirovic et al., 2011). 
 
Figure 5. Schematic representation of the cap structure.  
Capping of mRNAs is a common feature of all the RNA Polymerase II transcripts. Capping is a process that mainly occurs at the nucleus and consist in 
the addition of a methylated guanine by an inverse 5´-5´phosphate bridge at the 5’end of the mRNA. This structure is known as Cap 0 (black) and can 
undergo further methylation at the 2’O position on the ribose residue on the first adjacent nucleotide. This structure is termed Cap 1 (red). Cap 1 
structure can be converted to a Cap 2 (green) by further 2´O methylation on the following nucleotide. Dcp2 catalyse the hydrolysis of the cap 
structure between γ and β phosphates, giving m7GDP and 5´monophosphate as products. On the other hand, Dcp3 catalyse the hydrolysis of the cap 
structure between β and α phosphate, in a reaction that release m7GMP. 
1.2.1.1 Nudix hydrolases as decapping enzymes 
Dcp2, the best characterized decapping enzyme in eukaryotes (Arribas-Layton et al., 2013), belongs 
to the Nudix (nucleoside diphosphate linked moiety X) hydrolases superfamily (McLennan, 2006). These 
enzymes are highly conserved among species, being present on bacteria, yeast, archea, eukaryotes and 
viruses (Bessman et al., 1996). Nudix hydrolases are able to catalyse the hydrolysis of nucleoside 
diphosphates bound to another moiety X, which could be a wide range of substrates: di and tri-phosphates, 
canonical and oxidised nucleotide di-phosphates, dinucleoside polyphosphates, dinucleotide coenzymes and 
capped RNAs (McLennan, 2006). Catalytic activity of these enzymes relies on the Nudix motif or Nudix box, a 
23 amino acidic sequence highly conserved that presents the consensus sequence Gx5Ex5[UA]xREx2EExGU, 
where X could be any amino acid, and U is an hydrophobic residue. The structure of this motif is a loop-α 
helix-loop which is able to bind divalent cations (commonly Mg2+or Mn2+) and to act as the catalytic site. 
Glutamic residues of Nudix motif have been demonstrated to play an important role on divalent cation 
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binding and to be essential for the catalysis activity, although these enzymes hold a wide variation regarding 
the individual residues implicated in the attack and the number of cations involved on the reaction. Nudix 
motif forms part of the Nudix fold, an α/β/α sandwich which contains supplementary regions not conserved 
along all the members and that defines enzymes specificity (Gabelli et al., 2001; Mildvan et al., 2005). 
Indeed, the members of this huge family possess substrate multispecificy and ambiguity, meaning that the 
same Nudix hydrolase is able to act over different related or non-related substrates with same or different 
specificity (McLennan, 2013).  
Nudix hydrolases with decapping activity play an important role on mRNA metabolism, and they are 
also conserved from bacteria to mammals (McLennan, 2013; Song et al., 2013). In eukaryotes, Nudix 
hydrolases with decapping activity are able to hydrolyse the cap structure, releasing 7-methylguanosine 
monophosphate (m7GMP) or 7-methylguanosine diphosphate (m7GDP) and 5´-monophosphate mRNA 
(Figure 5) (Mildvan et al., 2005). In these enzymes, the conserved glutamic residues of the Nudix motif are 
essential for the decapping activity, because mutation of these amino acids in several Nudix decapping 
enzymes causes a loss of the decapping activity in vitro (Lin et al., 1996; Steiger et al., 2003; Wang et al., 
2002). 
1.2.1.1.1 Dcp2 
Dcp2 enzyme was firstly described as a decapping coactivator in S. Cerevisiae (Dunckley and Parker, 
1999). Subsequent studies demonstrated that purified Dcp2 proteins from different species, as yeast, plant 
or human, were able to decapp mRNAs in vitro, releasing m7GDP and 5´-monophosphorylated mRNAs as 
products (Iwasaki et al., 2007; Piccirillo et al., 2003; Steiger et al., 2003). In the case of yeast Dcp2, decapping 
reaction (measured as product release) is more efficient on large mRNAs (at least 29 nt)(Steiger et al., 2003), 
and is specific for the 5´UTR sequence: substitution of RNA sequence by DNA is not hydrolysed by Dcp2 
(Dunckley and Parker, 1999). 
Together with the Nudix motif, Dcp2 proteins present another two conserved motifs: Box A and Box 
B. Box B is situated down-stream the Nudix motif and it has been linked to the ability of Dcp2 to interact 
with the RNA body. RNA binding is essential to the catalysis by Dcp2, because this enzyme is not able to 
hydrolyze cap analogous which do not possess a RNA body, such as m7GpppG. Moreover, Dcp2 decapping 
activity is subrogated by uncapped mRNAs but not by cap analogous; and truncated Dcp2 proteins, which do 
not possess Box B and are not thus able to bind RNA, do not present decapping activity in vitro (Piccirillo et 
al., 2003). Dcp2 possesses a bipartite surface that creates a basic channel among Nudix motif and Box B 
sequences. This channel acts as a platform for RNA interaction and is important for the catalysis: single 
mutations of amino acids in the channel cause a loss on efficiency of decapping. Although cavity is present in 
other Nudix hydrolases, the basic channel is characteristic of Dcp2 (Deshmukh et al., 2008; She et al., 2008). 
Introduction 
49 
Kinetic assays demonstrated that Dcp2 binds RNA with high affinity, but low specificity; while cap structure is 
bound with high specificity but low affinity (Deshmukh et al., 2008).  
Dcp2 Box A is localised up-stream of Nudix box, in the highly conserved N-terminal regulatory 
domain (NRD). This motif has been related with fidelity of the hydrolysis process, because truncated proteins 
without Box A generate both m7GDP and m7GMP products (Piccirillo et al., 2003). The N-terminal domain of 
the protein is non-essential for the catalysis in vitro, although highly stimulates the decapping reaction. On 
the contrary, the N-terminal domain is essential for this activity in vivo (She et al., 2006). Moreover, it has 
been demonstrated that N-terminal domain directly interacts with the decapping co-activator Dcp1 
(Dunckley and Parker, 1999; She et al., 2006). The N-terminal domain and the Nudix domain of Dcp2 are 
linked by a flexible hinge region, allowing Dcp2 to adopt two conformations: one open and less efficient, and 
other closed and most active (She et al., 2008). Cap analogues and Dcp1 stimulate the closed conformation 
of Dcp2 (She et al., 2008). On the other hand, the C-terminal domain of Dcp2 is not conserved among 
eukaryotes. However, in both yeast and humans, this domain is implicated in the interaction with other 
decapping activators, such as Edc3 or Edc4 (Fromm et al., 2012; Jonas and Izaurralde, 2013).  
Dcp2 is a RNA-binding protein that displays substrate specificity: Dcp2 binds with more affinity 
mRNAs that possess a 5´ stem-loop structure. This structure was firstly described for the mRNA encoding for 
the exosome subunit Rrp41 (Li et al., 2008), but has been identified in several mRNAs, indicating that it could 
play a more general role in enhancing decapping (Li et al., 2009). The regulatory effect of the loop-structure 
relies on its structural integrity, and not on its primary sequence. Position of the loop is also important: RNA-
Dcp2 interaction is reduced when the loop-structure is located further than 10 nt from the cap structure (Li 
et al., 2009).  
1.2.1.1.2 Other Nudix decapping enzymes 
In mammalian cells, 24 Nudix hydrolase genes and at least 5 pseudogenes have been described 
(McLennan, 2006), being Dcp2 and Nudix-type motif 16 (Nutd16) the best known decapping enzymes. 
Nutd16 possess decapping activity in vitro (Taylor and Peculis, 2008), and was firstly discovered on Xenopus 
(Ghosh et al., 2004). Nutd16 has been pointed to act as an additional decapping enzyme together with Dcp2 
(Li et al., 2011; Song et al., 2010). In addition to Dcp2 and Nudt16, six additional mouse Nudix enzymes have 
been described to possess decapping activity in vitro: Nudt2, Nudt3, Nudt12, Nudt15, Nudt17 and Nudt19 
(Song et al., 2013).  
1.2.1.2  Decapping activators 
Dcp1 is the main activator of Dcp2. In yeast, Dcp1 directly interacts with Dcp2, stimulating Dcp2 
activity in vitro and being essential for this process in vivo (Beelman et al., 1996; Dunckley and Parker, 1999; 
Steiger et al., 2003). In mammalian cells, this interaction is more fragile and requires the presence of the 
enhancer of decapping Edc4 (Chang et al., 2014; Fenger-Gron et al., 2005). Dcp1 from yeast possesses an α-
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helix structure that is not conserved in other eukaryotic Dcp1 enzymes (α1 and α2) and that is the main 
domain involved in Dcp2 interaction, which could explain why other co-factors are needed to stabilize that 
interaction in higher eukaryotes (She et al., 2004; She et al., 2008). Dcp1 stimulates Dcp2 decapping activity 
by promoting the Dcp2 closed conformation (She et al., 2008). Indeed, Dcp1 not only activates by itself Dcp2 
activity, but also stimulates decapping by recruiting other decapping activators, as the enhancers of 
decapping proteins 1 and 2 (Edc1 and Edc2) or the enhancer of decapping protein 3 (Edc3) (Borja et al., 
2011; Tritschler et al., 2007).  
Edc4 is also known as human enhancer of decapping large subunit (Hedls) and as Ge-1 in Drosophila 
melanogaster. This decapping activator has no yeast homologs; it is only conserved in metazoans (Arribas-
Layton et al., 2013). Edc4 stimulates hDcp2 decapping activity in vitro (Fenger-Gron et al., 2005) and acts as 
a scaffold protein of the decapping complex, directly interacting with hDcp1, hDcp2 and Xrn1. Moreover, the 
association between these proteins is essential for decapping in vivo (Chang et al., 2014). 
Other important decapping activators are Edc1 and Edc2, Edc3, Pat 1, the Sm-like proteins 1-7 
(Lsm1-7) complex and the DEAD box helicase homolog Dhh1 (also known as Rck/p54 or DDX6 in humans and 
Me31B in Drosophila). All of them are present in the P-Bodies structures (reviewed on (Eulalio et al., 2007)), 
and stimulate the decapping activity of Dcp1:Dcp2 enzymes by several mechanism (Coller and Parker, 2005; 
Fischer and Weis, 2002; Fromm et al., 2012; Nissan et al., 2010; Schwartz et al., 2003; Tharun and Parker, 
2001; Tritschler et al., 2007). Pat1 and Dhh1 are also able to inhibit translation (Coller and Parker, 2005; 
Nissan et al., 2010). Due to this fact, both Dhh1 and Pat1 have been described as the effectors of a general 
mechanism that targets mRNAs from an active translation state to a repressed mRNP, which could end in 
decapping and 5´-3´RNA degradation. 
1.2.1.3 Decapping inhibitors 
Several evidences suggest that decapping and translation are mainly competitive process. It means 
that initiation translation factors might be removed from cap before decapping takes place (Schwartz and 
Parker, 2000). Translation initiation factors in fact inhibit decapping: mutations of several eIFs as eIF4E, 
eIF4G or eIF4A promote an increase of deadenylation and decapping rates (Schwartz and Parker, 1999).In 
yeast, eIF4E inhibits decapping in vitro (an effect that depends on eIF4E ability to bind the cap structure 
(Schwartz and Parker, 2000)) and in vivo, although in this case accessibility of the cap by decapping enzymes 
does not seem to be merely controlled by competition with eIF4E (Schwartz and Parker, 1999). Poly(A) tail 
and poly(A) binding proteins (Pab1 in yeast, PABP in mammals) are also inhibitors of decapping. In yeast, 
Pab1p is able to inhibit deadenylation and decapping in in vitro (Wilusz et al., 2001) and in vivo (Caponigro 
and Parker, 1995). PABP also interacts with the 5´cap structure in vitro. This interaction can occur 
concomitantly with PABP-poly(A) tail interaction (Khanna and Kiledjian, 2004), which suggest that PABP 
protects both 5´and 3´RNA ends of the exonucleases action.  
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mRNA turnover is not only important in cellular gene expression regulation, but it also plays an 
essential role on antiviral defence (Abernathy and Glaunsinger, 2015; Pichlmair et al., 2006; Rigby and 
Rehwinkel, 2015; Waterhouse et al., 2001). Uncapped 5´triphosphate viral mRNAs can be recognised by the 
host immune system and trigger antiviral responses, such as PKR or retinoic acid-inducible gene-1 (RIG-1) 
activation (Nallagatla et al., 2008; Pichlmair et al., 2006). In this regard, viruses have developed several 
strategies in order to protect their mRNAs from the cellular-induced mRNA decay routes and to avoid 
detection of viral mRNAs by the host innate immunity (Narayanan and Makino, 2013). Some viruses 
synthesise a cap structure similar to the one found in cellular mRNAs. Retroviridae and bornaviridae use 
both the cellular RNA polymerase II and the cellular capping machinery to synthesise their viral mRNAs; a 
strategy that makes viral transcripts exert the same cap structure that cellular mRNAs (Koonin and Moss, 
2010). Double-stranded DNA viruses, like vaccinia and ASFV, encode for their own capping enzymes which 
also produced viral mRNA with a cap structure that resembles the cellular one (Decroly et al., 2012; Pena et 
al., 1993). On the other hand, some viruses, such us influenza viruses, arenaviruses and hantiviruses, acquire 
the cap structure from cellular mRNAs, using a technique called “cap-snatching”. This technique consists in 
stealing the cap structure of the cellular mRNA through the activity of endonucleases, which cut the host 
transcript several nucleotides downstream of the 5´cap structure. After the cleavage, the resultant short 
capped mRNA is used as primer for the synthesis of the viral mRNA (Decroly et al., 2012; Koonin and Moss, 
2010). The yeast L-A double stranded RNA virus also uses cap-snatching (Fujimura and Esteban, 2011), but it 
displays a different cap-snatching mechanism to the one described above. Through the decapping activity of 
the viral capsid Gag protein, L-A viruses transfer only the m7Gp from cellular mRNAs to viral mRNAs. Many 
viruses also protect their mRNAs at the 3´end. This is the case of alphaviruses, picornaviruses, coronaviruses 
and ASFV, which polyadenylate their transcripts, adding a poly(A) tail similar to the one found in their 
eukaryotic counterparts (Narayanan and Makino, 2013; Salas et al., 1981). In addition to these cis-acting 
elements, other viruses use trans-acting elements to protect their mRNAs, as picornaviruses, calciviruses 
and astroviruses, which protect their 5´UTR by covalent interaction with viral proteins. In the case of 
picornaviruses, their viral mRNAs possess an internal ribosome entry site (IRES), which allows translation of 
viral mRNAs in a cap-independent manner and also acts as a barrier to the action of endonucleases 
(Narayanan and Makino, 2013).  
 
Viruses not only protect their mRNAs to avoid cellular mRNA decay routes, but also strongly alter 
RNA metabolism in order to block or subvert stress responses to facilitate viral replication (Reineke and 
Lloyd, 2013; Sanchez et al., 2013). 
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1.3.1.1 P-Bodies and viral infection 
Processing Bodies, or P-Bodies, are cytoplasmic messenger ribonucleoproteins (mRNPs) granules, 
which contain non-translating mRNAs and that are enriched for RNA decay machinery components (Decker 
and Parker, 2012). P-bodies are dynamic complexes constitutively present in cells, although their size and 
number can increase under stress stimuli or in circumstances when translational repression is augmented 
(Kedersha et al., 2005; Teixeira et al., 2005). Components of P-Bodies include the decapping enzymes Dcp1 
and Dcp2, the decapping activators Edc3 and Edc4, the Lsm1-7 complex and the translation repressors Dhh1 
and Pat1, among others (reviewed on (Eulalio et al., 2007)). In yeast and mammals, P-Bodies are structures 
where active RNA decay can take place (Cougot et al., 2004; Sheth and Parker, 2003), although formation of 
P-Bodies is not necessary for mRNA decapping or for translation repression (Buchan et al., 2008; Decker et 
al., 2007), indicating that mRNA decay can occur outside of this structures. Stress conditions, such as heat 
shock, oxidative stress or viral infections, can also trigger the formation of other cytoplasmic RNA granules, 
called stress granules (SGs). These structures share several features with P-Bodies: both of them contain 
non-translating mRNAs and RNA decay machinery components, such as Xrn1. However, stress granules 
present proteins that cannot be found in P-Bodies, such as eukaryotic initiation factors (eIF4G or eIF3), Ras 
GTPase-activating protein-binding protein 1 (G3BP) or the 40S ribosomal subunit (Eulalio et al., 2007). P-
Bodies and stress granules are dynamically linked and it is believed that mRNA can move between 
polysomes, P-Bodies and stress granules in a working model known as mRNA cycle. In this model, mRNA is 
translated until it is targeted by proteins that repress translation, such as Dhh1 or Pat1, in response to a 
defect on translation or through specific recruitment. After that, ribosomes can be removed and the rest of 
the decapping machinery can be recruited. Therefore, decapping and RNA degradation can take place. 
Alternatively, mRNAs can remain stalled in translation repression and accumulate in stress granules or they 
can re-enter in translation if degradation machinery is replaced by translation initiation factors (Decker and 
Parker, 2012).  
P-Bodies and stress granules are also involved in host defences (Beckham and Parker, 2008; Li et al., 
2015). In this regard, some mRNA decay pathways, such as micro RNAs (miRNAs) or siRNAs, contribute to 
antiviral defence in mammals and plants (Dykxhoorn, 2007). This decay routes stimulate the recruitment of 
P-Bodies components into targeted mRNAs, which enter into translation repression and mRNA degradation 
(Valencia-Sanchez et al., 2006). In addition, proteins that contribute to antiviral defence, like protein kinase 
R (PKR) and the apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G and 3F (APOBEC3G 
and APOBEC3F), are also accumulated in P bodies (Beckham and Parker, 2008; Hebner et al., 2006; 
Wichroski et al., 2006). It is not surprising that viruses have developed multiple mechanisms to interfere 
with these structures in order to promote efficient translation of viral mRNAs (Figure 6). Some viral 
strategies are focused on the disruption of the cellular mRNA decay machinery by inactivation of P-Body 
components. This is the case of the West Nile Virus, which causes a progressive decrease in P-Bodies number 
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and a relocalization of many of its components (such as DDX6, Lsm1, or Xrn1) into the viral replication sites, 
while neither Dcp1 nor Edc4 are recruited to the viral factories. Interestingly, the recruited P-Body 
components are important to West Nile Virus replication, as silencing of these proteins reduce percentage of 
infected cells and viral RNA (Chahar et al., 2013). Adenoviruses also promote a decrease in P-Bodies, and 
their components are also redistributed, but in this case to aggresomes, where they are probably inactivated 
or degraded (Greer et al., 2011). Polioviruses completely eliminate P-Bodies, and also degrade Xrn1, Pan3 
and Dcp1a proteins in a process that requires viral replication and the expression of the viral proteinases. 
Interestingly, other P-Body components like Edc3 or Edc4 are unaffected by poliovirus infection (Dougherty 
et al., 2011).  
 
Figure 6. Viruses manipulate cellular mRNA decay pathways.  
In order to successfully translate the viral mRNAs and avoid its degradation by the host immune defences, viruses have developed multiple 
mechanisms to subvert cellular RNA decay components. Poliovirus and adenovirus eliminates P-body components by the action of viral proteases or 
in by distributing them to agressomes, respectively. Vaccinia virus, West Nile virus, brome mosaic virus and hepatitis C virus use P-body components 
to their own benefit. Kaposi´s sarcoma-associated herpesvirus (KSHV), Epstein-Barr virus (EBV), severe acute respiratory syndrome coronavirus (SARS-
CoV) and Herpes simplex virus (HSV-1) directly degrade host mRNA by the action of endonucleases. Vaccinia virus also target cellular mRNAs using 
decapping enzymes. Arenaviruses, influenza viruses, hantaviruses and LA-viruses use the cap-snatching technique as a mechanism for capping viral 
mRNAs and for eliminate cellular mRNAs. 
 
Viruses have also developed mechanisms to use the mRNA decay components to their own benefit. 
Brome mosaic virus, vaccinia virus and hepatitis C virus (HCV) employ this strategy, and use the Lsm1-7 
complex to promote viral RNA replication and translation. (Mas et al., 2006; Narayanan and Makino, 2013; 
Scheller et al., 2009).Brome mosaic virus uses Lsm1-7 complex together with the decapping activators Pat1p 
and Dhh1 (DDX6) to recruit the viral RNA to the replication complex (Mas et al., 2006). Vaccinia intermediate 
and late mRNAs are characterized by the presence of a poly(A) track localized at the 5´ UTR of the viral 
mRNAs, and the Lsm1-7 complex is able to interact with this 5´ poly(A) sequence. This interaction leads to a 
stabilization of the mRNAs due to the inhibition of both the decapping and the exosome degradation routes, 
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and it has been proposed as a mechanism employed by vaccinia to protect late viral mRNAs from D9 and 
D10 decapping activity (Bergman et al., 2007). HCV hijacks the P-Body and stress granules components 
DDX6, Lsm1, Xrn1, G3BP and PABP1, and redistributes them to the HCV production factory around lipid 
droplets. DDX6, Lsm1 and PABP1 are essential to HCV replication, since the inhibition of their expression by 
both specific shRNAs and siRNAs causes a reduction on HCV RNA levels (Ariumi et al., 2011). Recently, it has 
been described that Lsm1 contributes to the activation of HCV IRES-mediated translation, but it is not 
required to stimulate viral replication (Roberts et al., 2014) (Figure 6). 
 
Additionally to the strategies mentioned above, during infection viruses can alter the distribution 
and quantity of cellular mRNAs by modifying cellular RNA metabolism functions. In the case of herpes 
simplex virus-1 (HSV-1), the splicing machinery is inhibited leading to an accumulation of cellular mRNAs at 
the nucleus of infected cells (Sandri-Goldin, 2011), while in the case of AdV, VSV, poliovirus or influenza virus 
host mRNAs export from the nucleus to the cytoplasm is impaired by targeting the nuclear pore complex 
(Blanchette et al., 2008; Castello et al., 2009a; Park et al., 2008; Satterly et al., 2007; von Kobbe et al., 2000). 
In this regard, adenovirus early proteins E4orf6 and E1B55K perform several functions, and, among them, 
they stimulate nuclear export of late viral mRNAs and block nuclear export of the majority of cellular mRNAs 
(Blanchette et al., 2008). VSV genome encodes for the matrix protein M, which directly interacts with the 
nucleoporin Nup98 and the mRNA export factor 1 (Rae1) and blocks mRNA nuclear export. M viral protein 
localizes at the nuclear envelope or rim, and it is dependent on Nup98 to carry out the inhibition of the 
nuclear transport, as demonstrated by VSV infection in Nup98-/- mouse cells (Quan et al., 2014; von Kobbe 
et al., 2000). Poliovirus infection also impairs mRNA nucleus-cytoplasm transport. The viral 2A protease 
interferes with the RNA transport from the nucleus to the cytoplasm, causing an accumulation of poly(A) 
RNA at the nucleus. This process is concomitant with the proteolysis and redistribution of the components of 
the nuclear pore complex Nup98, Nup153 and Nup62 (Castello et al., 2009a). Influenza virus also hijacks 
nuclear mRNA export. Viral NS1 protein interacts with several components of the nuclear pore complex, and 
its expression in cells causes nuclear retention of poly(A) RNAs (Satterly et al., 2007). In other cases, viruses 
stimulate directly mRNA degradation as occurs in alpha- and gamma-herpesvirus, severe acute respiratory 
syndrome coronavirus (SARS-CoV) and influenza virus, which encode to viral ribonucleases that induce 
cellular host shutoff by promoting mRNA degradation (Covarrubias et al., 2011; Feng et al., 2005; Huang et 
al., 2011; Jagger et al., 2012; Richner et al., 2011). Alpha-herpesviruses, such as HSV-1, encode for an 
endonuclease termed virion host shutoff protein (vhs), which cleavages mRNAs preferentially at an 
unstructured region of the capped mRNAs (Shiflett and Read, 2013). Vhs degrades both host mRNAs and 
viral mRNAs in order to eliminate the first and to ensure the temporal expression of the latter (Feng et al., 
2005; Taddeo et al., 2013). Gamma-herpesviruses genome also encodes for a viral endonuclease, known as 
host shutoff factor SOX in Kaposi´s sarcoma-associated herpesvirus (KSHV), muSOX in murine gamma-
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herpesvirus 68 and BGLF5 in Epstein-Barr virus (EBV). This endonuclease cleavages cellular and viral mRNAs 
anywhere along the RNA body, which subsequently undergoes degradation by the cellular exonuclease Xrn1 
(Covarrubias et al., 2011; Richner et al., 2011). SARS coronavirus non-structural protein 1 (nsp1) protein also 
promotes cellular mRNA degradation, but using a novel mechanism that inhibits translation initiation and 
promotes the endonucleolytic cut of cellular mRNAs by recruitment of a cellular endonuclease, which has 
not been identified, so far. Interestingly, SARS-CoV mRNAs possess a 5´leader sequence that makes them 
resilient to nsp1 activity (Huang et al., 2011). Viral RNA-dependent RNA polymerase complex-X (PA-X) 
protein of influenza virus is another mRNA endonuclease that increases cellular mRNAs degradation, but 
seems not to affect viral protein synthesis (Jagger et al., 2012). On the other hand, cap-snatching is also a 
mechanism used by some viruses to promote cellular mRNAs degradation, since uncapped cellular mRNAs 
can enter in the cellular 5´-3´degradation pathway (Figure 6). 
1.3.2.1 Viral decapping enzymes 
Only two families of viruses have been described to use direct decapping as part of their strategy to 
inhibit cellular translation and to promote viral protein synthesis: vaccinia virus, which possesses two viral 
decapping enzymes D9 and D10, and the yeast double-stranded L-A virus, which uses a specific mechanism 
of decapping related to cap-snatching that has been described previously in this section (Abernathy and 
Glaunsinger, 2015). 
1.3.2.1.1 D9 and D10 decapping enzymes of vaccinia virus 
As commented in previous sections, vaccinia genome encodes for two decapping enzymes, D9 and 
D10, which present approximately 25% of sequence similarity. Both proteins possess a Nudix motif, which, 
as we have described in section 1.2.1.1, is related to RNA decapping (Parrish and Moss, 2007; Parrish et al., 
2007).  
In vitro assays demonstrated that both D9 and D10 recombinant proteins exhibit decapping activity, 
being able to hydrolase the 5´RNA cap structure and release m7GDP and 5´-monophosphate RNA as 
products. In both cases, single site mutations of the conserved glutamic residues (E125Q, E129Q, and E130Q 
in D9 and E141Q, E144Q and E1145Q in D10) in the Nudix motif cause a loss of the decapping activity, 
indicating that the Nudix motif is essential for the catalysis (Parrish and Moss, 2007; Parrish et al., 2007). 
Although closely related, D9 and D10 present some differences between them. Both proteins require a RNA 
body attached to the cap structure to carry out the hydrolysis reaction. However, D9 needs longer capped 
RNAs for optimal activity: D10 efficiently decapps RNAs of 24 nt, while D9 requires at least a 39 nt RNA body 
displaying better decapping activity in longer RNAs. Moreover, D9 has stronger sensitivity to uncapped RNAs 
than D10. On the other hand, D10 is intensely inhibited by methylated cap analogues, showing more affinity 
for m7GpppG than for m7GpppA; while D9 is only weakly inhibited by this kind of substrates. Neither D9 nor 
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D10 are inhibited by non-methylated cap analogues (Parrish and Moss, 2007; Parrish et al., 2007). 
Additionally, D9 possesses an early promoter, while D10 possesses a late promoter (Shors et al., 1999). 
By using cotransfection assays, Shors et al. demonstrated that D9 and D10 endorse repression of 
lacZ reporter gene expression under control of both intermediate and late viral promoters (Shors et al., 
1999). Moreover, both D9 and D10 proteins cause a repression of lacZ expression when it was under control 
of the T7 promoter, but not when it was under control of the encephalomyocarditis virus (ECMV) leader 
sequence. These results indicate that D9 and D10 effect is not specific for viral promoters, and also that only 
capped mRNAs are targeted by these proteins (Shors et al., 1999). Vaccinia virus strains that possess an 
extra copy of D9 or D10 cause a decrease in viral protein synthesis at late times post infection (12 hpi to D10 
and 20 hpi to D9), and a reduction on the late F17 viral mRNA levels. Moreover, overexpression of D10 
causes a severe decrease on vaccinia viral production (Shors et al., 1999). 
Further analysis of D10 and D9 function has been performed by generation of D10 and D9 vaccinia 
deletion mutants (v∆D10 and v∆D9) (Liu et al., 2014; Parrish and Moss, 2006). Infection of v∆D10 on BS-C-1 
cells causes a delay in both early and late viral transcription initiation (Parrish and Moss, 2006) Furthermore, 
viral early and late mRNAs, together with cellular actin mRNA, persist longer in v∆D10 infected cells, a 
phenomenon which is concomitant to a prolonged synthesis of cellular and viral early proteins (Parrish and 
Moss, 2006). Additional characterization of these proteins has been achieved by generation of two 
alternative inactive D10 viruses: the first possesses site mutations in the catalytic Nudix domain (vD10mu), 
while the second one harbours STOP codons that prevent D10 expression (vD10stop). Infections with both 
viruses have a similar but less pronounced effect in cellular and viral mRNA levels compared to ∆D10 
infection (Liu et al., 2014). Despite this moderate effect on in vitro experiments, both vD10mu and vD10stop 
viruses cause a more attenuated infection in in vivo, suggesting that this decapping enzyme may help to limit 
antiviral responses by accelerating host mRNA degradation during poxvirus infection (Liu et al., 2014). Due 
to the evidences mentioned above, it has been described that both D9 and D10 enzymes are involved both 
in the degradation of cellular mRNA and in the temporal expression of viral mRNA (Parrish and Moss, 2007).  
Recently, vaccinia D9 and D10 double catalytic mutant has been successfully achieved (Liu et al., 
2015). This double mutant (vD9muD10mu) is not able to replicate in human and monkey cell lines, but 
effectively replicates in mouse cells. The infection of this double mutant virus in the non-permissive cell lines 
is characterised by a pronounced decrease in the amount of cellular and late viral mRNAs and in the protein 
synthesis, concomitantly with an increase in the double-stranded RNA (dsRNA) levels. dsRNA production is a 
common feature among RNA and DNA viruses, and a its accumulation triggers the activation of the host anti-
viral defences, such as protein kinase R (PKR) and the RNaseL (Onomoto et al., 2014; Perdiguero and 
Esteban, 2009). Activation of PKR causes the phosphorylation of eIF2α and translation repression, while the 
activation of RNaseL promotes RNA degradation. Both processes explain the decreased levels of mRNA in 
vD9muD10mu infected cells. These results indicate that vaccinia decapping enzymes are not only involved in 
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decay of host and viral mRNAs, but also in the degradation of dsRNAs to avoid cellular anti-viral defences 
(Liu et al., 2015). 
1.3.2.1.2 ASFV in vitro decapping enzyme: g5Rp 
As commented on section 1.1.5, ASFV genome encodes for an enzyme that possesses a Nudix 
hydrolase motif, g5Rp (or pD250R, depending on the viral strain). Cartwright et al. demonstrated that 
purified histidine-tagged g5Rp from E.coli hydrolases in vitro a wide range of guanine and adenine 
nucleoside 5´-triphosphates (GTP and ATP) and dinucleoside polyphosphates (Gp3G, Gp4G, Gp5G and Ap3A, 
Ap4A and Ap5A), exhibiting higher substrate efficiency with diphosphoinositol pentakisphosphate (PP-
InsP5). In these conditions, g5Rp was not able to hydrolyse cap analogues such as m7GpppG, m7GpppC, 
m7GpppA, m7GppGm7G or m7GpppGm7G (Cartwright et al., 2002). On a second study, Parrish et al analysed 
g5R mRNA decapping activity in vitro, and demonstrated that recombinant MBP-g5Rp is able to hydrolyse 
cap analogues when they are attached to a RNA body, releasing m7GDP as a product (Parrish et al., 2009). 
The Nudix motif of the protein is essential for the catalysis, because single site mutation of the conserved 
residues E147, E150 and E151 causes a loss of decapping activity. As demonstrated by electrophoretic 
mobility shift assay (EMSA), g5Rp is able to directly interact with the RNA body. Moreover, g5Rp activity is 
strongly inhibited by uncapped RNAs, but is not affected by cap analogues or methylated nucleotides, 
suggesting that g5Rp preferentially recognise the RNA moiety on the substrate.  
Nevertheless, the role of this protein in vivo is still unknown. g5Rp high homology (at least for the 
Nudix domain) with Dcp2 and the fact that this protein possesses decapping activity in vitro suggest its 
involvement in mRNA regulation. Therefore, this viral enzyme represents a good candidate to be the viral 
factor involved in the degradation of the cellular mRNAs (contributing in the cellular shutoff), and in the 
temporal regulation of viral mRNAs. 
In this Thesis, we have worked in deciphering the role of g5R in vivo. Both Ba71V D250R and Malawi 
g5R ORFs has been approached. However, by the time this Thesis started, only the protein form Malawi 
strain was characterized in vitro. Due to this fact, we adopted Malawi nomenclature, although in the 
experiments in which Ba71V-pD250R was studied, this last nomenclature should be used. 
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The main objective of this Thesis is to study the mechanism displayed by African Swine Fever Virus 
to manipulate RNA metabolism and cellular translation resources, in order to decipher how the virus impairs 
cellular protein synthesis while promotes temporal viral gene expression.  
To achieve this goal, we set the following specific objectives: 
1. To analyse mRNA status in ASFV infection. To achieve this, we focus, firstly, on the analysis 
of mRNA levels, and, secondly, on the study of the distribution of mRNA in ASFV-infected 
cells. 
2. To characterize the putative ASFV decapping enzyme g5Rp (also known as pD250R in Ba71V 
strain), due to the fact that it is a good candidate to function as an mRNA regulator during 
the infection. 
3. To study the role of g5R protein in the cellular shutoff and in the viral temporal gene 
expression in the context of the infection. In this regard, we have analysed both the g5Rp 
effect on ASFV infection, but also the proteins interacting with g5Rp to accomplish or 
modulate its function.  
4. To explore cellular components involved in the regulation of both cellular and viral protein 
synthesis during ASFV infection. We have focused on the analysis of the components of the 
cellular decapping machinery, specially P-Bodies and the cap structure, and on the study of 
ASFV-mediated control of the factors of the translational cellular machinery and of the 
cellular organelles as ribosomes.  
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Vero (CCL 81), COS-7 (CLR 1650) (epithelial and fibroblast kidney cells from African green monkey, 
respectively) and HeLa (ATTC CCL-2, epithelial cells of human cervix) cells were obtained from the American 
Type Culture Collection (ATTC). HeLa GFP stable cell lines were obtained, as detailed below, from HeLa cell 
line. All the three lines were cultivated in Dulbecco's Modified Eagle's medium (DMEM) (Dulbecco and 
Freeman, 1959) supplemented with 5% of fetal bovine serum (FBS) and maintained at 37ºC under a 
controlled 7% CO2 atmosphere saturated with water vapour. Medium was supplemented with 2 mM L-
glutamine, 0.4 mM nonessential amino acids and 0.05 mg/ml gentamicin for Vero and COS-7 cells and 
0.1mg/ml penicillin plus 102 U streptavidin for HeLa cells.  
 
Infections were carried out with the African Swine Fever Virus (ASFV) strain Ba71V (Vero adapted 
Ba71 strain) (Enjuanes et al., 1976). Virus preparations were obtained from cells cultured in bottles infected 
with BA71V with multiplicity of infection (M.O.I) 0.2 plaque former units (pfu) per cell. 72 hour post infection 
(hpi), cells were harvested and centrifuged at 3000 rpm for 15 minutes to eliminate cellular debris. 
Supernatant was clarified by overnight (16 hours) 7000 rpm centrifugation at 4º C and finally pellets were 
resuspended in 2% FBS complete medium, sonicated and viral particle were stored at -80º C. Ba71V was 
titrated by plaque assay in Vero cells as described before (Enjuanes et al., 1976). 
 
 
The following solutions were used: Phosphate buffered saline (PBS), Tris buffered solution (TBS), Tris 
Acetate EDTA Solution (2 M Tris base, 5.7 % glacial acetic acid and EDTA (pH 8) (TAE 50X)), 
ethylenediaminetetraacetic acid (EDTA), sodium dodecyl sulfate (SDS), Phenol: Chloroform: Isoamil Alcohol 
pH 8 (PCI) produced by the mixture of phenol pH 8 (Sigma) Chloroform (Merck) and Isoamil Alcohol (Merck) 
in 25:24:1 rate; Chloroform : Isoamil Alcohol (CI 24:1). Cytosine arabinose (AraC) was used a final 
concentration of 40μg/ml, and Cicloheximide(CHX) was used at 100 μg/ml. 
 
Antibodies used in this project are detailed in Table 1 
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Antigen Antibody Specie Technique 
Working 
Dilution  
Origin 
Human influenza hemagglutinin HA mouse 
FACS 1/100 Roche 
11867423001 Immunofluorescence 1/500 
Green Fluorescent Protein GFP mouse Western blot 1/1000 
Roche  
1181460001 
Dcp1A (C-terminal) Dcp1 rabbit 
Western Blot   1/ 1000 
Sigma Aldrich 
D5444 
Immunoprecipitation 1/200 
Immunofluorescence 1/100 
Edc4 (S-15) Edc4 goat Immunoprecipitation 1/100 
Santa Cruz  
sc- 137444 
USP10 (156-170) USP10 rabbit 
Western blot 1/1000 Sigma Aldrich 
U7384 Immunofluorescence 1/100 
C-terminus of eukaryotic acidic 
ribosomal P-proteins P0, P1 and P2 
3BH5 mouse Western blot 1/10 (Vilella et al., 1991) 
C-terminus of calnexin calnexin rabbit Immunofluorescence 1/200 
StressMarq 
SPC-108B 
β-actin β-actin goat Western blot 1/1000 
Santa Cruz Biotechnology  
sc-1616 
Tubulin Tubulin mouse Western blot 1/250 
Sigma-Aldrich 
T9026-100UL 
Cap structure of mRNA (clon H-20) Cap mouse 
Immunofluorescence  1/100 Synaptic Systems 
201 001 Immunoprecipitation 
 
Viral protein g5R g5Rp rabbit Western blot 1/1000 Generated in this thesis 
Viral protein p32 p32 mouse 
Western blot 1/1000 
(Prados et al., 1993) FACS 1/500 
Immunofluorescence 1/3000 
Viral protein p72 p72 rabbit Western blot 1/1000 Generated at our laboratory 
Viral protein p72 p72 17LD3 mouse 
FACS 1/100 Ingenasa 
(Sanz et al., 1985) Immunofluorescence 1/300 
Viral protein CD2v CD2v rabbit Immunofluorescence 1/750 (Galindo et al., 2000) 
Inducible proteins of ASFV ASFV rabbit Western blot 1/4000 
Generated at our laboratory 
(del Val and Vinuela, 1987) 
Rat IgG  Alexa fluor-488 donkey 
FACS 1/500 Invitrogen 
A-21208 Immunofluorescence 1/500 
Mouse IgG  Alexa fluor-488 donkey 
FACS 1/500 Invitrogen 
A-21202 Immunofluorescence 1/500 
Mouse IgG  Alexa fluor-555 donkey Immunofluorescence 1/500 
Invitrogen  
A-31570 
Mouse IgG  Alexa fluor-647 donkey 
FACS 1/500 Invitrogen 
A-31571 Immunofluorescence 1/500 
Rabbit IgG Alexa fluor-555 donkey Immunofluorescence 1/500 
Invitrogen 
A-31572 
Rabbit IgG Alexa fluor-647 donkey 
FACS 1/500 Invitrogen 
A-31573 Immunofluorescence 1/500 
Goat IgG Alexa fluor-555 donkey Immunofluorescence 1/500 
Invitrogen 
A-21432 
Goat IgG Alexa fluor-647 donkey Immunofluorescence 1/500 
Invitrogen 
A-21447 
Mouse IgG  
Mouse 
peroxidase 
  Western blot 1/10000 Amersham Biosciences 
Rabbit IgG 
Rabbit 
peroxidase 
  Western blot 1/4000 Amersham Biosciences 
Goat IgG Goat peroxidase   Western blot 1/20000 Sigma Aldrich 
Table 1. Antibodies used in this Thesis.  
Dcp1A: Decapping enzyme 1A; Edc4: Enhancer of decapping-4; ASFV: African Swine Fever Virus; IgG: Immunoglobulin G 
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Oligonucleotide probes used are detailed in Table 2 
Target Probe Sequence 
Working 
concentration 
Technique Origin 
Poly(A) tail Oligo d(T) TTTTT(n=50)TT-FitC 2.5 mM RT BioNova 
Poly(A) tail Oligo d(T) - FITC TTTTT(n=50)TT-FitC 1 μM FISH 
Sigma 
Aldrich 
Poly(A) tail 
Oligo d(T) - Texas 
Red 
TTTTT(n=50)TT-Texas Red 1 μM 
FISH 
Invitrogen Dual fluorescence 
method 
Viral A224L 
mRNA 
A224L mRNA 
GCTTTGATTTCGTGCATCTATGGA
GC 
1 μM FISH Invitrogen 
Table 2. Oligonucleotide probes used in this Thesis. 
FISH: Fluorescence In Situ Hybridization; RT: Retrotranscription 
 
 
During this study, several genes have been cloned in different plasmids to express both wild type 
(wt) and mutated proteins in eukaryotic or bacterial systems, to generate stable cell lines and to obtain viral 
mutated strains. In general, the gene of interest was amplified by PCR using specific probes (Table 2) and 
viral ASFV genome or certain vectors as DNA template. The cloning process of these products required the 
usage of the following techniques: 
 
PCR products were isolated with 0.7%-1% agarose gels. Gels were made in 1 x TAE buffer and 
percentage of agarose varied depending on amplicon size. For separation, PCR products were mixed with 
loading buffer (0.25 % Bromophenol Blue, 50 % glycerol and 1 mM EDTA) and electrophoreticaly separated 
in agarose gels for 1 hour (80 – 100 V). 
 
Products of interest were sliced from agarose gel using an U.V transiluminator and a scalpel. In order 
to extract the products from the matrix, we used the Wizard SV gel and PCR Clean-UP System (Promega) 
following manufacturer’s instructions. After purification, products were quantified in a Nanodrop ND-1000 
(Thermo Scientific). 
 
After purification, amplicon and vector were digested with specific restriction enzymes following 
manufacturer´s instructions to each enzyme (NEB). Digestion time was modified depending on product size 
and DNA ends. 
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Purified vector and insert were ligated overnight at 16º C with T4 ligase (Roche) following 
manufacturer’s protocol. Ligation rate varied depending on quantity and size products. In general, we used 
plasmid: insert rate of 1: 3 or 1: 10. 
 
Primers used this thesis are detailed in Table 3 
Name Sequence Description Application 
g5R FW ATGCAGCTTAAAACGTCTATTGG 
g5R mRNA detection primers PCR 
g5R RV CTAGTGCTTATATCGTAAATAGT 
p32 FW CCGAGCCCTCATCAGAGGAACC 
p32 mRNA detection primers PCR 
p32 RV GGGGTTCCATGAATGGTTTGG 
p72 FW CGCGGATCCATGGCATCAGGAGGAG 
p72 mRNA detection primers PCR 
p72 RV CGCGAGATCTAGCTGACCATGGGCC 
β actin FW GAGAAGATGACCCAGATCATG 
β actin mRNA detection primers PCR 
β actin RV TCAGGAGGAGCAATGATCTTG 
qA238L FW GCAGATCCGACTCAAAAAGACT 
A238L mRNA detection primers quantitaive PCR 
qA238L RV ACTCCATATTTCCTGTAAAGACTGC 
q p32 FW  CCGAGCCCTCATCAGAGGAACC 
p32 mRNA detection primers quantitaive PCR 
q p32 RV  GGGGTTCCATGAATGGTTTGG 
qA224L FW AAGCACCCTTTACAGGTGCATGGC 
A224L mRNA detection primers quantitaive PCR 
qA224L RV TCCTATAATGCCCAAGGTTGCACGG 
q p72 FW CCCGAGAACTCTCACAATATCC 
p72 mRNA detection primers quantitaive PCR 
q p72 RV CGTTGCGTCCGTAATAGGAG 
q g5R FW AATACCAAAAATTTAGGAAAAATTGG 
g5R mRNA detection primers quantitaive PCR 
q g5R RV GCCCTTTGCTTGGTTGATTA 
qBIRC2 FW GCTGACCCACCAATTATTCATTTTGG 
BIRC2 mRNA detection primers quantitaive PCR 
qBIRC2 RV CACACACGTCAACTGTTGAAAGAGAGC 
q eIF4A1 FW AATCCGCATCTTGGTGAAAC 
eIF4A1 mRNA detection primers quantitaive PCR 
q eIF4A1 RV CCCTCTCCACTGCCACAA 
q eIF4E FW CAGCAGAGACGAAGTGACCTT 
eIF4E mRNA detection primers quantitaive PCR 
q eIF4E RV ACATTAACAACAGCGCCACA 
q β actin FW AGGTCATCACCATTGGCAAC 
β actin mRNA detection primers quantitaive PCR 
q β actin RV CGTGGATGCCACAGGACT 
18S  M.m FW GGAGAGGGAGCCTGAGAAAC Macaca mulata 18S rRNA detection 
primers 
quantitaive PCR 
18S M. m RV TCGGGAGTGGGTAATTTGC 
18S  H.S FW GCAATTATTCCCCATGAACG Hommo sapiens 18S rRNA detection 
primers 
quantitaive PCR 
18S H.S RV GGGACTTAATCAACGCAAGC 
BamHI g5R 
FW 
GGGGGATCCATGGATACTGCCATGCAGCTT 
g5R cloning in pGEX-2T GST-g5R production 
EcoRI g5R RV GGGGAATTCCTACTAGTGCTTATATCGTAA 
EcoRI g5R FW GGGGAATTCATGGATACTGCCATGCAGCTT 
g5R cloning in pEGFP-C2 GFP-5R production 
BamHI g5R RV GGGGGGGGATCCCTACTAGTGCTTATATCGTAA 
KpnI GFP FW GGGGGTAACATGGTGAGCAAGGGCGAGGAG GFP-g5R cloning in pCDANFRT/TO 
Stable cell line 
generation 
g5RmutREEG
G FW 
TCGGACCTTACCTGTGCCATAGGGGGGTTTGAAGAAGAAACCGGGATT 
mutation R146G/E147G (REGG) g5R 
Nudix domain 
Punctual mutation 
g5RmutREEG
G RV 
AATCCCGGTTTCTTCTTCAAACCCCCCTATGGCACAGGTAAGGTCCGA 
g5RmutEEQQ 
FW 
TGTGCCATACGGGAGTTTGAACAACAAACCGGGATTACCCGCGAATAT 
mutation E150Q/E151Q (EEQQ) g5R 
Nudix doma 
Punctual mutation 
g5RmutEEQQ 
RV 
ATATTCGCGGGTAATCCCGGTTTGTTGTTCAAACTCCCGTATGGCACA 
F1 KpnI FW GGGGGGGGTAACAGGTGGTCAAATTTGCTATTA 
up stream flanking g5R sequence 
g5R ASFV deletion 
mutant F1 SmaI RV GGGCCCGGGCTGTAACGTTTTTGAACCAGA 
F2 PstI FW GGGCTGCAGGCTGTACGTTTTATTAGCAAA 
down stream flanking g5R sequence 
g5R ASFV deletion 
mutant  F2 HindIII RV GGGAAGCTTCAGATGTTGAGTGAAGAGGAA 
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Name Sequence Description Application 
Nexo GFP g5R FW 
TCGAGCTCAAGCTTCGAATTCATGGATACTGCCATGC
AGCTT 
pEGFP / g5R Stable cell line generation 
Nexo GFP g5R RV 
AAGCTGCATGGCAGTATCCATGAATTCGAAGCTTGA
GCTCGA 
BamHI g5R Nterm RV GGGGGATCCCTACTAAATTTCCCATAGAAGTGT 
BamH1/ STOP codons / g5R upstream 
Nudix 
Stable cell line generation 
Nexo GFP g5R Cterm 
FW 
AGCTCAAGCTTCGAATTCACCCGCGAATATTACCAG 
pEGFP / g5R down stream Nudix  Stable cell line generation 
Nexo GFP g5R Cterm 
RV 
AATCTGGTAATATTCGCGGGTGAATTCGAAGCTTGA
GCTCGA 
Nexo g5R N term C 
term FW 
TCAGAAACACTTCTATGGGAAATTACCCGCGAATATT
ACCAGATTCTC 
g5R upstream Nudix / g5R down stream 
Nudix 
Stable cell line generation 
Nexo g5R N term C 
term RV 
AATCTGGTAATATTCGCGGGTAATTTCCCATAGAAGT
GTTTCC 
g5R down stream Nudix / g5R up 
stream Nudix 
KpnI prom_g5R FW GCGGGTACCTGAATATCTTGTGAACACAGC 
g5R up stream sequence containing 
viral promoter cloning promoter and g5R in 
pHA-2 BamHI noSTOP_g5R 
RV 
GCGGGATCCGTGCTTATATCGTAAATAGTTTTTAATA
AA 
g5R 3´sequence without stop codons 
Table 3. Primers used in this Thesis 
FW: Forward sequence, RV: reverse sequence. All primer sequences are shown on its 5´- 3´orientation. 
 
 
Plasmids generated and used, except these mentioned as gift, in this study are:  
 pHA-2: eukaryotic expression plasmid designed to produce protein of interest tagged to HA 
epitope at its C-terminal domain. This vector was obtained after cloning HA protein into 
pCDNA 3.1 vector and was a kind gift from Dr. Ricardo Madrid (BioAssays, Madrid, Spain). 
 promg5R-HA: eukaryotic expression vector that contains Ba71V g5R gene (D250R) fused to 
HA sequence. Expression of g5R-HA protein is controlled by g5R viral promoter, so this 
vector allows g5R-HA protein expression only in infected ASFV cells. To generate this vector, 
g5R sequence was amplified by PCR with ASFV genome as template using KpnI_promg5R FW 
and BamHI_noSTOP_g5R RV primers (Table 3). g5R sequence was digested with KpnI/BamHI 
and ligated to pHA-2.  
 pCDNAg5R: eukaryotic expression vector that contains g5R gene from Malawi Lil 20/1 strain. 
This plasmid was a kind gift of Dr. Linda Dixon (The Pirbright Institute, Pirbright, United 
Kingdom). 
 pEGFP-C2: eukaryotic expression plasmid that express the enhanced Green Fluorescent 
Protein (eGFP) under the Cytomegalovirus (CMV) promoter (Invitrogen). This vector contains 
a polylinker at GFP C-teminal domain, which makes possible to generate GFP recombinant 
proteins. It has been used as template to generate GFP-gene of interest amplicons and as a 
transfection control. 
 pCFP-C2: eukaryotic expression plasmid that express the Cyan Fluorescent Protein (CFP) 
under the CMV promoter. This vector contains a polylinker at CFP C-teminal domain, which 
makes possible to generate CFP recombinant proteins. 
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 pCFP g5R wt, pCFP g5R EEQQ and pCFP g5R REGG: Ba71V g5R gene (D250R) was cloned into 
pCFP-C2 vector to generate pCFP-g5R wild type (wt) construction using EcoRI g5R FW and 
BamHI g5R RV primers (Table 3) and ASFV genome as DNA template. Product and vector 
were digested with BamHI/EcoRI enzymes and ligated overnight (O/N). To generate the two 
punctual mutants of the g5R catalytic domain (pCFP g5R EEQQ and pCFP g5R REGG) we used 
g5RmutREGG (FW and RV) and g5RmutEEQQ (FW and RV) primers and Pfu turbo (Agilent 
Technologies) and Dpn1 (Stratagen). Single-site mutation method is described in detail in 
section 3.8. 
 pOG44: vector that expresses Flp recombinase protein, an enzyme that enables specific 
gene insertion on Flp Recombination Target (FRT) sites. When co- transfected with pCDNA5 
FRT/TO vector containing the gene of interest, mediates integration of this gene on Flp in 
TREx cell lines genome (Invitrogen). This plasmid was used to generate HeLa GFP stable cell 
lines and was kindly gifted from Dr. Fernando Rodriguez Pascual (Centro de Biología 
Molecular “Severo Ochoa”, Madrid, Spain). 
 pCDNA5/FRT/TO: Inducible expression vector aimed for use with the Flp-In T-REx System 
(Invitrogen). When cotransfected with pOG44 plasmid into Flp-In-TREx mammalian host cell 
line, the pCDNA5/FRT/TO containing the gene of interest is integrated in the cellular genome 
in an Flp recombinase dependent manner. The plasmid contains CMV promoter fussed to 
TetO2 promoter, allowing the expression of the protein of interest only in presence of 
tetracycline. pCDNA5/FRT/TO was kindly gifted by Dr. Fernando Rodriguez Pascual (Centro 
de Biología Molecular “Severo Ochoa”, Madrid, Spain). 
 pCDNA5/FRT/TO GFP-g5R wt: pCDNA5/FRT/TO containing GFP-g5R wt sequence. The GFP-
g5R insert was obtained by fusion PCR using KpnI GFP FW, nexo GFPg5R FW and RV and 
BamHI g5R RV as primers; and pEGFP-C2 and pCFP g5R wt as DNA templates for eGFP and 
g5R wt sequences, respectively (Figure 7). 
 pCDNA5/FRT/TO GFP-g5R EEQQ and pCDNA5/FRT/TO GFP-g5R REGG: pCDNA5/FRT/TO 
containing GFP-g5R EEQQ and REGG catalytic site mutant sequences. These mutations affect 
the conserved amino acids at g5R catalytic domain (Nudix motif): in REGG mutation arginine 
146 and glutamic acid 147 were substituted by glycine (R146G/E147G); EEQQ mutation is a 
substitution of glutamic acids 150 and 151 by two glutamines (E150Q/E151Q). Both 
mutations have been described to produce a loss of catalytic activity (Parrish et al., 2009). 
GFP-g5R EEQQ and REGG inserts were obtained by fusion PCR using KpnI GFP FW, nexo 
GFPg5R FW and RV, and BamHI g5R RV primers and pEGFP-C2 and pCFP g5R EEQQ or REGG 
as DNA templates (Figure 7). 
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 pCDNA5/FRT/TO GFP-g5R N-terminal: pCDNA5/FRT/TO containing GFP fused to g5R N-
terminal sequence, defined as the sequence up-stream of Nudix domain. GFP-g5R N-
terminal insert was obtained by fusion PCR using KpnI GFP FW, nexo GFPg5R FW and RV, 
and BamHI g5R N-term RV primers and pEGFP-C2 and pCFP g5R wt as DNA templates (Figure 
7). 
 pCDNA5/FRT/TO GFP-g5R C-terminal: pCDNA5/FRT/TO containing GFP fused to g5R C-
terminal sequence, defined as the sequence down-stream of Nudix domain. GFP-g5R C-
terminal insert was obtained by fusion PCR using KpnI GFP FW, nexo GFPg5RCterm FW and 
RV, and BamHI g5R RV primers and pEGFP-C2 and pCFP g5R wt as DNA templates (Figure 7). 
 pCDNA5/FRT/TO GFP-g5R ∆Nudix: pcDNA5/FR/TO containing GFP sequence tagged to a g5R 
version that completely lacks Nudix domain (∆Nudix). GFP-g5R ∆Nudix insert was obtained 
by two fusion PCR: Inserts needed were obtained with KpnI GFP FW, nexo GFPg5R Fw and 
RV, g5RNtermCterm FW and RV and BamHI g5R RV primers. pEGFP-C2 and pCFP g5Rwt were 
used as DNA templates. First fusion PCR generated GFP g5R N-terminal insert; and second 
fusion PCR produced GFP-g5R ∆Nudix (Figure 7). 
 pGEX-2T: bacterial GST expression vector. This vector contains a polylinker at GST 3´end 
which make possible generate GST recombinant proteins (GE Healthcare). 
 pGEX-g5R wt. bacterial expression plasmid that contain GST-g5R wt sequence. This plasmid 
was obtained by cloning g5R gene (Malawi Lil 20/1) in the pGEX-2T vector. For that, BamHI 
g5Rwt FW and EcoRI g5Rwt RV primers were used to amplify g5R gene from pCDNAg5R. 
After digestion with BamHI/EcoRI, g5R sequence was inserted in pGEX-2T plasmid. pGEX-g5R 
wt was transformed in E.coli.to produce GST-g5R wt protein, which was used to generate 
specific anti g5R serum and to perform pulldown assays. 
 p72GAL10T: plasmid used to obtain deletion ASFV mutants. This vector was generated by 
cloning LacZ operon under viral p72 promoter into pUC118 plasmid (Garcia et al., 1995). 10T 
termination ASFV signal was added at the end of LacZ to ensure the end of transcription. At 
both sides of the operon, enzyme restriction sites were included to clone the sequences that 
flank the deletion gene (F1 and F2). 
 p72∆g5RGAL10T: p72GAL10T plasmid that contains the Ba71V g5R flanking sequences F1 
and F2. Both sequences were amplified from ASFV genome using F1 KpnI FW, F1 SmaI RV, F2 
PstI FW and F2 HindIII RV primers, respectively. After digestion with KpnI/SmaI or 
PstI/HindIII, Fi and F2 inserts were successively cloned into p72GAL10T plasmid. We used 
this vector to the generation of ASFV g5R deletion mutant, process detailed in following 
sections. 
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 p72∆EP153RGAL10T: p72GAL10T plasmid which contains Ba71V EP153R F1 and F2 
sequences. This plasmid was generated as described previously (Galindo et al., 2000). 
p72∆EP153R GAL10T was used as positive control in ASFV g5R deletion mutant assays. 
 p71∆CD2vGUS10T: p72GUS10T plasmid which contains Ba71V EP402R (CD2v gene) F1 and 
F2 sequences. This plasmid was generated in our laboratory as described on section 3.13 but 
using p72BetaGUS10T as vector. In this case, gusA is the reporter gene. p72∆CD2vGUS10T 
was used as positive control in ASFV g5R deletion mutant assays. 
 pZAB 11/7 42: p72Gal10T plasmid containing eGFP-g5R wt fused protein under control of 
g5R viral promoter (Ba71V). This vector allows the expression of GFP-g5Rp wt only under 
ASFV infection and was generated by BioAssays. 
 
 
Conventional reactions of PCR were used to obtain inserts in cloning processes, to check ligation 
after the cloning and to determine levels of some genes during infection and after different treatments. PCR 
reactions were performed in a final volume of 25 or 50 μl, depending on the desired quantity of amplicon. 
For each reaction, we added 1x PCR reaction buffer for Taq DNA polymerase (10 mM Tris-HCl, 50 mM KCl, 
pH 8.3) supplied by the manufacturer (Roche), 2 mM MgCL2, 0.2 mM of each dNTP´s, 250 ng of each primer, 
0.5-1 ng template DNA and 1 U of Taq polimerase (Roche). Thermocycler programme differed depending on 
the product size and the melting Temperature of primers. When needed, PCR products were isolated in 
agarose gels and purified as described in section 3.4.2.  
 
In order to obtain fused sequences of two genes, we performed fusion PCR. This technique was used 
to produce the GFP-g5R sequences for generating HeLa stable cell lines. Fusion PCR is performed in two 
steps that allow us to generate, in the first step, the two products that are going to be fused and, in the 
second step, the fused product (full length sequence). Along with the 5´ and 3´primers that amplify the full 
product and included the enzyme restriction sites, it is needed 5´and 3´ “nexo primers” that contain the 
3´end of the first sequence and the 5´end of the second one (Figure 7). 
In the first stage, we performed two separately PCRs: one using the 5´primer with the restriction 
site, the 3´nexo primer and the DNA template of the gene that is going to be in the 5´end of the final 
product; and another reaction with the 5´nexo primer, the 3´primer with the restriction site and the DNA 
template that encodes the protein that is going to be fused in the 3´end of the final product. Once both 
products have been amplified and purified by agarose gel, we performed the fusion PCR. In this case, we 
mixed products to be fused with all PCR reaction components except primers, and programmed 
Materials and Methods 
73 
thermocycler with the following conditions: 1 cycle of 30 sec at 98ºC and 5 cycles with 3 temperatures (30 
sec at 98º C, 30 sec at 56ºC, 45 sec at 72º C).  
 
Figure 7. Schematic representation of generation of GFP-g5R products by fusion PCR 
To generate the GFP-g5R sequences, fusion PCR was carried out, since it permits to fuse two sequences in a unique product by two PCR steps. In this 
case, we used pEGFP-C2 and pCFP g5R wt, EEQQ or REGG as templates for GFP gene and g5R wt, g5R EEQQ, g5R REGG, g5R N-terminal, C-terminal or 
∆Nudix sequences, respectively. Primers used in each case are detailed on Table 3. In general, FW and RV primers containing an enzyme restriction 
site (ERS) bind the 5´end of GFP and the 3´end of g5R wt, g5R REQQ or g5R REGG in A), or the N-terminal or C-terminal domains of g5R in B), C) and 
D). On the other hand, Nexo primers are designed to contain 21 nt of both the 3´and 5´sequences of the genes to be fuse, and hybridize with the 
3´end of GFP sequence and the 5´end of the g5R sequences (g5R wt, g5R catalytic mutants or g5R domains). First PCR adds the ERS and the 
complementary 21 nt to each sequence, while second PCR permits fusion of both sequences by hybridization of complementary nucleotides and 
amplification of full product with FW and RV primers. Final product is directly cloned into the vector of interest after enzyme digestion. eGFP 
sequence is represented in green, g5R N-terminal in red, Nudix domain in purple and g5R C-terminal domain in yellow. FW: forward sequence; RV: 
reverse sequence; ERS: enzyme restriction site. 
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This PCR allows both products to merge and generate the full product. After that, we added to the 
reaction 5´and 3´primers containing the enzyme restriction sites, and performed a PCR to amplify full length 
product. After amplification, products were purified by agarose gel and cloned into pCDNA5/FRT/TO vector 
(Figure 7). 
 
To analyse and quantify the expression of different genes in the infection context and to determine 
which mRNA´s were bound to g5R protein, we achieved qPCR assays. We used MicroAmp® Optical 384-Well 
Reaction Plate with Barcode and Fast Syber Green Master Mix (Life Technologies) in all cases. To quantify 
expression of genes from cells extracts, we used 5 ng per reaction of cDNA as template (3 technical 
replicates for each sample); to quantify and analyse RNA bound to g5R proteins (detailed in further 
sections), we amplified all cDNA obtained after the IP. Total reaction volume was 10 μl in both cases. For 
each gene, we prepared a Master Mix with 1x Syber Green Master Mix and 0.25 mM forward and reverse 
primers. After preparing each reaction, plates were covered with MicroAmp Optical adhesive films (Life 
Technologies) and qPCR was run with the following conditions: 1 cycle of  20 sec at 95º and 40 cycles with 
two temperatures ( 10 sec at 95º C and 20 sec at 60ºC) in a ABI PRISM 7900HT SDS thermocycler (Applied 
Biosystems). The amplification cycles were followed by a dissociation cycle, which was used to determine 
the specificity of each product. Results were analysed with SDS program. In the case of RNA extracted from 
cells, values were normalized to 18S gene, while in RNA extracted from immunoprecipitated proteins, values 
were normalized to starting quantity of RNA (Input RNA). Experimental values are expressed as mean +/- 
standard deviation (S.D) or standard error of the mean (S.E.M), as indicated. Statistical analysis was 
performed by Student´s t test and statistical significance was set at p<0.05. 
 
With the purpose of generating two mutants of the catalytic domain of g5R (Parrish et al., 2009), we 
used Pfu turbo (Agilent Technologies) and DpnI (Stratagen) enzymes. In general, 210 ng of vector containing 
the gen to be mutated were mixed with 1x Pfu reaction buffer (supplied by manufacturer), 10 mM dNTP´s 
mix and 5 U of Pfu Turbo enzyme. This master mix was split in three tubes: we added 1 μl of 5´primer 
containing the single mutation to first tube; 1 μl of 3´primer containing the single mutation to second tube, 
and 1 μl of H2O as negative control in the last tube. These samples were subjected to 3 PCR cycles with 
following conditions: 1 min at 95º C, 1 min at 55º C and 8 min at 68º C. This process will ensure copy of 
5´and 3´chains of vector using mutated primers as initiators. After that, we mixed tube 1 and 2 and prepared 
a second PCR: 1 cycle of 1 min at 95º C, 18 cycles with 1 min at 95º C, 1 min at 55º C and 8 min at 68º C, and 
a final cycle of 10 min at 68ºC. This PCR reaction amplifies both chains of vector containing mutation. Final 
product was treated with 10 U of Dpn1 enzyme for 2h at 37º C, which eliminates the original methylated 
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non-mutated plasmid. Resultant construction was transformed by electroporation into BL21 cells and 
amplified to DNA extraction. Mutations were validated by sequencing. 
 
 
In this Thesis, the following E.coli strains were used: 
 DH5α: [F-, RecA1, hsdR17, (rK-, mK-), LacZY, argF, U169, supE44, thil, gyrA96, relA1]. This 
strain (Hanahan, 1983) was used for amplification and purification of all vectors except 
pCDNA5/FRT/TO plasmids, that were maintained in TOP10 cells and pCFP g5R EEQQ and 
pCFP g5R REGG, which were maintained in BL21 (DE3) cells. 
 TOP10 Chemically Competent cells: [F- mcrA Δ( mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
Δ lacX74 recA1 araD139 Δ(araleu)7697 galU galK rpsL (StrR) endA1 nupG] This strain was 
used for propagation of pCDNA5/FRT/TO vectors (Invitrogen). 
 BL21 (DE3): [F-  ompT hsdS(rB- mB-) gal dcm(DE3)]. Derived from BL21, this strain contains 
the RNA polymerase gene of T7 bacteriophage (Studier and Moffatt, 1986). Protein 
expression is induced by IPTG. This strain was used for expression and purification of 
recombinant GST-g5R protein and for amplification of pCDNA g5R EEQQ and pCDNA g5R 
REGG. 
 
All E.coli strains were cultivated in Luria-Bertani medium (LB) supplemented with Ampicillin or 
Kanamycin (both 100 μg/ml) depending on plasmid resistance gene. For amplification in solid phase, 
bacteria were seeded on the same medium supplemented with 1.5 % bacto – agar and 100 μg/ml of 
corresponding antibiotic. For preservation, bacteria were conserved in the same media with 50 % of glycerol 
at -70º C. 
 
Bacteria were transformed by different methods reliant on bacterial strain: 
 Heat shock transformation of DH5α strains: 100 μl of competent cells were mixed with 100-
250 ng DNA and maintained for 30 min at 4º C , then 1 min at 42º C and finally at 4º C. After 
transformation, bacteria were recovered in SOC media (2% tryptone, 0.5% yeast extract, 10 
mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose) at 37ºC with 
gentle shaking for 1 hour. After recovery, bacteria were cultivated O/N at 37º C in LB-agar 
supplemented with selection antibiotic. 
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 Heat shock transformation of TOP10 cells: 50 μl of TOP10 cells were mixed with 10 μl of DNA 
and put on ice for 5 min. After that, mixture was resuspended in 200 μl of SOC medium and 
cultivated O/N at 37º C in LB-agar supplemented with selection antibiotic. 
 Electroporation of BL21 strains: 30 μl of BL21 cells were mixed with 1.5 μl of vector an kept 
at 4º C for 1 min. After that, cells + DNA were placed in an electroporation cuvette (0.2 cm 
electrode) previously cooled on ice, ensuring that mixture displayed a continuous phase in 
the bottom of the cuvette. Cells were pulsed using following conditions: 2.5 kV, 200 Ω, and 
25 μF. After transformation, bacteria were recovered in SOC media at 37ºC with shaking 
during 1 hour. After recovery, bacteria were cultivated O/N at 37º C in LB-agar 
supplemented with selection antibiotic. 
For DNA plasmid rescue, we used two kits: for recovering low quantity of DNA we used Wizard Plus 
SV Miniprep DNA purification Systems (Promega), and for recovering high quantity of DNA we used Qiagen 
Plasmid Maxi Kit (Qiagen). In both cases, we followed manufacturer’s protocols. 
 
All the viral infections of this work were done with the viral strain BA71V (Enjuanes et al., 1976). 
HeLa and Vero cells infections were done in DMEM 2% FBS, while COS-7 cells were infected in DMEM 5 % 
FBS. Depending on the requirements of the experiment, from 1 - 5 M.O.I was used. In general, viruses were 
inoculated in ¼ of total volume of the plate to allow viral adsorption with gentle shaking. After 90 min at 37º 
C, virus inoculum was removed and infection progressed until indicated times post infection for each assay. 
Recovery was made in DMEM 2% FBS for HeLa and Vero cells, and in DMEM 5 % FBS for COS-7 cells. Cells 
not infected were called Mock, and were currently used as controls. 
 
Transient transfections were carried out with LipofectAMINE PLUS reagent system (Invitrogen) 
following manufacturer’s instructions. In general, 1 μg of DNA was transfected per 1 x 106 cells. DNA : 
LipofectAMINE : PLUS reagent rate was 1 : 10 : 2.5, respectively. DNA and PLUS reagent were mixed at room 
temperature for 15 min. After that, LipofectAMINE reagent was added over DNA – Plus complexes and 
allowed to mix for 20 min at RT. DMEM medium was removed and transfection inoculum was added to cells 
in a free FBS and antibiotic medium for 4.5 - 5 hours. Cells were recovered with DMEM 5 % FBS O/N. After 
16 - 24 hours, cells were infected and analysed at indicated times post infection or directly analysed by 
CLSM.  
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In order to study g5R function, 6 inducible HeLa cell lines were established expressing GFP tagged 
g5R proteins: HeLa GFP-g5R wt expresses GFP fused to g5Rp wild type form, HeLa GFP-g5R REGG and HeLa 
GFP-g5R EEQQ cell lines expresses GFP tagged to two punctual mutants of g5Rp catalytic Nudix domain 
(R146G/E147G and E150Q/E151Q) which lack the decapping activity in vitro (Parrish et al., 2009); HeLa GFP-
g5R N-term and HeLa GFP-g5R C-term produce GFP fused to the N-terminus and the C-terminus domains of 
g5Rp, respectively, and HeLa GFP g5R ∆Nudix synthetize GFP tagged to a variant of g5Rp that lacks the 
catalytic Nudix motif. 
To obtain this stable cell lines, HeLa Flp-in TREx cell lines (a kind gift from Dr. Matthias Hentze, 
European Molecular Biology Laboratory, Heidelberg, Germany) were required (Flp-In TREx Core Kit, 
Invitrogen). HeLa Flp-In TRex are HeLa stable host cell line previously transfected and selected to integrate 
into its genome a Flp Recombination Target (FRT) site and a copy of Tet repressor (Strein et al., 2014). The 
FRT sites allows integration of gene of interest in a specific genomic location, while the presence of Tet 
repressor ensures protein synthesis only in presence of tetracycline. To generate the HeLa Flp in TREx GFP-
g5R cell lines, pOG44 plasmid must be co-transfected with each pCDNA5/FRT/TO GFP-g5R constructions. 
While these vectors contain the gene of interest, pOG44 codifies to Flp recombinase, needed to insert this 
gene in the FRT genomic site. Co-transfections were realized using the Effectene Transfection Reagent 
System (Qiagen) following manufacturer´s protocol. Briefly, 300 ng pCDNA5/FRT/TO vectors were mixed 
with 500 ng pOG44 plasmid and the Enhancer reagent in a DNA: enhancer rate of 1 μg : 8 μL (Vf = 100 μl). 
After vortexing 1 min, 10 μl of Effectene reagent was added to the mixture. Resultant solution was 
incubated 5 - 10 min at RT and diluted in 500 μl medium before added to cells (40 - 50 % confluent). Next 
day, antibiotics for selection were added: 1/1000 Blasticidin S (InvivoGen) and 1/500 Hygomycin B 
(Invitrogen). Blasticidin was added to selection of cells that contain pCDNA5/FRT/TO vectors, while 
Hygromicyn ensured selection of cells with Tet Repressor. When cells reached 90 - 100 % confluence 
(normally one day after antibiotics addition), they were split into 15 cm2 dishes without antibiotics, and 
allowed to grow until colonies reach confluence. Antibiotics for selection were added one day after. Colonies 
grew for 5 days, and then were seeded into a 6 well plate without antibiotics. This protocol will completely 
separate cells and make them accessible for antibiotics, so most of them died at this stage. Antibiotics were 
added next day. When some colonies grew over each other (approx. 3 week after transfection) cells were 
transferred to 10 cm2 dishes and successively sub-cultured into these plates until all non-transfected cells 
died. Finally, positive cells were enriched by FACS sorting (approx. 4-5 weeks after transfection). FACS was 
done in the Flow Cytometry Core Facility of the European Molecular Biology Laboratory. Proteins of interest 
were induced adding 1/4000 Tetracycline (5 mg/ml) for 16 - 20 hours. HeLa eGFP and HeLa MOV10-YFP 
stable cell lines were used as negative and positive controls for RNA-proteins assays, and were a kind gift of 
Dr. Matthias Hentze (European Molecular Biology Laboratory, Heidelberg, Germany). 
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For generation of g5R Ba71V deletion mutant, p72∆g5RGAL10 T plasmid was transfected in COS-7 
cells with LipofectAMINE PLUs Reagent System as detailed before. 24 hours post transfection, cells were 
infected with 0.2 M.O.I of BA71V strain to permit homologous recombination between plasmid and viral 
genome. Infection was allowed to progress until 72 hours, and supernatant containing recombinant particles 
was recovered. These particles were used to infect new COS-7 cells in presence of 0.7 % agar - 2 x DMEM (8 
mM L-glutamine, 0.1 mg/ml gentamicine, 0.8 mM nonessential amino acids, 160 μg/ml DEAE dextran 
sulfate, 4 % FBS). 48 - 72 hours after infection, positive colonies were selected by adding X-Gal (75 mg/ml) 
Cells infected with recombinant virus expressed β-Galactosidase, which produces a blue product in presence 
of its substrate (X-Gal). Blue colonies were extracted from agar by aspiration and amplified in a new round of 
infection, being this successive round-process repeated until only blue colonies appeared in the infected 
plates. 
 
With the purpose of studying g5Rp function in ASFV infection, we first tried to silence expression of 
g5R gene using small interference RNAs (siRNAs). siRNAs used in this study are listened below: 
Target Probe Sequence Working concentration Technique Origin 
g5R mRNA  
sig5R-1 sense GACCGCAUGUGGUAUCAUATT 
40 mM Silencing BioNova 
sig5R-1 anti sense UAUGAUACCACAUGCGGUCTT 
g5R mRNA  
sig5R-2 sense CAGAUUCUCCCAGAGUUUATT 
40 mM Silencing BioNova 
sig5R-2 anti sense UAAACUCUGGGAGAAUCUGTT 
g5R mRNA  
sig5R-3 sense UCCUUGCAAUGUUAUGUAATT 
40 mM silencing BioNova 
sig5R-3 anti sense UUACAUAACAUUGCAAGGATT 
Table 4. siRNA used to silence g5R gene expression 
To transfect siRNAs we used the LipofectAMINE 2000 Reagent system, following manufacturer´s 
instructions. Briefly, 40 or 100 nM siRNA against g5R mRNA were transfected per 2x106 Vero cells 24 hours 
before ASFV infection. Previous to transfection, cells were cultivated 24 hours FBS free. Adsorption was done 
without siRNA, which was added after this process. siRNA transfection mix was left until samples were 
recovered. To corroborate the efficiency of silencing process, g5R mRNA levels were analysed by PCR or 
qPCR. Effect of g5Rp suppression on ASFV infection was studied by qPCR of representative viral and cellular 
mRNAs. GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) and RPL0 genes were used as calibrators, and 
Mock infected cells were used as normalizer. Experimental values are expressed as mean +/- standard 
deviation (S.D). Statistical analysis was performed by Student´s t test and statistical significance was set at 
p<0.05. 
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Related to their origin, RNA samples were extracted by two methods:  
 
Total RNA was extracted from cells with RNeasy Plus Mini Kit (Qiagen) following manufacturer´s 
instructions, and quantified with a Nanodrop NP-1000.  
 
After immunoprecipitation or GFP pull down (see sections below), RNA bound to proteins was 
extracted using phenol : chloroform : isoamil alcohol (PCI). In general, 1 vol. of PCI was added to the 
precipitated samples, vortexed 31 sec and centrifuged at maximum speed for 5 min (RT). Upper phase was 
recovered after centrifugation and combined with 1 vol. of chloroform : isoamil alcohol (CI), mixed and 
centrifuged in the same conditions. New upper phase is transferred to a clean eppendorf and incubated with 
2 μg glycogen, 1/ 10 from total volume of NaCl and 2.5 vol. 100 % cold ethanol O/N at -20º C. Next day, 
samples were centrifuged at 14,000 rpm for 20 min. Supernatant was discarded and pellet washed with 70 % 
cold Et-OH. Precipitated RNA is let to dry and resuspended in RNAses free water. Quantification was made 
by Nanodrop ND-1000. 
Isolated RNA was retrotranscribed to cDNA using Retrotranscriptase enzyme (Roche) following 
manufacturer´s instructions. In general, we retrotrancribed 1μg of RNA when it was extracted from cell 
lysate, and all available RNA when it was extracted from immunoprecipitated samples (IP). Purified RNA was 
incubated with 2.5 mM Oligo d(T)50 and 2 mM random primers at 65ºC for 10 min in order to eliminate 
secondary RNA structure and facilitate retrotranscription. Immediately after that, samples were mixed with 
10 mM dNTP´s mix, 1x retrotranscription buffer, RNAses inhibitors (RNAsin Plus, Roche) and 1 U 
Retrotranscriptase enzyme. Samples were incubated 30 - 40 min at 55º C and finally enzyme was inactivated 
5 min at 85º C. cDNAs were analysed by PCR or qPCR, depending on assays requirements.  
 
In order to determinate g5Rp expression and localization, we generated a specific anti-g5Rp serum. 
With this purpose, g5R gene was cloned in pGEX vector to generate pGEX-g5R wt, which was transformed in 
BL21 cells. To induce GST-g5R protein synthesis, BL21 were grown in low oxygen conditions O/N at 37º C. 
After 16 hours, samples were recovered and lysate in Buffer 6 (50 mM Tris HCL ph7.5; 0.5 M ClNa; 1mM 
EDTA; 7 mM β-2-Mercatptoethanol; 5 % glycerol). GST-g5R protein was purified using glutathione columns 
and eluted with Eluting Buffer (50 mM Tris HCl pH 8; 100 mM ClNa; 10 mM glutathione). Correct expression, 
solubility and purification of GST-g5Rp wt was analysed by Coomassie blue stain and Western blot using anti-
GST antibody.  
Materials and Methods 
80 
 
Figure 8. Schematic representation of generation of specific anti-g5R antibody. 
GST-g5R wt protein was produced in Escherichia coli, purified by glutathione sepharose columns and mixed with Freund´s adjuvant to be successively 
injected into rabbits. Prior to first injection, rabbit serum was extracted as negative control (previous serum). Specific anti-g5Rp serum was tested by 
Western blot and ELISA assays after third, fifth and seventh injections. Once serum was determinate as positive, further validation was carried out 
with immunoprecipitation (IP) and Mass Spectrometry assays. 
 
Once GST-g5Rp wt was purified, we proceed to generate the specific antibody: 500 μg of GST-g5Rp 
wt were complemented with 50 % complete Freund’s adjuvant (Sigma), sonicated (6 x 10 sec at 4º C) and 
subcutaneously injected to each of rabbit (1232 and 1233 rabbits). Previously to first injection, rabbit sera 
were extracted as negative control (previous serum 1232 or 1233). 15 days after first immunization, rabbits 
were subcutaneously re-injected with 250 μg each of GST-g5Rp wt and 50 % complete Freund´s adjuvant. 
Next injections were inoculated intramuscularly (250 μg of protein and 50 % incomplete Freund´s adjuvant) 
once per month until anti-g5Rp was generated (7 injections). To check anti-g5Rp reactivity, serum samples 
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were recovered from both animals after third, fifth and seventh boost, and tested by Western blot and ELISA 
(Figure 8). To further confirmation, g5Rp antibody was used on immunoprecipitation assays and the gel band 
obtained was sequenced by LC-MS/MS (Ion Trap). This analysis was carried out in the CBMSO Protein 
Chemistry Facility, a member of the ProteoRed network. 
 
In order to determine sensitivity of g5Rp antibody, ELISA was completed in a Linbro 96 (Nunc). In 
general, 50 ng of GST (positive control) or GST-g5R wt protein (antigen) were attached to wells surface and 
incubated O/N at 4º C. Plates were washed 4 times with PBS 1x - 0.05 % Tween 20 and incubated with 
consecutive dilutions (1/100) of previous serum (negative control), anti-GST (positive control) or anti-g5Rp 
serum for 1h at 37ºC. After 4 washes with PBS 1x - 0.05 % Tween 20, plates were incubated with anti-rabbit 
or anti-mouse peroxidase antibodies (1h, 37º C). To eliminate excess of secondary antibodies, plates were 
washed 3 times with same solution. After final wash, plate was developed adding OPD reaction buffer: 2 
mg/ml OPD, citrate buffer (20 mM acetic acid,50 mM sodium phosphate, pH 5) and 30% H2O2. Reaction was 
stopped with 3 N SO4H2 when colour appeared, and absorbance values were measured in an EL 340 
Biokinetics Microplate Reader (BIO-TEK Instruments). Optimum working antibody concentration was then 
calculated.  
 
Total protein extracts were obtained from infected and non-infected cells as follows: seeded cells 
were harvested using a piston and then washed twice with cold PBS. Samples were lysate in modified RIPA 
buffer (mRIPA) containing 50 mM Tris-HCl pH 7.5; 1 % Nonidet NP-40; 0.25 % sodium deoxycholate; 150 mM 
NaCl, 1mM EDTA and 1x proteases inhibitors (c0mplete Mini, EDTA free protease inhibitor cocktail tablets, 
Roche) and 1 x phosphatases inhibitors (PhosSTOP EASY pack, Roche). To facilitate lysis, after mRIPA 
addition extracts were incubated at 4ºC for 5 min. Samples were processed or stored at -20 ºC, depending 
on the assay. For analysis, samples were centrifuged 5 min at 14.000 rpm to eliminate cellular DNA. 
Quantification of total protein was done using the Bicinchoninic acid (BCA) Protein Assay Kit (Pierce) 
following manufacturer´s protocol. For protein electrophoretic separation assays, 10 - 60 μg total proteins 
were mixed with Laemmli buffer (ref) and boiled at 95º C for 5 min. After centrifugation, extracts were 
separated by electrophoretic mobility in sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) in reductive 
conditions. Percentage of acrylamide varied between assays depending on proteins molecular weights. 
 
After electrophoretic resolution, proteins were non-specifically dyed with Coomassie brilliant blue. 
Gels were incubated for 20 min with Coomassie solution (10 % acetic acid, 25 % isopropanol and 0.1 % 
Coomassie Blue R250) to protein staining. For distaining, gels were washed with 10 % acetic acid - 20 % 
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ethanol solution until bands were distinguished. For storage and analysis, gels were dried in a DryGelSr 
(Hoefer Scientific Instruments). 
 
Alternatively to the Coomassie staining, polyacrylamide gels were dyed with silver staining solution. 
After electrophoretic resolution, gels were fixed with 30 % ethanol and 10% acetic acid during 15 min and 
thus, incubated with Sensitizing Solution (30 % ethanol, 5 % sodium thiosulfate, 7 % p/v sodium acetate, 
0.125 % glutaraldehyde) during 30 min. After sensitization, gels were washed three times for 1 min with 
distilled H2O and incubated with Staining solution (2.5 % p/v silver nitrate, 0.15 % formaldehyde), and, after 
that, gels were washed twice for 1 min with distilled water and the Developer solution was added (0.04% 
Formaldehyde, 2% Sodium Carbonate). The reaction was stopped with Termination solution (1 % acetic acid) 
when protein bands were detected.  
 
Following separation, proteins were electrophoretically transferred to Inmobilon-P membranes 
(Millipore). Blocking was made incubating membranes with methanol and letting them dried (30 min). 
Membranes were then incubated with primary antibodies diluted in blocking solution (1 % non-fat-dry-milk 
in TBS) at 4º C O/N. After washing 5 min with TBS 1x, peroxidase secondary antibodies were added in 
blocking solution 1h at room temperature. Antibodies dilutions are indicated in Table 1. For detection of 
band of interest, we used the chemiluminescent ECL Western blotting Analysis System (Amersham 
Pharmacia), following manufacturer´s instructions. Light was captured by photographic films (Agfa) and 
signal was analysed by densitometry when required.  
 
In order to study protein synthesis, we performed 35S metabolic labeling assays. Vero cells were 
infected or non-infected with ASFV (M.O.I = 5 pfu/cell) and harvested at indicated times post infection. 2 
hour prior to recovering samples, monolayer was incubated with 200 μCi 35S-methionine, which was 
incorporated to proteins synthetize de novo. Samples were resuspended on mRIPA buffer and labeled 
protein levels were analysed by SDS-PAGE. Gels were dried in a DryGelSr and radioactivity signal was 
captured by direct contact of gels with photographic films at -80º C. 
 
With the purpose to study RNA-protein interactions we used cCl and PAR-CL techniques, two UV 
light irradiation methods which fix these interactions only when contact is direct and do not cause protein-
protein connections (Pashev et al., 1991). Crosslinking methods used in this project are detailed below: 
Materials and Methods 
83 
 
Conventional crosslinking triggers covalent bound of natural photo-reactive nucleotide bases to 
specific amino acids (Phe, Trp, Tyr, Cys, and Lys) when samples are irradiated with 254 nm ultraviolet (U.V) 
light (Brimacombe et al., 1988). For cCL, cell monolayer was washed twice with RT PBS and then U.V 
irradiated at 256 nm (0.15 J/cm2) on ice and in absence of PBS. It is especially important no trace of medium 
or PBS remain at the dish when irradiated as it could interfere with crosslinking. Immediately after 
crosslinking, cold PBS was added to cells, which are maintained at 4º C until collection. Crosslinking was 
made in a SpectroLinker XL-1000 or XL-1500 (Spectronics Corporations). 
 
PAR-CL requires incorporation of the photoactivatable analogue nucleotide 4-thiouridine (4-SU, 
Santa Cruz) into nascent RNA, which is coupled to amino acids when excited at 365 nm UV (Hafner et al., 
2010). PAR-CL has been made following previous described protocols (Castello et al., 2012; Strein et al., 
2014): 100 μM 4-SU was added to plates for 2 to 16 hours. Incubation time varied related to experimental 
procedure (see section 1.20.1). After PAR-CL, samples were recovered following same protocol as for cCL: 
cells were washed with pre-warmed PBS, 365 nm UV irradiated with 0.15 J/cm2 (SpectroLinker XL-1000 or 
XL-1500, Spectronics Corporations) and maintained in cold PBS at 4º C until processing. 
 
With the aim of studying protein-protein and RNA-protein interactions, different 
immunoprecipitations assays were carried out. We used different techniques that we have classified by 
beads type. 
 
Two methods were developed to studying RNA-protein interaction based on the use of GFP_Trap_A 
beads (Chromotek) (Rothbauer et al., 2008). These beads are covalently bound to a small GFP-binding 
protein that allows an efficient in one step purification of GFP-fused proteins.  
3.21.1.1 Dual fluorescence method 
We used the protocol previously described in (Strein et al., 2014). 12 x 106 - 25 x 106 HeLa stable cell 
lines were induced with 1 μg/mL tetracycline (tet) for 20 hours before harvesting. Samples were 
conventional or PAR crosslinked (as described before) and resuspended in 300 μL of GBP lysis buffer (100 
mM KCl, 5 mM MgCl2, 10 mM Tris pH 7.5, 1% NP40, 1 mM DTT, 100 units/mL RNAsin [Roche], 1× 
phenylmethylsulfonyl fluoride (PMSF, Roche), and 200 μM ribonucleoside vanadyl complex [NEB]). Samples 
were incubated 5 min at 4º C, subjected to a frozen cycle to favoured lysis, centrifuged 10 min at 10.000 rpm 
to eliminate cellular debris and distributed to three tubes for technical replicates. As negative control, ½ of 
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total sample was treated with RNAses A and T1 before immunoprecipitation. In order to avoid unspecific 
binding to beads, each replicate was mixed with dilution buffer (500 mM NaCl, 1 mM Mg2Cl, 0.05% SDS, 
0.05% NP-40, 50 mM Tris-HCl pH 7.5, 100 units/mL RNAsin, 1× PMSF, and 200 μM ribonucleoside vanadyl 
complex) and incubated with 10 μL of GFP-Trap_A beads for 4 h at 4º C with rotation. After incubation, 
samples were washed with medium salt wash buffer (250 mM NaCl, 1 mM Mg2Cl, 0.025% SDS, 0.05% NP-40, 
20 mM Tris-HCl pH7.5) and treated with blocking buffer (200 mM LiCl, 20 mM Tris pH 7.5, 1 mM EDTA, 
0.01% NP40, 100 μg/mL Escherichia coli tRNA, 100 μg/mL BSA) for 15 min at 4º C with rotation. After 
blocking, beads were incubated for 1h at 4 º C with Hybridization buffer (500 mM LiCl, 20 mM Tris pH 7.5, 
0.05% LiDS, 1 mM EDTA, 5 mM DTT, 0.01% NP40, 100 units/mL RNaseOUT) supplemented with 40 nM of 
Oligo d(T)25-Tred (Sigma). To remove unspecific bound probe, samples were washed as described below: 
 Once (2 min) with High salt wash buffer (500 mM LiCl, 20 mM Tris pH 7.5, 0.01% LiDS, 0.01% 
NP40, 1 mM EDTA, 5 mM DTT). 
 Twice (2 x 2 min) with Medium wash salt buffer (200 mM LiCl, 20 mM Tris pH 7.5, 0.01% 
LiDS, 0.01% NP40, 1 mM EDTA, 5 mM DTT). 
All buffers described before were supplemented with RNAsin (1/500) and 1 x PSMF. After final wash, 
beads were transferred to a 96-well optical plate (CBG Thermo scientific, NUNC) and GFP an Texas-Red 
signals were measured in a TECAN Safire II microplate reader following these parameters: for GFP, excitation 
was made at 490 nm and emission was recovered at 515 nm; and for Texas Red, excitation was made at 590 
nm and emission was recovered at 616 nm. Experimental values are expressed as mean +/- standard 
deviation (S.D). Statistical analysis was performed by Student´s t test and statistical significance was set at 
p<0.05. Data shown proceed from at least three replicates. 
As commented in section 3.20, crosslinking is a useful and specific method to fixed RNA-protein 
interactions, but it has been described that, due to its chemical differences, cCL and PAR-CL could affect 
efficiency of protein capture process, being some proteins more effectively captured by cCL or PAR-CL 
(Castello et al., 2012). For this reason and in order to achieve the best results in the GFP-g5Rp 
immunoprecipitation assays here described, we optimised both crosslinking techniques. HeLa MOV10-YFP 
was used as positive control, as MOV10 is a well-known RNA binding protein (Gregersen et al., 2014). HeLa 
GFP-g5R wt, HeLa MOV10-YFP and GFP g5R EEQQ were induced O/N with tetracycline and subjected to cCL 
or PAR-CL as indicated in Figure 9. Cells were recovered and treated to dual fluorescence analysis as 
described in this section. We observed that both GFP-g5R proteins were more efficiently 
immunoprecipitated by PAR-CL, and consistently more RNA was detected bound with PAR-CL technique. 
Due to these results, we decided to carry out all dual fluorescence experiments with PAR-crosslinking (Figure 
9). 
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Figure 9. Optimization of the immunoprecipitation of GFP-g5R complexes. 
PAR-Crosslinking and conventional Crosslinking techniques were tested in order to determine which method was more optimum for the 
immunoprecipitation of GFP-g5Rp complexes. HeLa GFP-g5R wt and GFP-g5R EEQQ lines were induced and RNA-protein interaction were fixed by 
PAR CL and cCL respectively. GFP fusion proteins were immunoprecipitated using GFP_Tap_A beads and both GFP (A) and Texas Red signals (B) were 
measured in a TECAN Safire microplate reader. Data is represented in arbitrary units. Error bars: mean +/- S.D. (n = 3). 
3.21.1.2 Immunoprecipitation and RT-qPCR analysis 
In order to analyse g5Rp-RNA interaction in the context of infection, we optimised the GFP Trap_A 
beads immunoprecipitation protocol: after immunoprecipitation, RNA was extracted from the protein 
complexes and analysed by RT-qPCR. As explained before, 4-SU is a ribonucleoside analogue that 
incorporates to nascent RNA, having a possible undesirable effect on some cellular processes (Burger et al., 
2013). To assess this possibility, Hela GFP g5R wt cells were subjected to two different 4SU treatments: first, 
4SU was added 2 hour prior tet induction, and second, 4-SU was added after viral adsorption (Figure 10 A). 
In both cases, HeLa GFP-g5R wt cells were induced O/N with tet and Mock infected or ASFV infected M.O.I of 
5 pfu/cell. Cells were PAR-crosslinked and samples were collected at 6 and 14 hpi to analyse the viral 
proteins level by Western blot. By using the anti - tASFV serum, ASFV proteins were detected, showing that 
some late viral proteins expression (as p17 or p24) was affected by 4SU presence at 14 hpi (Figure 10 B). To 
further validate these results, we also tested ASFV infection in 4-SU presence or absence in Vero cells by 
Western blot. In this case we checked viral infection by detecting the early viral protein p32 and the late viral 
protein p72. We observed that 4-SU had an effect on synthesis of the late viral protein similar to that 
detected on HeLa cells (p72) (Figure 10 C). Due to this undesirable effect of 4SU, we decided to carry out the 
cross linking experiments in ASFV infection by using the conventional cross linking method. 
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Figure 10. Effect of 4 -SU in ASFV infection. 
In order to test the side effects of the 4-SU presence in ASFV infection, two different experimental procedures were carried out. In the first (A) HeLa 
GFP-g5R wt stable cell line was treated with 4-SU 2 hours prior to induction of the recombinant GFP-g5R wt protein with tetracycline (tet), and 
samples were recovered at the indicated times post infection. A schematic representation of the experimental procedure is shown in the upper 
panel. ASFV protein levels were analysed by Western blot using a specific serum able to recognise viral proteins induced with the infection (anti-
ASFV) (bottom panel). In the second approach (B) 4-SU was added to HeLa GFP-g5R wt expressing cells together with the viral inoculum (18 hours 
after the induction with tetracycline). A schematic representation of the experimental procedure is shown in the upper panel. ASFV protein levels 
were analysed by Western blot using the serum anti-ASFV (bottom panel). In both cases, actin was used as loading control .C) In order to validate the 
previous results, COS-7 cells were Mock-infected or ASFV-infected in the presence or the absence of tetracycline and 4-SU. ASFV p72 and p32 protein 
levels were analysed with specific anti-p72 and anti-p32 antibodies, respectively. 4-SU: 4-thiouridine. 
 
12 x 106 HeLa eGFP, 24 x 106 HeLa MOV10-YFP and 48 x 106 HeLa GFP g5R wt cells were induced for 
protein expression with tetracycline (0.6 μg/ml and 1.2 μg/ml, respectively) for 20 h, conventional 
crosslinked and harvested as described before. In this case, cells were resuspended in 0.3 - 1.2 ml of lysis 
buffer (100 mM KCl, 5 mM MgCl2, 10 mM Tris pH 7.5, 0.5 % NP40, 1 mM DTT, 100 units/mL RNAsin, 1× PMSF 
and 200 μM ribonucleoside vanadyl complex). After mixing with dilution buffer (500 mM NaCl, 1 mM Mg2Cl, 
0.05% SDS, 0.025% NP-40, 50 mM Tris-HCl pH 7.5, 1/500 RNAsin, 1× PMSF, and 200 μM ribonucleoside 
vanadyl complex), 10% of sample was removed as Input and stored at 4º C until RNA extraction. Samples 
were incubated with 20 μl of GFP-Trap_A beads for 4 h at 4º C with rotation, and washed as follows: 
 Once (2 x 2 min) with Wash buffer 1 (500 mM NaCl, 1 mM MgCL2,20 mM pH 7.5 Tris -HCl, 
0.025% NP-40, 1 / 500 RNasin and PMSF). 
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 Twice (2 x 2 min) with Wash Buffer 2 (250 mM NaCl, 1 mM MgCL2, 20 mM pH 7.5 Tris HCl, 
0.025% NP-40, 1 / 500 RNasin and PMSF). 
 Twice (2 x 2 min) with Wash Buffer 3 (150 mM NaCl, 1 mM MgCL2, 20 mM pH 7.5 Tris HCl, 
0.025% NP-40, 1 / 500 RNasin and PMSF). 
After final wash, 3 μl of sample were removed to check immunoprecipitation efficiency by Western 
blot. To elute immunoprecipitated proteins, beads were mixed with 2x Laemmli buffer and boiled 5 min at 
95º C. After centrifugation, supernatant was recovered and the process was repeated to ensure all proteins 
were extracted from beads. Samples were analysed by Western blot using anti-GFP as detector. Elution of 
RNA-protein complexes was made by direct treatment of beads with proteinase K: beads were incubated 
with 1 x Proteinase K buffer (50 mM Tris HCl pH 7.5, 750 mM NaCl, 1 % SDS, 50 mM EDTA, 2.5 mM DTT and 
25 mM CaCl2) and 10 μg Proteinase K in a final volume of 100 μl for 1h at 37º C with strong shaking. RNA was 
extracted from immunoprecipitates with phenol:chroloform:isoamil alcohol (See section 3.15.2) and 
analysed by qPCR as described in 3.7.3 section. In general, immunoprecipitated eGFP was used as calibrator, 
and samples were normalized to total RNA (Input). Experimental values are expressed as mean +/- standard 
error of the mean (S.E.M) and proceeded from three independent experiments. Statistical analysis was 
performed by Student´s t test and statistical significance was set at p<0.05. 
 
Agarose beads immunoprecipitations were used to study protein - protein interactions. 106 Vero 
cells were infected or non-infected (Mock) with ASFV (M.O.I = 5 pfu/cell) and lysate at indicated times post 
infection with mRIPA buffer containing 5 - 10 μg of specific antibody. For immunoprecipitation, each sample 
was incubated with 20 μl of equilibrated A/G or G agarose beads O/N at 4º C with gentle shaking. Next, 
samples were 6 times washed with PBS 1x - 0.05 % NP-40 and proteins were eluted by adding 2 x Laemmli 
buffer. Eluted proteins were then boiled 5 min at 95º C and centrifuged. Supernatant was removed and 
process was repeated twice to ensure all proteins were extracted. Finally, protein interactions were analysed 
by Western blot. 
 
In order to determine proteins that could interact with g5Rp, pulldowns assays were performed. GST 
or GST-g5R wt proteins were expressed in E.coli and purified by glutathione beads. After that, both proteins 
were incubated with Vero cells Mock-infected or ASFV-infected at 6 hpi or 16 hpi. After intensive washing, 
GST complexes were resolved by SDS-PAGE electrophoresis and peptides were sequenced by Mass 
Spectrometry (a work realised by the Proteomics Core Facility of CBMSO). Identification of the peptides 
were performed comparing sample peptides to UniProt ASFV-Ba71V data base (in order to identify viral 
proteins) or to UniProt Primates data base (in order to identify cellular proteins).  
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FACS technique was carried out with the purpose of studying protein expression in the context of 
ASFV infection. Cells were harvested and centrifuged at 2000 rpm at 4ºC for 5 min, washed twice with cold 
1x PBS and fixed for 30 min in 2 % paraformaldehyde (PFA) at 4º C. After that, cells were washed again 3 
times with PBS and permeabilized with Staining buffer (0.2 % saponin; 5 % BSA; 1 x PBS) for 15 min at RT. 
Primary antibodies were added to cells diluted (Table 1) in Staining buffer and incubated for 30 min at RT in 
absence of light. After one wash with staining buffer, cells were incubated at the specific dilution (Table 1) 
with secondary antibodies in same conditions settle for primary antibodies. Finally, samples were washed 
twice and protein presence was analysed in 2 x 106 cells in a FACSCalibur (BD Science). Experimental values 
are expressed as mean +/- standard deviation (S.D) or standard error of the mean (S.E.M), as indicated. 
Statistical analysis was performed by Student´s t test and statistical significance was set at p<0.05. 
 
In order to check GFP fusion proteins induction after tetracycline addition in HeLa stable cells lines 
or to corroborate transient transfections with eGFP constructions, cells were analysed in a Nikon 
microscope, which possess a fluorescence lamp. Photos were taken with a Nikon DSQ1 Mc camera attached 
to microscope and analysed with NIS-Elements F 3.2 program.  
 
To study protein interactions, expression and localization, we used immunofluorescence techniques. 
Cells were seeded on cover glasses, and either induced or transient transfected, or infected at indicated MOI 
and harvested at corresponding times post infection. Cell monolayer was washed 3 times with cold 1 x PBS, 
fixed with 4 % paraformaldehyde for 20 min at RT and washed again to eliminate PFA residues. Cells were 
permeabilized for 30 min with 0.2 % Triton X-100 PBS and blocked with 1 % BSA - PBS for 30 min to avoid 
unspecific interactions. Primary antibody was added diluted in 5 % BSA in PBS (Table 1) and incubated for 1h 
in absence of light at RT. Cells were washed 3 times with PBS and treated with fluorescent secondary 
antibodies. These antibodies were selected by its reactivity to primary antibodies specie. After successive 
washes with distilled water and ethanol, cover glasses were fixed to microscope slides with Prolong Gold 
(Invitrogen) or DAPI-fluoromount-G (SouthernBiotech) and analysed by CLSM.  
 
To analyse RNA expression, localization and RNA-protein interactions, we performed FISH technique. 
Cells were fixed with 4 % PFA and permeabilized with 0.2 % Triton-X 100 as described to 
Immunofluorescence and then washed with 1 x PBs to eliminate any detergent residues. Instead to blocking 
buffer, cells were washed once with 1 x SSC buffer (150 mM NaCl; 15 M sodium citrate pH 7.0) and once 
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with 2x SSC buffer. Cells were then incubated with Pre-Hybridization buffer (2x SSC, 20 % formamide; 0.2 % 
BSA, 1mg/ml yeast tRNA) for 15 min at37º C and next treated with Hybridization buffer, (Pre-Hybridization 
buffer plus 10 % dextran sulphate) and 1 μM fluorescein tagged probe for 4 h at 37º C. Once probe 
hybridized, samples were washed successively for 5 min at 42º C with 2x SCC - 20 % formamide, 2 x SSC, 1x 
SSC and finally with PBS. When protein detection was required, we proceeded to incubation of primary 
antibodies. We followed protocol for Immunofluorescence (described in section 3.25) but antibody 
incubations were made only in 1 x PBS. After primary and secondary antibodies incubations, cells were 
washed with PBS, fixed to microscope slides as describe before and analysed by CSLM. 
 
In this Thesis, two confocal systems were used: Zeiss LSM 710 Confocal Laser Scanning Microscope 
System coupled to a vertical AxioImagerM2 microscope (vertical LSM710) and Zeiss LSM510 META Confocal 
Laser Scanning Microscope System coupled to an inverted Axiovert200 microscope (LSM 710). Election of 
confocal microscope system was made in relation to the number of signal channels we needed to use (3 to 
LSM510 META and 4 to vertical LSM710). In general, laser conditions were adjusted using Mock cells as 
negative control and images were taken in a single plane with a 63 x objective and processed with ImageJ 
software. When required, quantification of intensity of signal was also analysed using ImageJ software. 
Experimental values are expressed as mean +/- standard deviation (S.D) or standard error of the mean 
(S.E.M), as indicated. Statistical analysis was performed by Student´s t test and statistical significance was set 
at p<0.05. 
 
With the aim of analyse the translation stage of infected and non-infected cells, polysome profile 
was performed. Protocol has been previously described in (Martinez-Azorin et al., 2008): 1 x 106 Vero cells 
were infected or non-infected with ASFV and samples were collected at indicated times post infection. Cell 
monolayer was removed with a scraper, centrifuged at 2,000 rpm for 5 min, washed with PBS supplemented 
with 100 μg/ml of cicloheximide (CHX) and resuspended in lysis buffer (15 mM Tris-HCl pH 7.5, 80 mM KCl, 5 
mM MgCL, 1 % Triton X-100, 1 % NP-40, 100 μg/ml CHX, 40 U/ml RNAsin and 1 x protease inhibitors 
cocktail). For polysome profile, 10 % to 50 % sacarose gradients were made by mixing 10 % and 50 % 
sacarose solutions in a gradient former. Both sacarose solutions were made by solving 10 mg or 50 mg of 
sacarose in buffer A (10 mM Tris HCl pH 7.4, 80 mM KCl, 10 mM MgCl2). Before gradient generation, these 
solutions were autoclaved and supplemented with 100 μg/ml CHX. Samples were loaded on top of sucrose 
gradients and centrifuged for polysome separation at 39,000 rpm for 2.5h at 4º C in a SW40 Ti rotor 
(Beckman Coultier). Gradients were fractionated in an ISCO density-gradient fractionator and polysome 
profile was obtained by continuous measurement of 260 nm absorbance in a ISCO UA-5 UV monitor. Data 
was collected by PicoLog software. 
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To study g5Rp homology sequence, we used Clustal Omega software, from EMBL-EBI platform 
(European Bioinformatics Institute). We analysed g5R amino acidic sequence comparing it with other 
described eukaryotic and viral decapping enzymes: human Dcp2, S.pombe Dcp2, S cerevisiae Dcp2 and D9 
and D10 from vaccinia virus. 
For tri-dimensional structural prediction and electrostatic surface representation of g5Rp, we used 
PyMol software (Schrödinger). Structural prediction was made based on S.pombe Dcp2 crystal structure (She 
et al., 2006). 
 
  
 
 
 
  
Results 
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As explained in Introduction section, the majority of viruses manipulate host gene expression in 
order to efficiently synthetize viral proteins, while impair cellular protein synthesis (Bushell and Sarnow, 
2002; Narayanan and Makino, 2013; Reineke and Lloyd, 2013; Schneider and Mohr, 2003). This phenomenon 
is called cellular shutoff. Viruses accomplish this singularity by numerous mechanisms: from viral 
endonucleases that eliminate cellular mRNAs (alpha-herpesviruses, gamma-herpesviruses, influenza viruses 
or SAR coronavirus (Abernathy and Glaunsinger, 2015)), to proteases that cleave eukaryotic initiation factors 
to difficult cellular protein synthesis while facilitate viral protein expression (picornaviruses, calciviruses or 
retroviruses (Castello et al., 2006; Lloyd, 2006)). 
 
It has been previously demonstrated that ASFV induces a strong cellular shutoff (Castello et al., 
2009b; Rodriguez et al., 2001), but the molecular mechanisms by which this important regulatory step is 
achieved remain elusive. In order to study that process, we analysed protein synthesis by incorporation of 
35S-methionine in ASFV-infected Vero cells.35S-methionine was added to cells 2 hours prior to sample 
collection at 8, 18, 24 and 40 hpi. Samples were lysed in modified RIPA buffer and protein levels were 
analysed by SDS-PAGE. We observed that, during ASFV infection, cellular protein synthesis was inhibited 
from 8 hpi and completely abolished at 24 hpi, concomitantly with an increment of viral protein synthesis 
(Figure 11 A). To determine if the previous result was due to a defect in translation rate, we analysed the 
polysome profile of Mock-infected and ASFV-infected Vero cells. Polysomes are mRNAs interacting with two 
or more ribosomes, and, in this kind of analysis, de novo protein synthesis is represented by the number and 
amount of ribosomes found within the polysomal mRNA fraction (Figure 11 B and (Martinez-Azorin et al., 
2008)). Mock-infected and 14 hpi ASFV-infected Vero cells (M.O.I = 5 pfu/cell) were washed and lysate in 
presence of 100 μg/ml cycloheximide (CHX), an inhibitor of proteins synthesis which blocks the elongation 
step of the translation process and causes ribosomes stall into mRNA (Schneider-Poetsch et al., 2010). This 
treatment allows polysome analysis in sacarose gradients (Martinez-Azorin et al., 2008). After high speed 
centrifugation, these gradients were examined in a polygraph and densitometry values were read at 260 nm. 
We observed that ASFV infection promoted a reduction in the total amount of polysomes (calculated as the 
area under the polysome fraction) but not in the polysomes number (calculated as the number of peaks in 
this fraction), which suggests that ASFV infection triggers a decrease on the rate of translation initiation 
(Figure 11 B). Indeed, when we calculated translation efficient rate in Mock-infected and ASFV-infected cells, 
we observed a slightly reduction induced by the infection (Figure 11 C). These results point to a decrement in 
protein synthesis as responsible of the cellular shutoff observed during ASFV infection. 
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Figure 11. ASFV infection promotes cellular shutoff and a decrease on the initiation translation rate. 
A) Analysis of cellular protein synthesis during ASFV infection by metabolic assay. Vero cells were Mock-infected or ASFV infected with M.O.I of 5 
pfu/cell and 35S-methionine was added to cells 2 hours prior to sample collection at 8, 18, 24 and 40 hpi. Samples were lysed in modified RIPA buffer 
and protein levels were analysed by SDS-PAGE. B) Polysome profile analysis. Vero cells were Mock-infected or ASFV-infected (M.O.I 5 pfu/cell) and 
samples were recovered at 14 hpi in presence of cyclohemide (100 μg/mL). Polysomes were fractionated in sucrose gradients and examined in a 
polygraph. Densitometry values were read at 260 nm and represented as a function of time (seconds,s). C) Translation efficient rate of samples 
described in B). Translation efficient rate was calculated as the ratio between the polysome fraction area and the 80S fraction area.  
 
After the previous results, we decided to analyse in deeply the cause of the cellular shutoff induced 
by ASFV. To explore this, we first analysed poly(A) RNA levels in infected cells by FISH. Vero cells were Mock-
infected or ASFV-infected with M.O.I of 5 pfu/cell and fixed at 8 and 16 hpi, then poly(A) RNA was detected 
with a fluorescein Oligo d(T) probe that specifically binds poly(A) RNA tails. To-Pro-3 was used to stain DNA 
and localize nucleus and viral factories (Figure 12 A). Poly(A) RNAs exhibited a diffuse pattern in the 
cytoplasm and a punctuated distribution in the nucleus of Mock-infected cells, whereas in infected cells, the 
Oligo d(T) signal was progressively clustered around the viral factory and increased in the nucleus (Figure 12 
A). These results could indicate that during ASFV infection poly(A) RNAs are being degraded in the cytoplasm 
and gathered in the nucleus. This nuclear increase is probably due to an impairment of nuclear export, in line 
with previously reported experiments showing that ASFV infection causes nuclear changes and partially 
supporting the idea of altered nucleus-cytoplasmic RNA carriage in ASFV infected cells (Ballester et al., 
2011). However, it could be also a consequence of the enhanced cytoplasmic RNA degradation rate triggered 
by ASFV, as occurs in other viral systems such as alpha- and gamma- herpesviruses or influenza viruses 
(Abernathy and Glaunsinger, 2015).  
In order to validate and quantify the decrease of poly(A) RNAs reported above, we further analysed 
some representative cellular mRNAs by RT-qPCR. Vero cells were Mock-infected or ASFV-infected (M.O.I = 5 
pfu/cell) and samples were analysed at the indicated times post infection (Figure 12 B). We observed a 
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significant decrease of all the analysed cellular mRNAs. Furthermore, at 14 hpi, mRNA levels were strongly 
reduced; correlating with the protein shutoff observed at 18 hpi in the 35S metabolic assays (Figure 12 B).  
 
Figure 12. Effect of ASFV infection on cellular and viral mRNAs. 
A) Analysis of poly(A) mRNA distribution during ASFV infection. Vero cells were infected with ASFV (M.O.I = 5 pfu/cell) and fixed to glass coverslip at 
indicated hours post infection (hpi). Poly(A) mRNAs were localized using a specific Oligo d(T) fluorescein tagged probe (green) and To-Pro-3 (blue) 
was used to stain viral and cellular DNA. Arrows show the viral factories. B) Quantification of the cellular mRNA levels during ASFV infection. Vero 
cells were infected with 5 pfu/cell and samples were recovered at different times post infection. After RNA extraction, cellular mRNA levels of 
representative genes were measured by RT-qPCR. RNA values (mean+/-S.D) were referred to Mock (n=3) *: p < 0.03 **:  p < 0.01 ***: p < 0.001. C) 
Quantification of the viral mRNA levels during ASFV infection. Vero cells were infected with 1 pfu/cell and samples were recovered at different times 
post infection. After RNA extraction, mRNA levels of viral representative genes (CP204L, A238L, A224L and B646L) were measured by qRT-PCR. RNA 
values (mean+/-S.D) were referred to Mock (n=2). 
 
Next we analysed representative early, early-late and late viral mRNA levels during ASFV infection. 
On the contrary to cellular mRNAs, viral mRNAs importantly increased during the infection. In this respect, 
mRNA from the early protein p32 (CP204L gene (Prados et al., 1993) ) displayed its maximum expression at 
6hpi (Figure 12 C, left panel), mRNA from the viral protein A238L began its expression at early times post 
infection but raised its maximum at later times post infection (Figure 12 C, middle-left panel (Granja et al., 
2006a)), and late viral genes such as A224L (Chacon et al., 1995) and B604L (p72 protein (Garcia-Escudero 
and Vinuela, 2000)) were expressed after viral replication (approximately 6-8 hpi) and raised its maximum at 
late times post infection (Figure 12 C, right panels). 
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Taken together, these results corroborate the previous data obtained in section 4.1.2, indicating 
that, during ASFV infection, degradation of cellular mRNA is activated, which produces a decrease of cellular 
protein synthesis at late times post infection. On the other hand, viral mRNAs are fully expressed and 
somehow excluded from this degradation by a still not fully understood mechanism.  
 
We demonstrated in previous section that despite mRNA levels decrease during the infection, a bulk 
of poly(A) mRNAs remains and is clustered around the viral factories (Figure 12). It has been previously 
described that in vaccinia infection, viral mRNAs are recruited to replication sites in order to promote and 
facilitate viral protein synthesis (Katsafanas and Moss, 2007). We hypothesise that ASFV could be using a 
similar strategy, and in order to explain the experimental observation described in 4.1.2, we analyse the 
location of viral mRNAs by FISH using FITC fluorescein probes that specifically recognise viral p72 and A224L 
mRNAs. Signals corresponding to p72 and A224L probes were mainly detected surrounding viral factories, 
while, as expected, no cytoplasmic signal in Mock-infected cells was detected (Figure 13). Considering that 
viral factory is a compartment in some way separated from the cytoplasm of the cell (Salas and Andres, 
2013), these images could indicate that viral mRNAs corresponding to late viral proteins are clustered close 
to viral replication sites, where they would be protected from cellular and viral mechanisms of degradation. 
 
Figure 13. Late viral mRNAs localize at the periphery of the viral factories. 
Vero cells were Mock-infected or ASFV-infected (M.O.I = 5 pfu/cell) and fixed at 16 hours post infection (hpi).Viral mRNAs were detected using 
specific fluorescein probes (green) against both viral p72 mRNA (upper panels) and A224L mRNA (bottom panels).Infection progress was tested in 
both cases using a specific antibody against the viral protein p72 (red). Cellular nucleus and viral factories were stained with To-Pro-3 (blue). Arrows 
show the viral factories. 
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After the findings presented above and due to the fact of ASFV encodes for a protein (g5Rp) that has 
been shown to display decapping activity in vitro (Parrish et al., 2009) we conjectured whether g5Rp could 
act as a viral decapping enzyme in vivo implicated in both the temporal regulation of viral genes and in the 
degradation of cellular mRNAs. 
 
ASFV Ba71V genome contains 150 ORFs encoding for numerous proteins (Dixon et al., 2013). One of 
them is g5Rp (D250R gene in Ba71V isolate), which possesses a canonical Nudix motif sequence (Cartwright 
et al., 2002; Parrish et al., 2009). In order to analyse the homology of Ba71V g5Rp Nudix motif with other 
well-known decapping enzymes, we aligned g5Rp Nudix amino acidic sequence with the corresponding 
Nudix motif of the human Dcp2 (hDcp2) and Nudt16 enzymes, yeast S.cerevisiae and S.pombe Dcp2 enzymes 
(SpDcp2 and ScDcp2) and the viral proteins D9 and D10 from vaccinia. We observed that g5Rp shares a 
minimum of 17% of identity with all the analysed sequences, sharing most similarities with Dcp2 from 
S.pombe (21.46 % of homology, Table 5 and Figure 14 A). Indeed, g5Rp not only possesses all the amino 
acids highly conserved among all these enzymes, but also shares structural homology with them: g5Rp 
structure could be predicted based on SpDcp2 crystal structure (Figure 14 B). Maximum structural 
similarities between both enzymes were found in the helix structure of the catalytic Nudix motif, while N-
terminal and C-terminal domains share lower similarities. These side domains of the Nudix motif are 
commonly implicated in regulation of the decapping activity and are less conserved in this kind of viral 
enzymes (McLennan, 2007). These results indicate that g5Rp possesses a conserved Nudix domain, signalling 
it as a possible ASFV decapping enzyme.  
 
Protein 
VACV 
D10 
VACV 
D9 
Human 
Nutd16 
ASFV 
g5Rp 
S.cerevisiae 
Dcp2 
human 
Dcp2 
S.pombe 
Dcp2 
VACV D10 100 23.79 15.44 16.49 18.81 12.87 18,81 
VACV D9 23.79 100 17.12 19.19 18.82 14.62 19,77 
Human Nutd16 15.44 17.12 100 17.61 16.77 16.35 18,87 
ASFV g5Rp 16.49 19.19 17.61 100 19.63 16.44 21,46 
S.cerevisiae 
Dcp2 18.81 18.82 16.77 19.63 100 26.96 29,86 
human Dcp2 12.87 14.62 16.35 16.44 26.96 100 37,5 
S.cerevisiae 
Dcp2 18.81 19.77 18.87 21.46 29.86 37,5 100 
Table 5. Percent identity matrix of ASFV g5R protein. 
The Nudix sequence of different decapping enzymes and ASFV g5R protein were aligned in order to determine g5Rp homology. Percentage of identity 
was extracted from the alignment using Clustal-Ω software.  
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Figure 14. ASFV g5R protein possesses a Nudix domain. 
A) Alignment of g5Rp Nudix motif sequence with other viral and eukaryotic conserved Nudix amino acidic sequences. Alignments were done with the 
Clustal-Ω software (EMBL). Colours represent the different characteristics of the amino acids: small and hydrophobic (red), acidic (blue), basic 
(magenta), Hydroxyl, sulfhydryl, amine or G residues (green) and others (grey). *: (asterisk) positions which have a single, fully conserved residue; : 
(colon) conservation between groups of strongly similar properties; . (period) conservation between groups of weakly similar properties. B) Structural 
prediction of g5R protein based in Dcp2 (Decapping Enzyme 2) of S. pombe. g5Rp structure is shown in pink and SpDcp2 structure is shown in green 
(left panel). g5Rp structure is represented alone in the right panel. The N-terminal domain, the C-terminal domain and the Nudix motif of the protein 
are shown in red, blue and green, respectively. 
 
In order to investigate the function of this protein, we first studied g5Rp expression in ASFV infected 
cells. With that purpose, we generated a specific anti-g5Rp serum by successive injection of purified GST-
g5Rp wt recombinant protein obtained from E.coli in two rabbits (1232 and 1233). Resulting serums were 
tested by Western Blot and ELISA (Figure 15 A), and its specificity validated by IP and Mass Spectrometry 
sequencing (data not shown). Both specific g5Rp serums recognized a protein with the expected size (30 
kDa) that was exclusively detected in ASFV-infected cells (Figure 15 B). To analyse the kinetic of expression 
of g5Rp during the infection, Vero cells were Mock-infected or ASFV-infected with M.O.I 5 pfu/cell and 
harvested at indicated times post infection. g5Rp levels were analysed by Western blot using the specific 
anti-g5Rp serum. Tubulin was used as loading control. We observed that g5R protein is expressed as early as 
4 hour post infection (hpi) and accumulates until late times post infection (24 hpi) (Figure 15 B).  
ASFV infection is characterized by a tune temporal regulation of viral gene expression, which allows 
transcripts to be classified as immediate early, early, intermediate or late depending on its distinctive 
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accumulation kinetics and on its expression in the presence of inhibitors of viral replication (reviewed on 
(Rodriguez and Salas, 2013). AraC is a cytosine analogue that possesses arabinose instead of the ribose 
motif. When added to cells, AraC incorporates to DNA and blocks replication, while in ASFV infected cells, 
AraC has been shown to impair viral replication, thus producing a loss of intermediate and late gene 
expression (Figure 15 C middle panels, Figure 15 D bottom panels and (Almazan et al., 1993; Rodriguez et al., 
1996)). Therefore, g5R mRNA and protein expression were tested in Mock-infected or ASFV-infected cells in 
the presence or absence of AraC. g5R protein and mRNA levels were analysed by Western Blot and RT-PCR, 
respectively. In these conditions, both g5R mRNA and protein were detected in the presence of AraC, 
indicating that g5Rp expression does not require viral replication and/or viral late protein expression (Figure 
15 C and D, upper panels). However, AraC presence also produced a slightly decrease in both protein and 
mRNA g5Rp levels, suggesting that g5R mRNA could be synthetized at two different times during ASFV 
infection. This is, in fact, a common feature of some early and immediate early ASFV genes (Rodriguez and 
Salas, 2013). 
 
Figure 15. g5Rp expression during ASFV infection. 
A) Specific serums raised against g5R protein were obtained by successive injection of the recombinant GST-g5R protein in two different rabbits 
(1232 and 1233) and titrated by ELISA. Previous serums from both rabbits (SP 1232 and SP 1233) were used as negative control (purple and blue). 
Specific anti-g5Rp serums form rabbits 1232 and 1233 are represented in green and orange, respectively. B) g5Rp is expressed at early time post 
infection and accumulates until late times post infection. At indicated times after infection, Mock-infected and ASFV-infected Vero cells (M.O.I = 5 
pfu/cell) were lysate in sample buffer and g5R protein levels were analysed by Western Blot (WB) using the specific anti-g5Rp serum (1233). Tubulin 
was used as loading control. C) and D). Vero cells were Mock-infected or ASFV-infected in the presence or the absence of the inhibitor of the viral 
replication, AraC (40 μg/mL). Samples were recovered at indicated times post infection to analyse g5R protein or mRNA levels by Western blot (C) or 
RT-PCR (D), respectively. In both cases, p32 (an early viral gene) and p72 (a late viral gene) protein or mRNA were used to confirm the effect of AraC, 
and actin was used as loading control. C) g5R protein levels were measured by WB using the specific anti-g5Rp serum, while p72 and p32 levels were 
analysed using specific antibodies. D) mRNA levels of g5Rp, p32 and p72 were measure by RT-PCR using specific probes. Data are representative 
images from two separate experiments. 
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Once we determined the kinetic of expression of g5Rp, we elucidate the subcellular distribution of 
the protein, to further study its role during the infection. Cartwright et al. previously suggested that g5Rp 
exhibits an endoplasmic reticulum (ER) pattern. To localize the protein, the authors used a construction that 
expresses g5Rp from Malawi ASFV strain tagged to the HA epitope under control of its own viral promoter 
(Cartwright et al., 2002). With the purpose of validate that suggestion in our conditions, we generated a 
similar construction to that mentioned above, which contains Ba71V g5R protein tagged to HA epitope 
under the control of viral g5Rp promoter (promg5Rp-HA), in such a way that ASFV infection is required to 
express the cloned g5Rp-HA. A schematic representation of this vector is shown in Figure 16 A. After 
transfection in COS-7 cells followed by infection with ASFV Ba71V (M.O.I = 5 pfu/cell) this construction 
allowed us to locate g5Rp in the context of the infection. We used a specific antibody that recognise the 
well-known ER protein calnexin (Tjoelker et al., 1994) to detect ER, and anti-HA antibody to localize g5Rp. At 
the indicated times post infection, cells were fixed and protein localization was analysed by 
immunofluorescence and CLSM. Mock cells were used as negative control. Progression of viral infection was 
assessed by the presence of the viral factories, which, together with cellular DNA, were stained with DAPI. 
We detected that g5Rp presented a similar distribution pattern to that displayed by calnexin during all the 
viral cycle, indicating that g5Rp exhibits ER localization, a fact possibly related to its function (Figure 16 B). 
Interestingly, g5Rp was accumulated to the periphery of the viral factories at late times post infection. ASFV 
infection leads to the collapse of ER (Andres et al., 1998; Windsor et al., 2012). Indeed, it has been previously 
described that viral membranes precursors are derived from the ER cisternae, which are recruited to the 
viral factory and later modified (Salas and Andres, 2013). This fact explains the presence of both calnexin and 
g5Rp at the periphery of the viral replication sites at late times post infection. To confirm our results, we 
further studied g5Rp location by analysing the distribution of g5Rp compared with the ASFV major capsid 
protein p72, which localizes at the viral factories (Epifano et al., 2006; Garcia-Escudero et al., 1998). We used 
the anti-g5Rp serum (1233) and a specific monoclonal anti p72 antibody to localize both proteins. As it is 
shown in Figure 16 C, at 16 hpi p72 was found within the viral factories, while g5Rp was located at the 
surroundings of these structures. Additionally, and in order to discard possible side effects of HA epitope, we 
analysed g5Rp-HA location using both anti HA and anti g5Rp specific antibodies by CSLM in ASFV-infected 
COS-7 cells (16 hpi). Both products co-localized precisely (Figure 16 D), indicating that HA flag did not 
interfere in g5Rp distribution. 
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Figure 16. Localization of g5R protein during ASFV infection. 
A) Schematic representation of the promg5R-HA plasmid used to localize g5Rp during ASFV infection. g5R sequence was cloned in frame with the 
Hemaglutinin (HA) epitope under the control of the g5R viral promoter. B) and D) COS-7 cells were transfected with promg5R-HA vector, infected 
with ASFV (M.O.I = 5pfu/cell) and fixed at indicated times post infection. B) Calnexin and g5Rp were localised using specific anti-HA (green) and anti-
calnexin (red) antibodies. The progress of the infection was checked by detecting the presence of the viral factories. Cellular and viral DNA was 
stained with DAPI (blue). C) g5R protein localizes on the surroundings of the viral factories in ASFV-infected COS-7 cells at late times post infection (16 
hpi). g5Rp and p72 locations were detected using anti-g5Rp (1233) and anti-p72 specific serums (green and red, respectively). D) HA epitope does not 
affect g5Rp distribution. g5Rp-HA location was analysed in ASFV-infected COS-7 cells (16 hpi) using both ant-HA antibody and the specific anti-g5Rp 
serum (1233). Arrows show the viral factories. Data are representative images from two separate experiments. 
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In order to analyse g5Rp function in vivo, we generated six stable HeLa Flip TREx cell lines that 
express GFP tagged to g5Rp wt form or different GFP-g5Rp variants. GFP-g5Rp REGG and GFP-g5Rp EEQQ 
possess single-site mutations in two different conserved glutamate residues of the g5Rp Nudix motif that 
make them unable to decapp in vitro (Parrish et al., 2009). With the aim of mapping the g5Rp functional 
domains, three additional variants of the protein were constructed. The constructions named GFP-g5R N-
term and GFP-g5R C-term contain only the g5Rp N-terminal or C-terminal domains, respectively. (We 
stablished both domains taking Nudix sequence as reference: N-terminal domain protein contains the 
sequence of g5Rp upstream of the Nudix conserved motif, while C-terminal domain protein covers the 
sequence downstream of the Nudix). The GFP-g5Rp ∆Nudix is a fusion protein that possesses both N-
terminal and C-terminal domains but lacks the g5Rp Nudix motif. A schematic representation of all 
generated constructions is showed in Figure 17 A and a more detailed description of the constructions can 
be found in Material and Methods section. 
 
 
Figure 17. Generation of stable HeLa cell lines GFP-g5Rp. 
A) Schematic representation of the six vectors constructed containing GFP tagged to i) g5R wild type (wt), ii) two punctual mutants of the Nudix 
domain of g5R (GFP-g5R R146G/E147G or REGG and E150Q/E151Q or EEQQ),iii) the N-terminal domain of g5R (GFP-g5R N-term), iv) the C-terminal 
domain (GFP-g5R C-term), and v) a deletion mutant that lack the Nudix domain (GFP-g5R ∆Nudix motif). These vectors were used to generate 6 stable 
HeLa cell lines able to express the recombinant proteins after the addition of tetracycline (tet). B) and C) Analysis of the size (B) and the kinetics of 
expression (C) of the recombinant proteins by Western Blot. Specific anti-GFP antibody was used to analyse the expression of the GFP-g5Rp fusion 
proteins and tubulin (B) and actin (C) were used as loading control. Data are representative images from two separate experiments. h:hours 
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HeLa Flip TREx cell lines (Invitrogen) are characterized by containing a unique genomic site for 
integration of the gene of interest (Flp site) and by holding a copy of the Tet Repressor. Co-transfection of 
pCDNA5/FRT/TO (enclosing the gene of interest) and pOG44 (codifying for Flp recombinase) allowed us to 
generate stable cells lines with one copy of the gene of interest integrated on its genome that express the 
fusion protein only in the presence of tetracycline. Size and expression of the different GFP-g5R proteins 
were analysed by fluorescent microscopy (data not shown) and by Western blot (Figure 17 B and C). As 
expected, GFP-g5Rp fusion proteins were only expressed in tetracycline presence (indicating that there was 
no unspecific protein synthesis) and all of them showed the expected sizes (Figure 17 B). Furthermore, and 
in respect to the kinetic of expression of the constructs, all of the fusion proteins tested were expressed 
from 8 until 72 hours in constant presence of tetracycline (Figure 17 C). 
In order to determine the possible role of g5Rp in mRNA metabolism in cultured cells, after 
screening the level of expression of the different GFP-g5Rp constructs, we next analysed RNA binding ability 
of the recombinant proteins. We used a dual fluorescence method, which has been described as a useful 
technique to measure RNA-protein interactions (Strein et al., 2014). In this system, HeLa eGFP is used as 
negative control (as GFP is a well-known non RNA-binding protein) (Strein et al., 2014). Figure 18 shows a 
schematic representation of the experimental procedure.  
 
Figure 18. Schematic representation of the dual fluorescence method. 
HeLa cells were treated with tetracycline during 18 hours (O/N) in order to induce the expression of GFP-g5Rp recombinant proteins. RNA-protein 
interaction was fixed by PAR-Crosslinking (PAR-CL), and the fusion proteins were immunoprecipitated using an antibody anti-GFP covalently coupled 
to the surface of agarose beads (GFP-Trap_A). The immunoprecipitated complexes were then incubated with Oligo d(T) Texas Red probe (T Red). 
Quantification of the RNA bound to the different proteins was carried out by measuring the GFP and the Texas red signal in a TECAN Safire II 
microplate reader. 
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Briefly, the different HeLa cell lines expressing GFP-g5Rp wt, GFP-g5Rp constructs or eGFP were 
induced with tetracycline (tet) and incubated with 4-thiouridine (4-SU) O/N (18 hours), which was added 2 
hours prior the induction in order to be incorporated into nascent RNA and to fix the RNA-protein 
interactions by PAR-crosslinking. GFP fusion proteins were then immunoprecipitated using GFP-Trap_A 
beads and resulting complexes were incubated with Oligo d(T)-Texas Red probe. Specificity of 
immunoprecipitation process was tested by SDS-PAGE and silver staining (data not shown), while the 
specificity of the RNA binding was demonstrated by treatment with RNases A and T1. GFP and Texas red 
fluorescent signals were measured and Texas Red signal/eGFP signal rate was used as a method to quantify 
the RNA bound per complex. As Figure 19 shows, GFP-g5Rp wt protein was able to bind around 25 folds 
more RNA compared to eGFP, demonstrating that g5Rp is acting as a RNA-binding protein in this system. In 
addition, the level of RNAs bound to the g5Rp catalytic mutants showed no significant differences in relation 
to GFP-g5Rp wt, suggesting that these mutations, although reported to be important for the catalytic 
process in vitro (Parrish et al., 2009), are not implicated in RNA binding. 
 
Figure 19. g5R protein binds poly(A) RNA in cultured HeLa cell lines. 
HeLa cells were induced with tetracycline O/N for the expression of eGFP, GFP-g5Rp wt and GFP-g5Rp catalytic mutants (REGG and EEQQ). RNA levels 
bound to the different fusion proteins were analysed by the dual fluorescence method. RNAses A and T1 treatment was carried out as specificity 
control. +/– symbols indicates presence or absence of this treatment. RNA values (mean+/-S.D) were expressed at the ratio of the Texas Red 
signal/eGFP signal and referred to eGFP. **: p < 0,01 (n=3). 
 
Interestingly, when we analysed the RNA bound to the different g5Rp domains (described in Figure 
17), we observed that GFP-g5Rp N-terminal was able to bind 10 folds more RNA than either GFP-g5Rp wt or 
GFP-g5Rp C-terminal domain, while the ∆Nudix construction bound considerably less than the N-terminal 
domain but more than the wt form (Figure 20 A).These results point to the N-terminal domain as a main 
player in g5Rp-RNA interaction, while the C-terminal domain seems not to be directly implicated in this 
function. On the other hand, the Nudix domain, although indispensable for the decapping activity in vitro 
(Dunckley and Parker, 1999; Parrish et al., 2009; Parrish et al., 2007; Song et al., 2013) is not essential for the 
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RNA binding. Furthermore, and interestingly, the absence of the Nudix domain contributed to the stability of 
the RNA binding, probably due to the fact of no degradation of the bound RNA, as no decapping activity in 
this mutant can be expected. In order to further study the difference among RNA levels bound to the 
different domains of the viral protein, we have accomplished g5Rp surface electrostatic representation using 
PyMol software. According with the charge, protein surface is represented in red (negative) or blue (positive) 
(Figure 20 B and C). We observed that the N-terminal domain of the protein presents a basic channel, which 
could act as a RNA-binding platform (Figure 20 B). This structure is characteristic and exclusive of this 
domain, as we did not find it when the C-terminal domain was explored (Figure 20 C). These results correlate 
with the experimental data obtained from dual fluorescence analysis and support the hypothesis that g5Rp 
N-terminal domain is the main responsible for the g5Rp-RNA interaction. This data also draw a parallel with 
the data reported in the literature, conferring importance to this channel in the RNA-binding activity 
(Deshmukh et al., 2008; She et al., 2008).  
 
Figure 20. The N-Terminal domain of g5Rp is mainly involved in the RNA-g5Rp interaction. 
A) RNA levels bound to the recombinant proteins GFP-g5Rp wt, GFP-g5Rp N-terminal, GFP-g5Rp C-terminal and GFP-g5Rp ∆Nudix were measured 
after its induction in HeLa cell lines using the dual fluorescence method. In this case, RNA values (mean+/-S.D) were expressed at the ratio of the 
RNAses treatment/no RNAses treatment and referred to eGFP. *: p < 0,01. (n=3) B) and C) Electrostatic surface representation of g5R protein. 
According with the charge, protein surface is represented in red (negative) or blue (positive). B) Electrostatic surface representation of the g5Rp N-
terminal domain and the Nudix motif. The hypothetical interaction site of cap structure and mRNA is shown in orange. C) Electrostatic surface 
representation of the g5Rp C-terminal domain. 
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Our previous results indicate that g5Rp is able to bind RNA in vivo, which point to g5Rp to be 
implicated in RNA regulation during the infection, which probably affects to the synthesis of the viral 
proteins overall. To test this possibility we studied ASFV infection on HeLa cells ectopically expressing 
different constructions of g5Rp, after induction with tetracycline (tet). First, and in order to elucidate 
possible side-effects of tet on ASFV infection, we tested viral protein synthesis in the presence of the 
antibiotic in COS-7 cells by using Ba71V (M.O.I = 2 pfu/cell) to infect cells. The ASFV protein levels were 
analysed by Western blot using a specific antibody developed against ASFV-infected Vero cells (kindly gifted 
by Dr. A.L. Carrascosa) (anti-ASFV). We confirmed that the presence of tet did not affect the viral protein 
synthesis (Figure 21 A). Next, and in order to analyse the effect of the GFP-g5Rp wt protein on ASFV 
infection, we induced the expression of eGFP or GFP-g5Rp wt in HeLa cells and then infected the cultures 
with ASFV (M.O.I = 2 pfu/cell). Viral protein levels were analyzed by Western blot with anti-ASFV antibody. 
 
Figure 21. Expression of GFP-g5Rp wt causes a slightly decrease on several ASFV viral proteins on infected HeLa cells. 
A) Effect of tetracycline in ASFV infection. COS-7 cells were Mock-infected or ASFV-infected (M.O.I = 2 pfu/cell) in the absence or presence of 
tetracycline (tet), and samples were recovered at 16 hours post infection (hpi). ASFV protein levels were analysed by SDS-PAGE and immunoblotting 
with a specific antibody that recognises ASFV induced proteins (anti-ASFV).B) and C) Effect of GFP-g5Rp wt overexpression on ASFV infection. HeLa 
cells were treated with tetracycline (tet) O/N to induce eGFP and GFP-g5Rp wt proteins (B) or GFP-g5Rp wt, REGG, and EEQQ proteins (C) and then 
Mock infected or ASFV-infected with M.O.I of 2 or 5 pfu/cell, respectively. ASFV protein levels were analysed by Western blot using anti-ASFV serum 
in both cases. Data are representative images from two separate experiments. 
 
As Figure 21 B shows, a slightly decrease on the level of several late ASFV proteins, like p17 and p12, 
was observed in extracts from GFP-g5Rp wt-expressing cells, compared to GFP. Finally, we induced and 
infected HeLa cells stably expressing GFP-g5Rp wt, GFP-g5Rp REGG and GFP-g5Rp EEQQ and analysed ASFV 
protein levels by Western blot in the presence or the absence of tet. Again, we observed a slightly decrease 
in the level of ASFV-proteins corresponding to molecular weight (MW) 32, 22, 17 and 12 KDa when HeLa 
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GFP-g5Rp wt cells were analysed, a reduction that was less significant in HeLa GFP-REGG-or EEQQ expressing 
cells (Figure 21 C). These results suggested that g5Rp expression under the control of the stable pCMV 
promoter from the beginning of the viral cycle could affect viral protein synthesis due to the putative 
decapping activity of g5Rp, reinforced by the fact of minor effect was observed in the Nudix-mutants 
expressing cells. 
 
Figure 22. ASFV-infected HeLa cells expressing GFP-g5Rp wt display reduced levels of the viral protein p72. 
HeLa cells were Mock-infected or ASFV-infected (M.O.I = 5 pfu/cell) after O/N induction with tetracycline (tet) to express eGFP or GFP-g5Rp wt. At 16 
and 24 hours post infection (hpi) eGFP, GFP-g5Rp wt and p72 levels were analysed by FACS. p72 protein was detected using a specific monoclonal 
antibody. A) Representative images of the population of HeLa cells expressing GFP-g5Rp wt (upper panels) or eGFP (middle panels) and p72 (x axis). 
Quantification of the percentage of GFP positive or p72 positive cells at 16 and 24 hpi are showed at the bottom (percentage of cells +/- S.D, n=2). B) 
Percentage of GFP positive and p72positive cells at 16 hpi in eGFP or GFP-g5Rp wt expressing cells (right graphic bars, percentage +/- S.EM, n=5) and 
quantification of the p72 mean signal in these populations of cells (mean fluorescence intensity, MFI +/- S.E.M; n=5). 
Results 
108 
Since the results mentioned above are important in terms of defining g5Rp as a decapping enzyme 
during ASFV infection, we further validated the effect of g5Rp expression on the level of viral p72 protein by 
FACS. To achieve this, HeLa eGFP and HeLa GFP-g5Rp wt cells were induced with tetracycline, Mock-infected 
or ASFV-infected (M.O.I = 5 pfu/cell), and p72 levels were analysed by using an anti p72 monoclonal 
antibody at 16 and 24 hpi. As shown in Figure 22 A, both HeLa GFP-g5Rp wt (upper panel) and HeLa eGFP 
(lower panel) cells were successfully infected and able to synthetized viral p72 protein. Percentage of GFP 
positive or p72 positive cells in the presence of the absence of tet were represented as bars graphics in 
Figure 22 A bottom panels (histograms). Both eGFP and GFP-g5Rp wt expression was maintained during the 
infection (left histogram), and, on the other hand, percentage of p72 positive cells was similar in both stable 
cell lines and in the presence or absence of tetracycline (right histogram). Interestingly, when the p72 mean 
fluorescent signal was analysed in GFP positive and p72 positive populations at 16 hpi, a significant decrease 
in GFP-g5Rp wt cells vs GFP was observed (Figure 22 B). These data indicated that overexpression of GFP-
g5Rp wt causes a reduction on p72 levels and that this reduction was not due to a minor infection rate but a 
specific effect of g5Rp activity on p72 viral protein expression. Taken together, these results suggest a role of 
ASFV g5Rp as a putative viral decapping enzyme, which seems to function regulating the synthesis of several 
viral products during the viral cycle.  
 
Figure 23. Ectopically expression of g5Rp affects late viral protein CD2v expression. 
A) Analysis of cells co-expressing g5Rp-HA and p32 or CD2v viral proteins by CSLM. COS-7 cells were transfected with promg5R-HA vector and ASFV-
infected with M.O.I of 5 pfu/cell. At 16 hpi, monolayer was fixed and g5Rp-HA, p32 and CD2v distribution was analysed using specific antibodies. 
g5Rp-HA is shown in green while p32 and CD2v are shown in red (upper and bottom panels, respectively). B) Quantification of cells co-expresing 
g5Rp-HA and p32 or Cd2v. Data was obtained by counting 339 and 130 transfected cells per condition and is represented referred to total g5Rp-HA 
expressing cells (mean +/- S.E.M, n = 2). *: p < 0.05. Data are representative images from two separate experiments. 
 
Interestingly, we have also observed by CLSM that the number of cells co-expressing g5Rp-HA and 
p32 (an early, abundant ASFV protein (Prados et al., 1993)) was significantly higher than the number of cells 
co-expressing g5Rp-HA and CD2v, a late viral protein (Rodriguez et al., 1993) (Figure 23 A). 
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Quantification of co-expressing cells (g5Rp-HA and p32 or g5Rp-HA and CD2v) was made counting at 
least 120 g5Rp-HA cells per condition. Percentage was calculated related to total g5Rp-HA transfected cells. 
(Figure 23 B).  
In summary, these results not only corroborated the result explained above, since indicate that g5Rp 
regulates the expression of ASFV proteins, but also added information about the specific regulation g5Rp-
dependent of ASFV late proteins, since it is likely that when g5Rp is overexpressed, a significant lower 
number of cells expressing both g5Rp and CD2v late protein were detected.  
 
During this Thesis we have demonstrated that g5Rp perse is able to bind cellular mRNA when 
ectopically transfected in HeLa cells (section 4.2.4); furthermore, when overexpressed in the context of the 
infection, g5Rp produced a decrease in late viral protein levels. Next, we further explore whether this RNA-
binding ability also occurs during the viral infection to reinforce the putative role of the protein in binding 
specific mRNAs. 
4.3.2.1 g5Rp is able to bind both viral and cellular mRNAs in the context of ASFV infection 
We have analysed g5Rp-RNA interaction by GFP immunoprecipitation and RT-qPCR during the 
infection. A schematic representation of the experimental procedure is shown in Figure 24 A. HeLa cells 
stably expressing eGFP and GFP-g5Rp wt were induced with tetracycline and ASFV-infected (M.O.I = 5 
pfu/cell) during 7 or 14 hours. RNA-protein interaction was fixed by conventional crosslinking (cCL) and GFP 
complexes were immunoprecipitated with GFP Trap_A beads. We performed Western blot analysis using 
anti-GFP antibody to detect fused proteins and to check immunoprecipitation process; and MOV10-YFP 
expressing cells were used as a positive control of protein-RNA binding (Figure 24 B). After 
immunoprecipitation, we extracted the RNA bound to the complexes, which was analysed by RT-qPCR 
amplifying representative cellular (eIF4E and B-actin) and viral (A238L as early-late gene and A224L and p72 
as late genes) mRNAs. We observed that GFP-g5Rp wt protein was able to bound both viral and cellular 
mRNAs in the context of ASFV infection (14 hpi), while eGFP control was not able to bind mRNA at all. 
Hence, the binding is likely to be specific, as mRNA corresponding to actin, despite the high amount present 
in the cells, is only weakly bound, compared to eIF4E which is, interestingly, efficiently bound by g5Rp 
(Figure 24 C). 
Furthermore, the fact that g5Rp was able to bind both cellular and viral RNAs, partially supported 
the hypothesis that the viral protein could be involved in both cellular shutoff and in the regulation of 
temporal viral RNAs expression. 
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Figure 24. GFP-g5Rp wt is able to bind both viral and cellular mRNAs in the context of ASFV infection. 
A) Schematic representation of the experimental procedure. After induction of the recombinant proteins with tetracycline (tet), HeLa cells were ASFV 
infected (M.O.I = 5 pfu/cell) and crosslinked at 7 or 14 hour post infection (hpi). eGFP and GFP g5Rp wt were immunoprecipitated with GFP_Trap_A 
beads and RNA bound to them were extracted using phenol:chlorofom:isoamil alcohol (25:24:1) and analysed by RT-qPCR. HeLa stable cells 
expressing MOV10-YFP were used as positive control. B) Immunoprecipitation of all the fusion proteins was checked by Western blot prior to RNA 
extraction. Complexes were detected using a specific anti-GFP antibody. C) Quantification of representative cellular (eIF4E and B-actin) and viral 
(A224L, A238L and p72) mRNAs extracted from the immunoprecipitated fusion proteins by RT-qPCR at 14 hpi. Values are represented as the RNA 
bound to GFP-g5R protein relative to the RNA bound to eGFP (mean +/- S.E.M) n=3. * p < 0.05. 
4.3.2.2  Effect of g5Rp on viral mRNAs expression 
After demonstration that g5Rp binds viral mRNAs and in order to clarify the consequence of this role 
on the expression of specific ASFV mRNAs, we analysed by CSLM the level of A224L mRNA in infected cells 
overexpressing g5Rp-HA. 24 hours post transfection, COS-7 cells were Mock-infected or ASFV-infected with 
M.O.I = 5 pfu/cell, fixed at 7 hpi and 24 hpi post infection, and viral A224L mRNA level was analysed using an 
specific Texas red tagged probe (Figure 25). As expected, no signal of A224L mRNA probe was detected in 
Mock cells. At 7 hpi, A224L mRNA was clearly detected in eGPF cells (Figure 25 upper pannels), while in cells 
expressing g5Rp-HA a lower signal was perceived (Figure 25 lower panels), indicating that overexpressed 
g5Rp enhances degradation of the A224L mRNA. At 24 hpi, A224L mRNA was detected in both eGFP and 
GFP-g5Rp cells, although the signal was again reduced in overexpressing g5Rp-HA cells, supporting a 
discriminatory expression of g5Rp together with late viral proteins. It is also important to highlight that 
Results 
111 
ectopic g5Rp expression in these experiments is regulated by the viral promoter, and it should behave in the 
infected cells as an “extra copy” expression of the g5R gene. 
 
Figure 25. Localization of A224L viral mRNA in ASFV-infected COS-7 cells overexpressing g5Rp-HA protein. 
COS-7 cells were transfected with eGFP (upper panles) or promg5R-HA (bottom panels) and Mock-infected or ASFV-infected with M.O.I = 5pfu/cell. At 
7 and 24 hpi, monolayer was fixed and viral A224L mRNA was detected using a specific probed tagged to Texas Red (red). g5Rp-HA was detected 
using a specific anti-HA antibody (green). Viral factories and cellular nucleus were stained with DAPI (blue). 
 
In order to further study the effect of g5R protein over viral mRNAs, we analysed A238L, A224L and 
p72 mRNA levels by RT-qPCR in HeLa cells, after ASFV-infection (16 hpi, M.O.I = 5 pfu/cell) and expression of 
eGFP or GFP-g5Rp wt. We observed that in HeLa cells expressing GFP-g5Rp wt, all the viral mRNAs studied 
were decreased compared to eGFP expressing cells (Figure 26). This data corroborated CSLM results showed 
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above, and indicated that g5Rp overexpression causes a reduction of at least two late viral mRNAs, which 
also support the decrease observed in the protein levels in section 4.3.1. 
 
Figure 26. Expression of GFP-g5Rp wt protein in ASFV infected cells causes a decrease of late viral mRNA levels. 
HeLa cells were induced to express eGFP and GFP-g5Rp with tetracycline 18 hours prior to ASFV-infection (M.O.I = 5 pfu/cell). At 8 hpi, cells were 
harvested and total mRNA was extracted. Viral A224L, A238L and p72 mRNA levels were analysed by RT-qPCR using specific primers. Values 
represent RNA levels present in GFP-g5Rp wt expressing cells related to eGFP expressing cells and are normalized to 18S RNA (media +/- S.D, n=3)  
*: p < 0.05.  
4.3.2.3 Effect of g5Rp on cellular mRNAs 
The results showed above indicate that g5Rp overexpression affects viral mRNA levels. On the other 
hand and in order to clarify the possible role of the protein in the cellular shutoff, we also study the effect of 
g5Rp overexpression on cellular mRNAs. We analysed eIF4E and β-actin mRNA levels by RT-qPCR in ASFV-
infected (16 hpi, M.O.I = 5 pfu/cell) stably HeLa cells, which were previously induced with tetracycline to 
express eGFP or GFP-g5Rp wt, respectively. As Figure 27 shows, levels of both RNAs were decreased in ASFV-
infected HeLa cells expressing GFP-g5Rp wt compared to cells expressing eGFP alone. This result indicates 
that g5Rp is not only able to promote viral mRNA decay, but also cellular mRNA degradation in the context 
of the infection. Moreover, this degradation appears to be a selective process, because g5Rp effect is more 
patent in eIF4E mRNA than in B-actin mRNA levels.  
In summary, these results point to g5Rp as a new viral decapping enzyme, functioning as a regulator 
of both viral and cellular protein synthesis by specifically modulating mRNA levels. 
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Figure 27. Expression of GFP-g5Rp wt protein causes a decrease of cellular mRNA levels in ASFV-infected HeLa cells. 
HeLa cells were induced to express eGFP and GFP-g5Rp with tetracycline (O/N), and then ASFV-infected with M.O.I = 5 pfu/cell. At 8 hpi, cells were 
harvested and total mRNA was extracted. eIF4E and B-actin mRNA levels were analysed by RT-qPCR using specific primers. Values represent RNA 
levels present in GFP-g5Rp wt expressing cells related to eGFP expressing cells and are normalized to 18S RNA (media +/- S.D, n=3) **: p < 0.05. 
 
The results explained above showed that g5Rp binds both viral and cellular mRNAs in vivo, thus 
suggesting that the role of the viral protein during the infection could be related to the regulation of the 
temporal expression of the viral mRNAs during the viral cycle and also in the degradation of cellular mRNAs. 
To further study g5Rp function during ASFV infection and to characterize the molecular mechanism 
employed by the protein, we set up two types of strategies. 
1.3.3.1. Silencing g5R expression by using specific siRNA  
 
Figure 28. Partial depletion of g5R gene. 
Vero cells were serum deprived for 24 hours and transfected or non-transfected with 40 nM of a specific g5R siRNA . 24 h after transfection, Vero 
cells were Mock or ASFV-infected (M. O. I = 1 pfu/cell). Samples were recovered at 6 and 16 hours post infection and total RNA was extracted and 
retrotranscribed. mRNA levels of g5R mRNA were analysed by PCR and qPCR. Graphic bars show RNA levels referred to non-silenced Mock and 
normalized to ribosomal protein P0 (PRLP) and peptidylprolyl isomerase A (PPIA) mRNAs (mean +/- S.D, n=2). 
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Three specific g5Rp-siRNAs were used under different conditions to optimize silencing reactions. 
However, for all the conditions tested, we only achieved approximately a 40% of silencing rate (Figure 28). 
This limited result prevented us from observing significant differences between silenced and non-silenced 
samples in terms of levels of mRNAs corresponding either to viral or cellular transcripts (data not shown). 
Thus, clear conclusions from these experiments could not be extracted.  
1.3.3.2. Generation of a deletion ASFV mutant lacking of the g5R gene. 
As a second approach to study the specific role of the viral protein, we tried to generate an ASFV 
g5Rp deletion mutant (ASFV∆g5R, Ba71V strain) following a protocol that has been widely used in our lab to 
generate ASFV recombinant mutants. 
 
Figure 29. g5R gene is important to effective viral production.  
Generation of ASFV g5R deletion mutant (ASFV∆g5R). A) Schematic representation of the experimental procedure. The gene of interest (in this case 
g5R) and its flanking sequences were cloned in the p72BetaGAL10T vector (p72∆g5RGAL10T). Vero cells were transfected with this construction and 
ASFV-infected to allow homologous recombination between the vector and the viral genome. Positive recombinant viral particles should carry a copy 
of the Beta galactosidase gene instead of the gene of interest, which allowed its selection by titration in presence of X-gal. B) g5R is an important 
gene for ASFV infection cycle. p72∆EP153R Gal 10 T and p72∆EP402R Gal 10 T, which are constructions that had been successfully used to generate 
ASFV deletion mutants previously in our lab, were used as positive controls (upper panels). First round of transfection and infection with 
p72∆g5RpGAL10T generate small positive clones (middle panels), but disappear in the following infection steps (bottom panels). Data are 
representative images from two separate experiments. 
 
To achieve this, we constructed a vector containing g5R gene flanking sequences (F1 and F2, see 
Materials and Methods) at both sides of β-Gal gene (p72∆g5RGAL10T) and then transfected this plasmid in 
Vero cells. Followed by ASFV infection, this procedure should allow recombination between homologous 
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regions of the construction and the viral genome, in such a way that resultant viral particles containing β-Gal 
gene instead of g5R can be routinely selected by titration in agarose plates and in X-Gal presence (Garcia et 
al., 1995).Figure 29 A shows a representation of the experimental process. As an internal control of the 
transfection-infection procedure, reflecting the somatic recombination we used two vectors generated in 
our group, p72∆EP153RGAL10T (Hurtado et al., 2004) and p72∆EP402RGUS10T (Rodriguez et al., 1993), 
which have been previously used to successfully obtain the corresponding ASFV deletion mutants: 
Ba71V∆EP153R and Ba71V∆EP402R (∆CD2v). Using similar conditions, we intended to generate the virus 
ASFV∆g5R.  
 
Figure 30. Experimental approximation to obtain a helper cell line that supports ASFV∆g5R infection. 
COS Flip in cell line possess a Flip Recombination Site (FRT) integrated at its genome. Cotransfection of pCDNA5/FRT/TO GFP-g5R wt and pOG44 
vector (that encodes for the FLP recombinase) will allow the integration of GFP-g5Rp wt and Hygromicine resistance sequences into the cellular 
genome. Positive clones will be selected by their resistance to Hygromicine. 
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However, after different trials, and although we were able to obtain blue viral particles after the first 
transfection/infection steps, these positive clones presented a smaller size comparing to the positive 
controls (Figure 29 B, upper and middle panels), and were lost in the successive rounds of infection (Figure 
29 B bottom panels). This procedure was repeated unsuccessfully several times in separated experiments, 
thus suggesting an important role for g5Rp in the viral infection, which explains that viral particles lacking 
this protein cannot productively grow. In parallel, a similar protocol was developed to delete another non-
related ASFV gene, A238L, which was successfully achieved, thus guarantying the efficiency of the 
experimental procedure (data not shown). 
Since this conventional method failed to generate the ASFV g5R deletion mutant virus, we are 
currently working on the development of a helper cell line which constitutively expressed g5Rp and might be 
able to support ASFV∆g5R growth since ectopically provides the essential g5R protein. To generate this 
helper cell line we will use COS Flip in cells, a kind gift of Dr. Carlos Martins (Facultad Técnica de Veterinaria, 
Lisboa, Portugal), that are further transfected with pCDNA5/FRT/TO GFP-g5Rp wt vector, and selected with 
hygromicine. Resultant COS GFP-g5Rp wt cells will be sorted by FACS and next used to generate ASFV ∆g5R. 
A schematic representation of the experimental procedure is shown on Figure 30. 
 
In this Thesis, we observed that g5Rp played a role on decay of both viral and cellular mRNAs. To 
further deciphering the molecular mechanism performed by g5Rp during ASFV infection, we analysed the 
cellular machinery of decapping during ASFV infection and when g5Rp is overexpressed.  
As mentioned in the Introduction section, in the 5´- 3´ RNA degradation route the cellular decapping 
Dcp2 subunit has been described as the catalytic enzyme, in charge of hydrolyse the cap structure from the 
5´end of RNAs. However, RNA degradation is a tightly controlled process that is modulated by numerous 
regulators. Among these, cellular Dcp1 has a determinant role, but other proteins as Edc3, Edc4, Lsm1-7 
complex, Pat1 or Dhh1 have been described to be also implicated (Arribas-Layton et al., 2013; Garneau et 
al., 2007; Ling et al., 2011). All these proteins have been described to localize in cytoplasmic foci (known as 
Processing Bodies or P-Bodies) in normal cells (Eulalio et al., 2007). The number and size of these RNA 
granules rise in conditions that trigger an increase in non-translating RNAs, such as stress stimuli or viral 
infections (Decker and Parker, 2012). Indeed, some host viral defence proteins accumulate at these 
structures (Beckham and Parker, 2008) and, for this reason, viruses have developed several mechanisms to 
subrogate P-Bodies formation. In some cases, viruses are also able to use P-body components to their own 
benefit (Narayanan and Makino, 2013; Reineke and Lloyd, 2013). In order to determinate if ASFV infection is 
modulating the decapping machinery and in some way affecting the P-bodies structure and/or size, we 
decided to analyse the levels and subcellular distribution of Dcp1 and Edc4 during the infection.  
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To analyze DCP1 and Edc4 localization during ASFV infection, COS-7 cells were Mock-infected or 
ASFV-infected with M.O.I = 2 pfu/cell. At 16 hpi, cells were fixed and both proteins were detected with 
specific antibodies by CSLM, whereas ASFV infection was assessed by the presence of viral factories (Figure 
31 A) or p72 protein expression (Figure 31 B). 
 
Figure 31. Localization of Dcp1 and Edc4 in ASFV infected cells. 
A) COS-7 cells were Mock-infected or ASFV-infected with M.O.I of 5 pfu/cell. At 16 hpi, monolayer was fixed and Dcp1 and Edc4 were detected by 
CLSM using specific antibodies. Edc4 and Dcp1 distributions are shown in gray at the individual panels and in green and red, respectively, in the 
Merge panels. Infection progress was checked by the presence of viral factories (blue in the merge panels). B) COS-7 cells were ASFV-infected (M.O.I 
of 5 pfu/cell) and Dcp1 and Edc4 were localized using specific antibodies by CSLM at 16 hpi. Edc4 and Dcp1 distributions are shown in gray at the 
individual panels and in green in the Merge panels. Infection progress was checked by the presence of the viral protein p72 (red, in the merge 
panels). Arrows show the viral factories. Data are representative images from two separate experiments. 
 
As expected, we observed that in Mock-infected cells, Dcp1 and Edc4 co-localized and presented a 
punctuated pattern (Figure 31 A, upper panels). However, in ASFV infected cells, this pattern was missing, 
and both Dcp1 and Edc4 proteins showed a more heterogeneous distribution, that was, furthermore, less 
intense (Figure 31 A bottom panels) probably due either to the general shutoff induced by the infection or, 
alternatively, to a specific virus-induced down regulation mechanism. Furthermore, Dcp1 signal was 
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distributed around the viral factories, indicating that Dcp1 should play a virus-regulated role (Figure 31 B, 
upper panels). On the other hand, Edc4 signal was clearly excluded from the viral factories (Figure 31 B, 
bottom panels). In the merge panel, the difference on Edc4 pattern between un-infected and infected cells 
can be clearly appreciated, as in the cell positive for p72 (red), almost any green mark corresponding to Edc4 
was observed, and, on the contrary, in the cell aside, no red mark corresponding to infection appeared, but 
green granules corresponding to Edc4 are very patent. This change on localization and structure of the P-
Bodies components is very common among viruses, which are able to interact with these cellular anti-viral 
defence mechanisms in order to facilitate viral replication. 
 
Further the effect of ASFV overall on distribution of P-Body components, we focused our attention 
on studying the potential interaction between g5Rp and Dcp1 or Edc4. Taking into consideration the possible 
role of g5Rp as a decapping enzyme, we hypothesised that the protein could be using these decapping 
activators to perform its function in a similar manner to Dcp2.  
 
Figure 32. g5Rp co-localizes, but not directly interacts, with Dcp1 at the periphery of the viral factories. 
A) COS-7 cells were transfected with pZAB 11/7 42 vector, which contains GFP-g5R sequence under control of g5R viral promoter. After transfection, 
cells were ASFV-infected and GFP-g5Rp (green), Dcp1 (red) and Edc4 (cyan) location was analysed by CLSM. Dcp1 and Edc4 were detected using 
specific antibodies. DAPI was used to stain cellular nucleus and viral factories (blue). Bottom panels represent a detail of the viral factories. Arrows 
show the viral factories. B) Coimmunoprecipitation assays using specific anti-g5Rp serum. Vero cells were Mock-infected or ASFV-infected at 16 hpi 
and samples were collected in presence of anti-g5Rp serum. Thus, samples were incubated with agarose beads O/N, and after intensive washing 
Dcp1, Edc4 y g5Rp levels were analysed by Western blot. Protein detection was carried out using specific anti Dcp1 and anti-Edc4 antibodies, while 
g5Rp was detected with anti-g5Rp serum. Data are representative images from two separate experiments.. 
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With this objective, we analysed g5Rp location in relation to Dcp1 or Edc4 during ASFV infection by 
CSLM. COS-7 cells were transfected with pZAB 11/7 42 vector, a construction that contains the GFP-g5Rp 
fused protein under control of the g5Rp viral promoter, and then infected with a M.O.I of 5 pfu/cell. At 16 
hpi, cells were fixed and GFP-g5Rp, Dcp1 and Edc4 distribution was analysed. As it is shown Figure 32 A, the 
pattern of distribution of GFP-g5Rp was different from the one corresponding to Edc4, suggesting that both 
proteins do not mainly co-localize. On the other hand, both GFP-g5Rp and Dcp1 accumulated at the 
surroundings of the viral factories, where they partially co-localized (Figure 32 A).  
To further study the possible interaction between g5Rp and Dcp1 or Edc4, we performed 
coimmunoprecipitation assays. Vero cells were Mock-infected or ASFV-infected with M.O.I of 5 pfu/cell and 
samples were recovered at 16 hpi in presence of the specific anti-g5Rp serum. After immunoprecipitation 
with this antibody, possible g5Rp-protein interactions were analysed by Western Blot using specific 
antibodies against Dcp1 or Edc4 (Figure 32 B). Results demonstrated that g5Rp is not directly interacting 
neither Dcp1 nor Edc4. Furthermore, and as we will show later, Dcp1 did not appear as a protein binding 
GST-g5R in pull-down assays. However, the fact of Dcp1 accumulates at the surroundings of the viral 
factories suggest that Dcp1 could be playing a role on ASFV infection and maybe in viral-induced mRNA 
decay. 
 
Due to the fact that the cap is a key player of the decapping process and that g5Rp is a putative viral 
decapping enzyme, we examined the distribution of this structure in the context of ASFV infection and its 
possible localization versus g5R protein. To achieve this, we used a specific antibody able to recognise both 
m7G and m3G structures by CSLM. It should be noted that the antibody recognizes both the cap structures 
attached to the RNA body and the free cap analogous (such as m7Gp or m7GpppG), but, however, it does not 
have affinity to uncapped RNAs (Bochnig et al., 1987). COS cells were Mock-infected or ASFV-infected (M.O.I 
= 5 pfu/cell) and fixed at 16 hpi. g5R protein was detected using our specific serum and nucleus and viral 
factories were stained with DAPI. In Mock-infected cells, the cap structure was localized both at the 
cytoplasm and, strongly, at the nucleus (Figure 33 A, upper panels), suggesting that the capped RNAs are 
present in both compartments. The observed increase at the nucleus is not surprising, given that RNA 
capping is a process that mainly occurs at this organelle. On the contrary, in ASFV-infected cells cap signal 
was augmented in the cytoplasm, especially at the periphery of the viral factories, where it partially co-
localized with g5Rp (Figure 33 A, bottom panels). The reduction of the cap signal in the nucleus of infected 
cells may be due to an impairment of both nuclear transport and functions, as we commented in section 
4.1.2. Conversely, the increase of the cap signal at the viral replication sites may corresponds to capped viral 
mRNAs, which, as described in (Castello et al., 2009b) and as we demonstrated in section 4.1.3, are 
surrounding these structures. The fact that the cap co-localize with g5Rp at these sites indicates that both 
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factors could be interacting, which would corroborate the role of g5Rp as a decapping enzyme. Interestingly, 
when we analysed cap signal intensity, we observed it was slightly increased in ASFV-infected cells when 
compared to Mock-infected cells (Figure 33 B). Given that ASFV infection causes a decrease in the Oligo d (T) 
signal and in the mRNA levels (section 4.1.2), we could expect a similar phenomenon regarding the cap 
levels. However, it should be noticed that the antibody not only recognise capped mRNAs, but also free cap 
structures, which may rise due to the ASFV-stimulated rates of RNA decapping and degradation. 
 
Figure 33. ASFV infection affects the location and levels of the 5´ cap structure. 
A) Analysis of the location of the cap structure in ASFV-infected cells. COS-7 cells were infected with M.O.I = 5 pfu/cell and fixed at 16 hpi. Cap 
structure (red) and g5R protein (green) were detected by using an anti-cap specific antibody and the anti-g5Rp serum, respectively by CSLM. Cellular 
and viral DNA was stained with DAPI (blue). Arrows show the viral factories B) Quantification of the cap signal in Mock-infected and ASFV-infected 
cells by ImageJ software (mean fluorescence intensity, MFI +/- S.D, n = 2). *: p < 0.05. Data are representative images from two separate 
experiments. 
 
Data presented in this section corroborates our previous findings with the specific viral mRNAs 
probes (section 4.1.3), indicating viral mRNAs are located at viral factories, and also reinforces the clue of 
g5Rp as a viral decapping enzyme.  
 
Viruses not only manipulate the cellular decapping machinery in order to avoid defence responses, 
but also manipulate the translation initiation machinery to enhance its own viral protein synthesis and to 
impair cellular protein synthesis: this is the case of vaccinia infection, where eukaryotic translation initiation 
factors (eIFs) are redistributed to viral factories (Katsafanas and Moss, 2007; Walsh et al., 2008)). Once that 
we have demonstrated that viral mRNAs are located at the periphery of viral factories in previous sections 
(section 4.1.3), we then hypothesised that translation could also take place at these sites, and that eIFs could 
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be recruited to ASFV viral factories, as happens in vaccinia infection. This is an important point to explore in 
the virus biology, since it was not previously described the regulation of eIFs during ASFV infection, a topic 
that was further studied in (Castello et al., 2009b). In this work, we previously demonstrated that ASFV 
translation relies on the host cap-dependent translation machinery. Indeed, both eIF4E and eIF4G are 
essential for the progression of the infection, since deletion of both factors triggers a decrease in the 
number and size of viral factories and a reduction of the viral titre. Moreover, during ASFV infection 
formation of the translation initiation complex is stimulated by phosphorylation of eIF4G, eIF4E and 4E-BP, 
while eIF2α is maintained unphosphorylated to avoid translational repression. 
 
To analyse eukaryotic translation initiation factors distribution, Vero cells were Mock-infected or 
ASFV-infected (M.O.I = 5 pfu/cell) and fixed at 16 hpi. Location of eIF4G and eIF4E were then analysed by 
CSLM (green and red, respectively, in Figure 34 A).To-Pro-3 was used to visualize viral factories (blue). In 
Mock-infected cells, both initiation translation factors were spread in the cytoplasm (Figure 34, upper 
panels). However, in ASFV-infected cells both factors are clustered at the viral factories (Figure 34, bottom 
panels), indicating that, as we expected, ASFV triggers the redistribution of eIFs to the viral factories to its 
own benefit, facilitating the translation of viral mRNA and thus the viral protein synthesis. Taken together 
with the data exposed on the above section, these results indicate that viral factories are structures where 
active translation takes place, but also structures where viral mRNA degradation can occur . 
 
Figure 34. eIF4G and eIF4E are redistributed to the viral factories during ASFV infection. 
Vero cells were Mock-infected or ASFV-infected with M.O.I = 5 pfu/cell, and fixed to glass coverslip at 16 hpi. eIF4E (green) and eIF4G (red) location 
was detected by indirect immunofluorescence by CLSM. Cell nuclei and ASFV viral factories were stained with To-Pro-3 (blue). Arrows show the viral 
factories. Data are representative images from two separate experiments. 
 
The above findings demonstrated that translation initiation factors are redistributed to viral 
factories. In order to test if ASFV infection was affecting to other components of the translation process, we 
studied ribosomes redistribution by CSLM. Ribosomes were detected with a specific antibody that 
recognises ribosomal P protein (a kind gift of Dr. Juan Pedro García Ballesta, CBMSO, Madrid, Spain 
(Martinez-Azorin et al., 2008)) and p72 viral protein was used to detect viral factories (Figure 35). Ribosomal 
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P protein presented a similar pattern of eIFs and localized spread at the cytoplasm of Mock-infected cells. In 
contrast, in ASFV-infected cells Ribosomal P protein co-localized with p72 protein and is clustered at the 
periphery of viral factories, suggesting that also ribosomes were mobilized to the viral factories.  
 
Figure 35. P-ribosomal protein is clustered at the periphery of ASFV viral factories. 
Vero cells were Mock-infected or ASFV-infected with 5 pfu/cell and fixed at 16 hpi. Ribosomal P-protein (red) and ASFV p72 protein (green) were 
detected by immunofluorescence by using specific antisera. Nucleus and viral factories were detected with To-Pro-3 (blue). Arrows show the viral 
factories. Data are representative images from two separate experiments. 
 
Considering, as we have demonstrated in this work, that ASFV infection promotes a cellular mRNA 
decay, all together the results presented here suggest that ASFV uses different mechanisms to carry out the 
cellular shut off: on one hand, ASFV impairs cellular protein synthesis by mRNA degradation, on the other 
hand, ASFV recruits eIFs and ribosomes to viral factories where are not accessible for cellular mRNAs. 
Furthermore, it is likely ASFV modulates both translation and mRNA metabolism not only to impair cellular 
protein synthesis, but also to facilitate viral infection progression, using the components of the translation 
machinery to that purpose. 
 
Due to the fact that eIFs, ribosomes and g5Rp are clustered at the periphery of viral factories at late 
times post infection, we decided to analyse if the viral protein could be interacting with any of these 
translation machinery components in the context of the infection. Additionally, and in order to further 
analyze the mechanism of g5Rp function as a protein that cleaves viral mRNAs, thus acting as a regulator of 
viral temporal expression, we also explored whether g5Rp could be interacting with viral proteins. To 
achieve this, we performed pulldown assays as follows: purified GST and GST-g5R proteins were coupled to 
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glutathione beads, then incubated with extracts of Mock-infected or ASFV-infected Vero cells recovered at 6 
or 18 hpi (M.O.I = 5 pfu/cell), and, after intensive washing, resultant protein complexes were sequenced by 
Mass Spectrometry. In order to identify the interacting cellular and viral proteins, we analysed the obtained 
peptides matching them against two different data bases: firstly, we used Uniprot ASFV-Ba71V strain 
database, which allowed us to identify the viral peptides bound to GST or GST-g5Rp samples (Table 6), and 
secondly, Uniprot Primates data base allowed us to identify cellular proteins interacting with both GST and 
GST-g5Rp complexes (Table 3). 
Accession 
number 
Protein Identified sequences Score 
Q08358 
Polyprotein pp220 African swine fever virus (strain Badajoz 1971 Vero-
adapted) GN=Ba71V-92 PE=1 SV=3 - [PP220_ASFB7] 
FSGLVSAENIAEFEK 9,60 
VGGAALTVEELGLSK   
VAAEIQQGR   
P22776 
Major capsid protein p72 African swine fever virus (strain Badajoz 1971 Vero-
adapted) GN=Ba71V-081 PE=1 SV=2 - [MCP_ASFB7]  
NLVYYCEYPGER 5,73 
IILAQDLLNSR   
Q89769 
Structural DNA-binding protein p10 African swine fever virus (strain Badajoz 
1971 Vero-adapted)GN=Ba71V-049 PE=1 SV=1 - [P10_ASFB7] THASSSMHSGMLYK 2,35 
Table 6. Identification of viral proteins interacting with g5Rp. 
Data found by sequencing the peptides interacting with GST-g5Rp after incubation of the recombinant protein with extracts of ASFV-infected cells (18 
hpi). Identification of peptides was carried out using Uniprot ASFV-Ba71 strain data base. The table shows the Uniprot accession number (accession 
number), the identified protein (protein), the peptide sequences which allowed identification of the protein (identified sequence) and the score. 
Regarding viral protein analysis, in samples where GST-g5Rp was incubated with Mock-infected or 6 
hpi -infected extracts no viral peptides were found (data not shown). Obviously, Mock sample was used as 
negative control, as no viral proteins are expected in this sample. These results indicate that, at early times 
post infection, g5Rp is not interacting with other viral proteins. However, when GST-g5R protein was 
incubated with extracts from 18 hpi- infected Vero cells, we were able to identify at least three viral proteins 
interacting with GST-g5Rp: the DNA binding protein p10, the polyprotein pp220 and the major protein of the 
capsid, p72 (Table 6). All these proteins are packaged into the virion particles, and therefore are recruited to 
viral factories at late times post infection. The fact that g5Rp is able to interact with these proteins went in 
parallel with the results obtained by CSLM in section 4.2.3, which showed location of g5Rp at the edge of the 
viral factories at late times post infection. This result also suggests that g5Rp could be packaged into the 
virions. 
When we analysed cellular peptides in GST-g5Rp samples, we observed that in all the conditions 
tested (Mock, 6hpi and 18hpi) GST-g5Rp was interacting with several ribosomes components, such as the40S 
ribosomal protein S14 or the 60S ribosomal protein L8, which are proteins involved in the regulation and in 
the correct reconstitution of the ribosome. These results support g5Rp presence at the ER and the 
hypothesis of g5Rp implicated in mRNA metabolism. Not only that, but interestingly, g5Rp is interacting with 
cytoplasmic Poly(A) binding protein (PABPC) exclusively at early times (6hpi) post infection, as no bound 
PABPC was detected in the sample corresponding to 16 hpi. This fact reinforces the idea of g5Rp interacting 
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with the translation complex. In all the cases, GST samples were used to discriminate between specific and 
unspecific interactions. 
Sample 
Accesion 
number 
Protein Indetified sequences Score 
M
o
ck
 
P62263 
40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 
PE=1 SV=3 - [RS14_HUMAN] 
TPGPGAQSALR 7,29 
ELGITALHIK   
IEDVTPIPSDSTR   
E9PKZ0 
60S ribosomal protein L8 (Fragment) OS=Homo sapiens 
GN=RPL8 PE=1 SV=1 - [E9PKZ0_HUMAN] 
ASGNYATVISHNPETK 6,77 
AVVGVVAGGGR   
C9J4Z3 
60S ribosomal protein L37a OS=Homo sapiens 
GN=RPL37A PE=4 SV=1 - [C9J4Z3_HUMAN] 
TVAGGAWTYNTTSAVTVK 5,65 
AVGIWHCGSCMK   
A
SF
V
 6
 h
p
i 
J3KTJ8 
60S ribosomal protein L26 (Fragment) OS=Homo sapiens 
GN=RPL26 PE=4 SV=4 - [J3KTJ8_HUMAN] 
KDDEVQVVR 9,01 
DDEVQVVR   
YVIYIER   
FNPFVTSDR   
A0A024R9E2 
Poly(A) binding protein, cytoplasmic 1, isoform CRA_c 
OS=Homo sapiens GN=PABPC1 PE=4 SV=1 - 
[A0A024R9E2_HUMAN] 
VEIIANDQGNR 8,15 
LLQDFFNGK   
STAGDTHLGGEDFDNR   
E9PKZ0 
60S ribosomal protein L8 (Fragment) OS=Homo sapiens 
GN=RPL8 PE=1 SV=1 - [E9PKZ0_HUMAN] 
ASGNYATVISHNPETK 6,08 
AVVGVVAGGGR   
AVDFAER   
A2A3R7 
40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 
PE=1 SV=1 - [A2A3R7_HUMAN] 
MATEVAADALGEEWK 6,06 
LNISFPATGcQK   
P62263 
40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 
PE=1 SV=3 - [RS14_HUMAN] 
TPGPGAQSALR 5,60 
IEDVTPIPSDSTR   
E9PPU1 
40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 
PE=1 SV=1 - [E9PPU1_HUMAN] 
DEILPTTPISEQK 4,86 
TEIIILATR   
A
SF
V
 1
8
 h
p
i 
Q9BS10 
Similar to ribosomal protein S8 (Fragment) OS=Homo 
sapiens PE=2 SV=1 - [Q9BS10_HUMAN] 
ISSLLEEQFQQGK 11,66 
ADGYVLEGK   
B5MCT8 
40S ribosomal protein S9 OS=Homo sapiens GN=RPS9 
PE=3 SV=1 - [B5MCT8_HUMAN] 
LFEGNALLR 7,02 
LIGEYGLR   
P62263 
40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 
PE=1 SV=3 - [RS14_HUMAN] 
IEDVTPIPSDSTR 6,36 
TPGPGAQSALR   
K7EMA7 
60S ribosomal protein L23a OS=Homo sapiens 
GN=RPL23A PE=3 SV=1 - [K7EMA7_HUMAN] 
VNTLIRPDGEK 5,59 
LAPDYDALDVANK   
F8W7C6 
60S ribosomal protein L10 OS=Homo sapiens GN=RPL10 
PE=1 SV=2 - [F8W7C6_HUMAN] 
FNADEFEDMVAEK 5,59 
MLSCAGADR   
V5XJZ0 
Ribosomal protein S4, X-linked (Fragment) OS=Macaca 
fascicularis GN=RPS4X PE=4 SV=1 - [V5XJZ0_MACFA] 
VNDTIQIDLETGK 5,55 
LSNIFVIGK   
C9JXB8 
60S ribosomal protein L24 OS=Homo sapiens GN=RPL24 
PE=1 SV=1 - [C9JXB8_HUMAN] 
AITGASLADIMAK 5,38 
CESAFLSK   
M0R0P7 
60S ribosomal protein L18a OS=Homo sapiens 
GN=RPL18A PE=1 SV=1 - [M0R0P7_HUMAN] 
SSGEIVYCGQVFEK 4,80 
DLTTAGAVTQcYR   
Table 7. Identification of cellular proteins interacting with g5Rp. 
Data found by sequencing the peptides interacting with GST-g5Rp after incubation of the recombinant protein with extracts of Mock-infected or 
ASFV-infected cells and recovered at 6hpi and 18 hpi. Identification of peptides was carried out using Uniprot Primates data base. The table shows 
the Uniprot accession number (accession number), the identified protein (protein), the peptide sequences which allowed identification of the protein 
(identified sequence) and the score. 
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Due to the limited size of their genomes, viruses rely on the host translation machinery for the 
efficient synthesis of the viral proteins (Schneider and Mohr, 2003). Therefore, viruses must manipulate 
cellular mRNA metabolism and translation to impair host protein synthesis and to liberate cellular resources, 
in order to ensure and facilitate their own viral protein expression. Viruses have developed multiple 
mechanisms to achieve this goal. In this Thesis, we have demonstrated that ASFV infection causes active 
cellular mRNA degradation: poly(A) mRNA signal decreases progressively form the cytoplasm of infected 
cells, being only detectable at the periphery of the viral factories at late times post infection. Moreover, 
mRNA levels of all the cellular genes tested by RT-qPCR diminish with ASFV infection, a phenomenon 
concomitant with a progressive reduction on cellular protein synthesis at late times post infection and with a 
reduction of the translation efficient rate. This inhibition of the cellular protein synthesis, known as cellular 
shutoff, is accompanied by an increase of viral protein synthesis, suggesting that ASFV infection promotes 
cellular mRNA degradation in parallel to viral mRNA expression. Thus, viral mRNAs are somehow excluded 
from this massive mRNA degradation, but the mechanism used by the virus to accomplish this phenomenon 
is still unknown.  
Interestingly, during ASFV infection we also observed an accumulation of the poly(A) mRNA at the 
nucleus, which could be due to an ASFV-induced impairment of the nuclear-cytoplasm transport. In this 
regard, a previous study has demonstrated that ASFV activates the disruption of the nuclear organization at 
early times post infection, causing the disassembling of the nuclear lamina and the redistribution to the 
cytoplasm of nuclear proteins from 4 hours post infection (Ballester et al., 2011). Additionally, poly(A) 
mRNAs nuclear accumulation could be a secondary effect of the aberrant accumulation of the cytoplasmic 
poly(A) binding protein (PABPC) at this organelle, as occurs in other viral infections (Abernathy et al., 2014). 
PABPC is a protein that binds both the poly(A) tail of the mRNAs and proteins involved in the initiation 
translation complex in the cytoplasm, contributing to the stability of the mRNA and enhancing translation. 
PABPC also possesses nuclear localization signals that are only exposed when the protein is not interacting 
with the poly(A) tail. A rapid decrease of poly(A) mRNA, due to the viral infections, can cause the release of 
PABPC from poly(A) tails at the cytoplasm, leading to the exposure of PABPC nuclear localization signal that 
could be then recognised by the nuclear import machinery (Kumar et al., 2011). In this regard, cells 
expressing the viral endonucleases vhs (alpha-herpesvirus), SOX (gamma-herpesvirus), PA-X (influenza virus) 
or nsp1 (SARS coronavirus) present an anomalous accumulation of PABPC at the nucleus. This accumulation 
leads to a hyperadenylation of nascent transcripts and to their retention at nucleus, probably because they 
are recognise as aberrant by the nuclear mRNA surveillance machinery (Abernathy and Glaunsinger, 2015; 
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Arias et al., 2009; Khaperskyy et al., 2014; Kumar and Glaunsinger, 2010). Due to the fact that poly(A) RNAs 
also accumulates at the nucleus and that mRNAs are eliminated at the cytoplasm, we cannot discard that a 
similar process could be happening in ASFV infection. However, PABPC localization in ASFV-infected cells 
should be further investigated in order to validate this hypothesis.  
Nevertheless and due to the results obtained in this Thesis, it is likely that both strategies (active 
mRNA degradation at the cytoplasm and accumulation at the nucleus) are used by ASFV to perform the 
cellular shutoff.  
We have also observed that late viral mRNAs are localized in cytoplasmic granules clustered near the 
viral factories. This fact could be a viral mechanism to protect their mRNAs to the massive RNA degradation. 
In this regard, a similar mechanism has been proposed to vaccinia infection, as D10 does not localize in viral 
factory areas (Parrish et al., 2007). This topic will be further discussed in this section.  
 in vivo
5.1.2.1 g5Rp expression and localization 
ASFV is able to control accurately the expression of its genes in a time-dependent manner. 
Immediate early and early viral genes are expressed after viral entry and repressed before or during viral 
replication, respectively, while intermediate and late genes are expressed after viral replication. 
Intermediate genes are rapidly degraded before the accumulation of late transcripts, while late mRNAs are 
slowly degraded after their accumulation (Rodriguez and Salas, 2013). Thus, the temporal expression of 
ASFV genes involves regulation of both mRNA transcription and degradation. As mentioned above, ASFV 
displays viral mRNA expression concomitantly with cellular mRNA degradation. In this regard, ASFV genome 
encodes for a protein called g5Rp (pD250R in Ba71V strain) that harbours a Nudix domain, which is 
comparable to other Nudix hydrolases such as the host decapping enzyme 2 (Dcp2) or the viral proteins D9 
and D10 of VACV (McLennan, 2007). Additionally, g5Rp possesses decapping activity in vitro (Parrish et al., 
2009). These two features suggest g5Rp involvement in mRNA decapping and make it a candidate to be the 
viral factor involved in both the viral mRNAs degradation (which may contribute to the viral temporal 
expression) and the cellular mRNA degradation (which could contribute to the cellular shutoff). 
g5Rp Nudix motif is similar to that found in other cellular and viral decapping enzymes, but its 
sequence presents a higher similarity to the yeast SpDcp2 (McLennan, 2007). Contrary to what happens in 
vaccinia, ASFV genome contains only this Nudix hydrolase (Parrish et al., 2009). In this Thesis, we have 
demonstrated that g5R mRNA is expressed since 4 hpi until late times post infection in ASFV-infected Vero 
cells (MOI of 5 pfu/cell) and that g5R protein accumulates progressively during the infection. Experimentally, 
ASFV immediate early and early genes are described by their expression in infected cells in the presence of 
inhibitors of the viral replication, such as cytosine arabinoside (AraC) (Salas et al., 1986). We demonstrated 
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that g5R mRNA and protein expression takes place in the presence of this compound, indicating that g5R is 
an early viral gene. However, in the presence of AraC, g5R mRNA levels slightly decrease, suggesting that a 
second boost of g5R expression takes place after viral replication. In vaccinia, the decapping enzymes D9 and 
D10 present different times of expression during the infection: D9 is expressed at early times post infection, 
while D10 is a late viral gene, and it has been suggested that both enzymes act in an overlapping and 
complementary manner (Parrish and Moss, 2006; Parrish and Moss, 2007). However, and as explained 
above, g5Rp is the unique enzyme in ASFV genome which harbours a Nudix motif. As a putative viral 
decapping enzyme implicated in the cellular shut off and/or in the temporal viral gene expression, it can be 
possible that ASFV carry out two boost of expression to assure the presence of the g5R protein during all the 
infective cycle, in order to perform both putative functions.  
Regarding g5Rp subcellular localization, our results indicate that the protein presents an 
endoplasmic reticulum (ER) distribution pattern, which was previously suggested by Cartwright et al. The 
authors proposed that, as g5Rp sequence does not harbours any ER peptide signal, it is probably that the 
protein associates with ER at the cytosolic side and does not translocate into the ER lumen. They also 
suggested that this localization could be related to a localized activity of the protein (Cartwright et al., 2002). 
In eukaryotic cells, translation could occur both in ribosomes freely spread on the cytoplasm and in 
ribosomes bound to the surface of the ER. Traditionally, it was stabilised that mRNAs translated at the ER 
codify to secretory or membrane proteins, while mRNAs encoding for cytosolic proteins were translated at 
the cytosolic ribosomes. However, recent findings have demonstrated that a large fraction of mRNAs 
encoding for cytosolic proteins are also translated at the ER-associated ribosomes (reviewed in (Reid and 
Nicchitta, 2015)). Given that ER is a site where active translation is concentrated, g5Rp location at this 
organelle could be related to its possible role in cellular mRNA degradation and protein synthesis 
impairment. In this regard, pulldown assays in which GST-g5R protein was incubated with lysates of ASFV-
infected Vero cells collected at 6 hpi demonstrate that g5Rp is able to interact with the translation 
machinery component PABPC and with the 40S and 60S ribosomes subunits, supporting g5Rp presence at 
the ER and at the translation complexes. Interestingly, it has been described that KSVH SOX endonuclease 
co-sediments with the 40S ribosomal subunit (Covarrubias et al., 2011). The authors suggest that SOX could 
be recruited to the mRNA by association with the translation initiation machinery. Due to the fact that g5Rp 
interacts with both 40S and 60S, could be possible that ASFV g5R protein uses a similar mechanism to SOX. 
On the other hand, pull down assays of GST-g5R protein after incubation with infected extracts collected at 
16 hpi show that g5Rp still interacts with ribosomes at late times post infection, but no longer interacts with 
PABPC. These data is in parallel with the hypothesis of PABPC being relocated to the nucleus during ASFV 
infection.  
Remarkably, g5Rp could be also clearly detected at the periphery of the nucleus during the infection. 
In this regard, it has been described that the viral matrix protein of VSV localizes at the periphery of the 
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nucleus, in the nuclear rim (von Kobbe et al., 2000). M protein interacts directly with the nucleoporin Nup98, 
which is a component of the Nuclear Pore Complex (NPC) involved in the mRNA export process (Powers et 
al., 1997). This interaction causes a blockade of mRNA transport and leads to the accumulation of poly(A) 
mRNAs at the nucleus. Due to the fact that g5Rp localization is similar to the M protein, and that during 
ASFV infection poly(A) mRNAs are clustered to the nucleus, it may be possible that this protein is also 
involved in some way in targeting mRNA nuclear-cytoplasm transport.  
On the other hand, at late times post infection, g5Rp accumulates at the periphery of viral factories. 
ASFV factories are areas enclosed by ER membranes, which explains the presence of g5Rp and calnexin (a 
well-known ER protein (Tjoelker et al., 1994)) at these structures at late times post infection. Interestingly, 
g5Rp is able to interact with the viral proteins pp220, p72 and p10 at late times post infection. All these 
proteins are packaged into the virion, thus will be located at the viral factories at later times, partially 
explaining its interaction with g5Rp. Other possibility is that g5Rp could also be packaged into the virion. 
Further experiments at our laboratory will be conducted to decipher this possibility. The fact that g5Rp is 
only gathered at this structures late during the infection could be related to its function as a dual regulator 
of both cellular and viral mRNA metabolism. At early times post infection, g5Rp is associated at the ER of 
infected cells, maybe to degrade cellular mRNAs and impair cellular protein synthesis. Whereas, at late times 
post infection, this enzyme accumulates where late mRNAs localize probably to stop late viral transcription 
and keep the energy resources. These resources could be then used in the viral morphology and viral egress 
processes. 
5.1.2.2 g5Rp function 
It has been described that g5Rp holds two enzymatic activities in vitro. First description of the 
protein demonstrated that g5Rp possesses high affinity substrate for PP-InsP5 (diphosphoinositol 
polyphosphates) and pointed to a possible implication of g5Rp in viral membrane morphogenesis 
(Cartwright et al., 2002). However, a second study demonstrated that g5Rp is able to hydrolyse cap 
structures in vitro when attached to a RNA body, a common feature of decapping enzymes (McLennan, 
2007; Parrish et al., 2009) (Song et al., 2010). High variability of substrates is a shared characteristic among 
Nudix enzymes (McLennan, 2013). In mammalian cells, six Nudix hydrolases with diverse enzymatic activities 
have been described to possess also decapping activity in vitro (Song et al., 2013). Thus, it is possible that 
g5Rp be a dual enzyme able to display both activities. 
On the subject of g5Rp decapping activity, it has been previously demonstrated that this protein is 
able to bind RNA in vitro by EMSA assays (Parrish et al., 2009). Moreover, its decapping activity is highly 
inhibited by uncapped mRNAs, suggesting that g5Rp recognises its substrate mainly by the RNA body 
(Parrish et al., 2009). In this Thesis, we described for the first time that this protein is able to bind RNA in 
vivo. Substitutions of the conserved glutamic residues 147, 150 and 151 impair strongly g5Rp decapping 
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activity in vitro (Parrish et al., 2009). However, we have demonstrated that these mutations do not affect 
g5Rp RNA-binding capacity. These residues are highly conserved among different Nudix hydrolases, and in 
yeast and mammals, it has been described that they are involved in coordinating the divalent cation 
essential for the catalysis (Mildvan et al., 2005; She et al., 2006). Due to its position in the Nudix pocket in 
comparison with SpDcp2, and after mutational analysis, the VACV D10 homologous residues, glutamics 141, 
144 and 145, have been also described to be involved in the catalytic reaction and in the direct contact with 
the cap structure (Souliere et al., 2009; Souliere et al., 2010). Given that these residues are as well highly 
conserved in g5Rp and that g5Rp and SpDcp2 Nudix motif are structurally similar, it could be expected that 
E147, E150 and E151 are playing a similar role on g5Rp catalytic pocket, being mainly involved in the 
catalytic reaction and/or in the cap recognition, but not in the RNA-interaction. 
Dual fluorescent method allowed us to identify the N-terminal domain of g5Rp as the main player of 
RNA-g5Rp interaction. On the other hand, g5Rp C-terminal domain seems to be not implicated. Electrostatic 
surface representation confirmed these results and showed that g5Rp N-terminal domain possesses a basic 
channel that could be acting as a RNA-binding platform. A positively charged channel is also present at the 
dorsal surface of the Nudix domain of S.pombe, S.cerevisiae and human Dcp2 enzymes, and it has been 
described as the RNA-binding region: mutations of residues of this channel drive to a decrease on Dcp2 
substrate affinity (Deshmukh et al., 2008; She et al., 2008). Furthermore, in these enzymes, residues from 
the Box B, which are essential for the RNA-binding activity in biochemical studies (Piccirillo et al., 2003), 
located directly on this dorsal surface. However, amino acidic sequence of the Box B region is not clearly 
conserved in the viral decapping enzymes D10 and g5Rp (McLennan, 2007; Souliere et al., 2009). In this 
regard, and unlike the cap-binding cavity, basic amino acids of the positive channel are only discreetly 
conserved at the level of primary sequence between SpDcp2 and ScDcp2, while the surface of this region in 
both enzymes is enriched in positive charged residues (Deshmukh et al., 2008). Indeed, D10 presents a 
similar number of basic amino acids in this region (McLennan, 2007). These results suggest that only the 
positive surface is important to the RNA-binding, and support our results of the basic channel of the N-
terminal domain of g5Rp as the RNA-binding motif of this enzyme.  
RNA-binding plays a critical role on the substrate recognition of eukaryotic decapping enzymes. In 
vitro assays demonstrated that hDcp2 is not able to hydrolyse cap analogues, and only displays decapping 
activity when the cap is attached to a RNA body (Piccirillo et al., 2003; van Dijk et al., 2002). Moreover, 
hDcp2 enzymatic activity is not inhibited in cap analogue competition assays and it requires long RNA 
substrates (at least 23 nt) (Wang et al., 2002). Yeast and C.elegans Dcp2 proteins also prefer long RNAs and 
display tiny activity on cap analogue substrates (Cohen et al., 2005; Steiger et al., 2003). According to these 
evidences, it has been suggested that eukaryotic Dcp2 enzymes are unable to recognize the cap directly and 
they require binding to the RNA to detect the cap substrate. On the other hand, viral decapping enzyme D10 
is strongly inhibited by uncapped RNA and by methylated cap analogues (Parrish et al., 2007), suggesting 
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that differences in substrate recognition between this viral enzyme and its eukaryotic counterparts exist. The 
first seems to recognize its substrate by the interaction of both the RNA and the cap structure, while the 
latter mainly recognize its substrate by RNA body-interaction. Interestingly, VACV D9 enzyme prefers longer 
mRNA substrates, is more efficiently inhibited by uncapped mRNAs and is less affected by methylated cap 
analogous than D10 (Parrish and Moss, 2007). In this regard, D9 behaves in a similar way to eukaryotic 
decapping enzymes. g5R protein is strongly inhibited by uncapped mRNAs (whose inhibitory effect is higher 
in this enzyme than in D9 or D10), and its decapping activity is not affected by free methylated cap 
derivatives (Parrish et al., 2009), suggesting that g5Rp may have higher affinity to mRNA than that VACV 
enzymes have. These evidences, and also the fact that ASFV enzyme displays more sequence similarity with 
eukaryotic Dcp2 than with its viral counterparts (McLennan, 2007; Parrish et al., 2009), suggest that the 
mechanism used by g5Rp for substrate recognition is closer to the one resembled by eukaryotic enzymes. 
Thus, g5Rp substrate recognition may occur mainly by interaction through the RNA domain, highlighting the 
importance of the RNA binding in g5Rp catalytic process. 
The fact that the g5Rp N-terminal domain was able to bind more RNA than the g5Rp wild type form 
is surprising. However, it should be taken into consideration that g5Rp is a putative catalytic enzyme, whose 
function might be to accelerate the hydrolysis of the cap structure. In this regard, g5Rp-RNA interaction 
should be fast, causing RNA rapidly releases after decapping. This will explain the lower levels of RNA that 
we are able to detect interacting with the g5Rp wt form when compared to the N-terminal form, which is 
able to bind RNA but unable to decapp. Our results also indicate that the Nudix motif is not necessary to the 
RNA-g5Rp interaction, as the g5Rp N-terminal construction does not possess this sequence and fully 
interacts with the mRNA. This fact suggests that g5Rp RNA-binding capacity is independent to its catalytic 
activity. This feature has also been shown in Dcp2. Studies carried out in vitro to identify the minimal domain 
with decapping activity in human Dcp2 showed that a construction that harbours incomplete Nudix fold and 
does not present enzymatic activity is able to bind RNA (Piccirillo et al., 2003). However, further studies 
mapping different regions of the g5Rp N-terminal domain should be carried out to determine the exact 
areas and amino acids implicated in the RNA-binding.  
Interestingly, g5Rp ∆Nudix domain is also able to bind RNA, although in a lesser extent than the N-
terminal construction. Given that both proteins only differ on the presence of the C-terminal domain in the 
g5Rp ∆Nudix construction, one possible explanation may be that the C-terminal domain is involved in the 
destabilization and release of the RNA. 
In this Thesis, we have established that g5Rp does not only bind cellular mRNAs in cultured cells, but 
also host and viral mRNAs in the context of the infection. The fact that this protein interacts with cellular 
mRNAs suggests that g5Rp is involved in the cellular shutoff observed in ASFV infection, while g5Rp - viral 
mRNAs interaction may be related to the viral temporal gene expression. This is the mechanism that has 
been proposed to vaccinia, whose decapping enzymes D9 and D10 eliminates both viral and cellular mRNAs 
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(Liu et al., 2014; Parrish and Moss, 2006; Shors et al., 1999). In this regard, there are several examples of 
viruses that display mechanisms to massively degrade host cellular mRNAs and that also affect its own viral 
mRNAs. This is the case of alpha- and gamma- herpesviruses, which encode to viral endonucleases able to 
eliminate both cellular and viral mRNAs (Abernathy et al., 2014; Taddeo et al., 2013). Alpha-herpesviruses 
are characterised by the temporal expression of their genes, and the viral endonuclease , vhs, has been 
involved in mediating the effective transition between the immediate early, early and late genes (Taddeo et 
al., 2013) (Abernathy and Glaunsinger, 2015). Gamma-herpesvirues-encoded SOX protein also target viral 
mRNAs, and its inactivation causes an altered composition of progeny virions, suggesting that during 
gamma-herpes virus infection regulation of viral mRNAs by degradation plays an important role on gene 
expression and on viral particle composition (Abernathy et al., 2014). 
Regarding cellular mRNA-g5Rp interaction, we have observed that eIF4E mRNA levels attached to 
GFP-g5Rp wt and related to eGFP are clearly superior than the B-actin mRNA levels bound to GFP-g5Rp wt 
and referred to eGFP. These results suggest that g5Rp may display more affinity for determinate cellular 
substrates. Selectivity in host mRNA degradation has been previously described to other viral systems, such 
us alpha-herpesvirus or vaccinia. Concerning alpha-herpesviruses, it has been described that the 
endonuclease vhs rapidly degraded stable host mRNAs like β-actin or GAPDH, while mRNAs containing AU-
rich sequences are translational repressed and their decay rates are slowed, indicating that vhs discriminates 
between different classes of cellular mRNAs (Esclatine et al., 2004). Regarding vaccinia infection, microarrays 
analysis of cDNA from Mock-infected and VACV-infected cells revealed that host mRNAs are differently 
regulated (Guerra et al., 2003). The vast majority are downregulated during vaccinia infection, and, among 
this, Guerra et al. differentiate three clusters: the first includes transcripts that are upregulated at 2 hours 
post infection (hpi) and repressed at 6 and 16 hpi, the second contains transcripts that are repressed at 6 
and 16 hpi and the last includes transcripts that are repressed from 2 hpi to 16 hpi (Guerra et al., 2003). Due 
to this different cellular mRNA degradation patterns, it has been suggested that D9, which presents more 
affinity to the RNA body than D10, may be able to discern among different mRNA sequences (Parrish and 
Moss, 2007). In a similar manner, ASFV infection may be discriminating among cellular transcripts, using 
g5Rp as a mechanism to recognise different cellular mRNAs. This hypothesis is supported by the fact that 
g5Rp is even more inhibited than D9 by uncapped mRNAs and that it is not affected by methylated cap 
analogous, as mentioned above. In this regard, in vitro RNA-binding assays demonstrated that g5R protein is 
able to interact with uncapped cellular mRNAs, but the observed shift in the EMSA was not complete 
(Parrish et al., 2009). Parrish et al suggest that this could have two different explanations: first is the 
requirement of the cap structure to stabilize g5Rp-RNA interaction; and the second is that g5Rp only displays 
strong affinity for molecules with certain features, as it has been described to Dcp2 (Li et al., 2009; Li et al., 
2008). This second hypothesis goes in parallel with our suggestion.  
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One might infer that g5Rp is also able to differentiate between different viral mRNAs, in order to 
carry out the temporal regulation of viral gene expression. We have observed that p72 mRNA levels bound 
to GFP-g5Rp wt and referred to eGFP are lower than the A224L and A238L mRNAs attached to GFP-g5Rp wt 
and referred to eGFP at 14 hpi, supporting the idea of a specific recognition of the viral substrate. However, 
a broader study should be conducted in order to determine specific g5Rp interactions with early and late 
viral mRNAs during all ASFV viral cycle to confirm this hypothesis and to define the exact mechanism used by 
g5Rp, as well as the possible sequences recognised by this protein. Viral mRNA specificity has been also 
suggested to D10 decapping enzyme. This enzyme is more effectively inhibited by m7GpppG than m7GpppA, 
thus it has been described that possesses more affinity by the first cap analogue structure (Parrish et al., 
2007). Given that cellular mRNAs and vaccinia early mRNAs have both m7GpppGm and m
7GpppAm structures 
at their 5´ends, and that intermediate and late VACV mRNAs present exclusively m7GpppAm caps, it has 
been proposed that D10 could be preferentially recognising the host and early viral mRNAs (Parrish et al., 
2007). However, and for the reasons mentioned above, we are more inclined to think that the possible 
mechanism used by g5Rp to differentiate among different viral mRNAs would implicate recognition of the 
RNA sequence, instead of recognition by the cap structure. A possible explanation to the RNA affinity 
differences found between ASFV and VACV decapping enzymes could be related to the fact that g5Rp is the 
only protein encoded by ASFV genome that possesses a Nudix motif. VACV uses two enzymes with different 
substrate affinity to degrade viral mRNAs in a complementary way, while ASFV may use only one enzyme 
able to differentiate different substrates by the RNA body. 
Regarding g5Rp function, in this work we have demonstrated that infected cells expressing 
recombinant GFP-g5Rp wt protein present a slightly reduction on some late viral proteins levels when 
compared to cells expressing eGFP or the catalytic mutant versions of the protein (GFP-g5Rp REGG and 
EEQQ). Moreover, analysis by FACS proves that p72 levels in cells overexpressing g5Rp are also reduced, and 
that the percentage of cells co-expressing CD2v and the recombinant protein g5Rp-HA is clearly reduced 
when compared to percentage of cells co-expressing g5Rp-HA and p32. We have also observed that A224L 
mRNA signal is decreased in infected cells expressing g5Rp-HA protein and that expression of GFP-g5Rp in 
the context of the infection leads to a decrease of both cellular and late viral mRNA levels. Although we have 
not been able to demonstrate the mechanism used in ASFV to eliminate mRNAs, all the evidences presented 
above indicate that g5Rp is involved in the cellular shutoff and in the temporal viral genes expression 
processes, as described to other viral systems (Abernathy and Glaunsinger, 2015). In this regard, modified 
VACV virus that possess and inducible extra copy of D9 and D10 and that consequently overexpress both 
proteins during vaccinia infection, present a decrease on viral protein synthesis and a reduction of viral late 
mRNA levels (Shors et al., 1999). That suggests g5Rp could be acting in a similar manner to VACV decapping 
enzymes and supports the idea that g5Rp function as a regulator of both cellular and viral RNA metabolism.  
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Additionally, it is probable that ASFV uses different strategies in a complementary manner, and that 
g5Rp may act synergistically with other viral proteins. Following this further, ASFV genome encodes for a 
viral AP endonuclease, pE296R, which has been described to be involved in the viral DNA repair system 
(Redrejo-Rodriguez et al., 2006). However, it could be possible that this enzyme also displays 
endoribonuclease activity, as it has been described to the human AP endoribonuclease Ape1 (Barnes et al., 
2009). Other viral endonucleases with a dual function have been also described in viral systems, such as the 
gamma-herpesviruses Epstein-Barr virus (EBV) and Kaposi´s sarcoma-associated herpesvirus (KSHV). Both 
viruses encode for nucleases implicated in viral genome maturation and mRNA degradation processes 
(Abernathy et al., 2014; Feederle et al., 2009; Glaunsinger et al., 2005; Rowe et al., 2007).  
Suppression of the expression of the gene of interest is a common technique used to study gene 
function. In this regard, deletion of the viral endonuclease vhs in HSV-1 causes a persistence of cellular 
mRNAs and a delay on the initiation of the expression of early and late viral mRNAs (Taddeo et al., 2013). In 
a same manner, deletion of D10 in vaccinia virus (∆D10) causes that viral transcription initiates more slowly. 
Early viral mRNAs accumulated to higher levels, and, in addition, early, late and cellular mRNAs persist 
longer on ∆D10-infected cells when compared to VACV wt infection (Liu et al., 2014; Parrish and Moss, 
2006). Contrary to what was expected, infection with the double D9 and D10 vaccinia mutant causes a sharp 
decrease of both cellular and viral mRNA, a stop of late viral protein synthesis and an inhibition of the viral 
replication in non-permissive cells (Liu et al., 2015).  
In order to test the effect of g5R deletion on ASFV infection, we tried to silence g5R mRNA 
expression by using a specific siRNA. However, silencing achieved was not enough to observe significant 
difference between silenced and non-silenced cells. We have also tried to obtain ASFV∆g5R mutant by 
substitution of the g5R gene by a β-gal reporter gene. Unfortunately, after serial passages and rounds of 
amplification, we were not successful and no g5R-deleted virus was achieved, thus indirectly suggesting that 
g5Rp is important to ASFV infection. In vaccinia, due to the fact that D9 and D10 function in a 
complementary manner, Parrish et. al succeeded in the collection of each deletion virus (∆D9 and ∆D10, 
respectively) (Parrish and Moss, 2006). However, double D9 and D10 mutant has been very hard to obtain, 
and only recently has been successfully achieved, proving the important function of these genes in vaccinia 
infection and maybe indicating that vaccinia is able to use the cellular machinery of decapping during the 
infection (Liu et al., 2015). Importantly, this double D9 and D10 VACV mutant has been generated by point 
mutations in the conserved amino acids of the catalytic Nudix motif of both enzymes, therefore is not a 
“canonic” deletion mutant since contains both genes although they are putatively unable to decapp. Indeed, 
it has been previously described that deletion of D10 gene by its substitution with a GFP reporter gene is 
more deleterious for the progression of vaccinia infection than D10 point catalytic mutant (muD10), since 
∆D10 virus presents smaller lysis plates than muD10 virus (Liu et al., 2014). These results prompted us to 
develop a similar approach in ASFV generating an ASFV with a catalytic inactive g5Rp, instead to try the ASFV 
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∆g5Rp. However, it should be taken into consideration that Liu et all generated D10 point mutation virus by 
homologous recombination between the GFP gene inserted in the ∆D10 virus and a D10 mutated gene 
present in a vector. Due to the fact we have not been able to generate the first ∆g5Rp deletion mutant, we 
had to develop alternative strategies to obtain it. We are currently working on developing a helper cell line 
that constitutively expresses the g5R protein, providing the g5R copy needed to support ASFV∆g5Rp 
infection. We have choose COS Flip in cell line because this system allows the integration of a single copy of 
the gen of interest in a specific genomic location (FLP site), eliminating the risk of random insertion. 
Additionally, it is possible to integrate in COS Flip in genome a TET Repressor gene, generating COS Flp in 
TREx cells lines. This procedure allows the generation of stable cell lines with inducible expression of your 
gene of interest, thus providing an additional approximation to obtain the deletion mutant.  
 
In order to ensure viral translation, viruses have to avoid the cellular mRNA degradation pathways. 
Given that RNA granules play a key role on mRNA translation and decay, most viruses have developed 
strategies to subvert the components of these structures (Narayanan and Makino, 2013; Reineke and Lloyd, 
2013). Two kinds of RNA granules can be found in eukaryotic cells: the Processing-Bodies (P-Bodies) and the 
Stress Granules (SGs). P-Bodies are constitutively present in cells and enriched in decapping machinery 
components. Moreover, P-Bodies size and number increase when translation rate decays and their 
formation depends on the presence of mRNA decay intermediates. Stress granules forms in specific stress 
conditions, and disappear when the stress stimuli stops. SGs are composed of decapping machinery 
components, but also of ribosomes and some eukaryotic initiation factors (eIFs) (Reineke and Lloyd, 2013). 
While P-bodies have been defined as structures where active mRNA degradation can take place, SGs have 
been defined as sites of translational repression (Decker and Parker, 2012). Due to this fact, we have focused 
our attention on P-bodies more that in SG. 
We have described that ASFV infection causes a reduction of P-bodies, and consequently, a loss of 
interaction between the P-Body components Dcp1 and Edc4. Furthermore, both Dcp1 and Edc4 signals 
decrease in ASFV-infected cells when analysed by CSLM. Edc4 is spread at the cytoplasm of ASFV-infected 
cells, while Dcp1 accumulates at the surroundings of the viral factories. As explained above, disruption of P-
bodies and re-localization of the components is a common mechanism used by viruses in order to avoid the 
cellular mRNA decay routes and facilitate viral infection (Reineke and Lloyd, 2013). And so, for instance, in 
the case of West Nile Virus, P-Body components (such as Lsm1, Gw182, DDX3, DDX6 and Xrn1) are recruited 
to the viral factories and needed to viral replication, whereas neither Dcp1 nor Edc4 are recruited (Chahar et 
al., 2013). Hepatitis C Virus also disrupts P-bodies and hijacks P-Body components (Lsm1,DDX3, DDX6, Xrn1, 
Pat1 and Ago2, but not Dcp2) to the viral production sites, and silencing of some of these components 
suppresses HCV RNA accumulation, indicating that these proteins are required for HCV replication (Ariumi et 
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al., 2011). In this regard, it could be interesting in the near future to check if Dcp1 is essential to ASFV viral 
replication.  
We have observed that Dcp1 and g5Rp co-localize at the periphery of the viral factories. Due to the 
fact that Dcp1 is a decapping activator (She et al., 2008), we speculate that this protein could be stimulating 
the RNA decay process at these structures. However, and due to the fact that g5Rp is not directly interacting 
with Dcp1, this activation could be achieved by Dcp1 ability to interact with other decapping activators, such 
as Edc3 or Xrn1 (Fromm et al., 2012; Jonas and Izaurralde, 2013; Tritschler et al., 2007). Edc3 is a RNA 
binding protein that could associate with other decapping activators as Pat1, Lsm 1-7, Dhh1 or Xrn1 acting as 
a scaffold protein in the formation of the P-Bodies (Fenger-Gron et al., 2005; Fromont-Racine et al., 2000; 
Ling et al., 2011), thus the presence of Dcp1 at these structures could be accompanied to other decapping 
factors, which together would facilitate the RNA degradation process. Further studies should be conducted 
in order to clarify if other decapping activators could also be recruited to the viral replication sites and the 
mechanism displayed by ASFV to achieve this goal. 
During ASFV infection, the location of the cap structure is especially interesting, both by itself and in 
relation with g5Rp distribution. In order to determine its relation to g5Rp, we used a specific antibody that 
recognizes both m7G and m3G structures (monoclonal antibody H-20, Synaptic Systems (Bochnig et al., 
1987)), which means that this antibody is able to recognise both m3G and m
7G-capped mRNAs. The capping 
process consists in the addition of a 7-methylated-guanosine (m7G) by an inverted 5´-5´triphophate bridge to 
the first RNA nucleotide (m7GpppN, where N is any nucleotide) (Ghosh and Lima, 2010), while m3G cap 
structure is a Nuclear Localization Signal (NLS) for the spliceosomal UsnRNPs, whose biogenesis involves a 
nucleus-cytoplasm cycle. In this regard, ASFV genome encodes by a viral capping enzyme (NP868R), which 
displays gyanylyltransferase activity (Pena et al., 1993). In Mock-infected cells, cap signal is spread at the 
cytoplasm and is more intense in the nucleus, while in ASFV-infected cells the nuclear signal decreases and 
accumulates at the periphery of the viral factories. Nuclear signal of Mock-infected cells could be due to the 
capping process, which takes place mainly at this structure, and cytoplasmic signal may correspond to the 
capped mRNAs. In ASFV infected cells, the increased signal accumulates at the periphery of the viral 
factories could correspond to the viral capped mRNAs, which have been described by our lab (Castello et al., 
2009b) and in this Thesis to be located at the viral replication sites. Interestingly, when we measured cap 
signal mean intensity, we observed an increase in ASFV-infected cells compared to Mock-infected cells. We 
have proved here that poly(A) mRNA signal decays at the cytoplasm of infected cells, and that cellular mRNA 
levels also decreased with ASFV infection, thus this cap signal increment was surprising to us. However, as 
mentioned before, the cap species recognised by the anti-cap antibody should be taken into consideration 
(Bochnig et al., 1987), since it recognizes not only capped mRNAs, but also the structures m7Gp (m7GMP) 
and m7GpppA. In vitro, g5Rp hydrolyses capped mRNAs releasing m7GDP and 5´monophosphorylated RNAs 
as products, thus we speculate that ASFV-infection may trigger an accumulation of m7GDP, probably due to 
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g5Rp decapping activity. In mammalian cells, this decapping product elimination involves m7GMP production 
(Taverniti and Seraphin, 2015), which could also rise as a consequence of the accumulation of m7GDP and 
may be the cause by which the cap signal increases. Another possibility to explain the cap augmented signal 
in infected cells would be the accumulation of the m3G capped RNAs at the cytoplasm of infected cells on 
account of the ASFV-induced impairment of the nucleus-cytoplasm transport. 
We have also described that the cap structure together with g5Rp co-localize at the edge of the viral 
factories. Indeed, localization of g5Rp at the periphery of viral factories at late times post infection was 
surprising. In vaccinia, viral mRNAs are recruited to the replication sites (Katsafanas and Moss, 2007). 
However, D10 is not recruited to the viral factories (Parrish and Moss, 2006), thus it has been proposed that 
this re-localization could be used as a viral tool to avoid late viral mRNAs degradation (McLennan, 2007). The 
fact that g5Rp co-localizes with the cap structure at these areas suggest that active decapping could be 
taking place, thus indicating that ASFV uses a different mechanism to vaccinia to this end. In this regard, 
g5Rp could be regulated by other cellular or viral proteins, as it happens in alpha-herpesvirus infection. Vhs 
endonuclease is regulated by several viral factors (UL47, VP16 and VP22) and at least one cellular protein. All 
of them are packaged into the virions, and it has been suggested that they regulate vhs activity in a temporal 
manner (Abernathy and Glaunsinger, 2015; Shu et al., 2013a; Shu et al., 2013b; Taddeo et al., 2007). In this 
regard, we have demonstrated that g5Rp is able to interact at late times post infection with at least three 
different viral proteins: pp220, p10 and p72. pp220 is a polyprotein that is processed by proteolysis during 
the maturation process of the virion, giving rise to the structural proteins p150, p37, p34 and p14, which are 
the major components of the core shell layer (Andres et al., 2002b; Andres et al., 1997; Simon-Mateo et al., 
1993). p10 is a structural viral protein that is localized at the nucleoid of the virion particles and that exerts 
DNA binding activity (Nunes-Correia et al., 2008). Finally, p72 is the major component of the viral capsid and 
it is essential for the formation of this structure (Garcia-Escudero et al., 1998). All these proteins are part of 
the virion and are localised at the viral factories at late times post infection, probably interacting with g5Rp 
at these structures. This fact makes them candidates as late regulators of g5Rp function. Furthermore, we 
cannot exclude the possibility that g5Rp may be regulated by phosphorylation and/or unphosphorylation 
events. In this regard, ASFV genome encodes for a viral serine-threonine protein kinase (j9L in Malawi strain) 
that displays phosphorylation activity in vitro (Baylis et al., 1993). According to this hypothesis, analysis of 
g5Rp sequence using Prosite Server revealed that the protein possesses two putative phosphorylation sites 
(data not shown). Interestingly, j9L protein is packaged into virions, which indicates that at late times post 
infection it is recruited to the viral factories. Although speculative, j9L could be acting as a regulator of g5Rp 
activity at these structures as a mechanism to ensure late viral translation. 
We have previously described that ASFV translation relies on host translation machinery (Castello et 
al., 2009b). Deletion of eIF4E and eIF4G leads to a decrease in the number of viral factories, in the case of 
eIF4G elimination, and to the formation of aberrant viral replication sites, when eIF4E is supressed. 
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Moreover, ASFV infection stimulates the formation of the translation initiation complex by phosphorylation 
of eIF4E, eIF4G and the eIF4E Binding Protein 4E-BP, which phosphorylated is not able to interact with eIF4E 
(Castello et al., 2009b). During ASFV infection, eIF2α phosphorylation is avoided in order to ensure 
translation, a process which seems to involve the viral protein DP71L (Rivera et al., 2007; Zhang et al., 2010). 
In this regard, we have demonstrated that ASFV infection triggers the re-localization of eIFs and ribosomes 
to the viral factories. The fact that all these components, together with late viral mRNAs, localize at the same 
cytoplasmic areas suggests that transcription and translation take place at this foci in close proximity, which 
maximize the efficiency of both processes. Coupling between replication, transcription and translation has 
been suggested to many other viruses, such as vaccinia, Sindbis virus or vesicular stomatitis virus (Katsafanas 
and Moss, 2007; Sanz et al., 2007; Whitlow et al., 2008).  
Our laboratory has also described that eIF4G location at the viral factories changes during the 
infection. At 8-10 hpi, this initiation translation factor is accumulated together with the viral DNA, whereas 
at late times post-infection (18 hpi), eIF4G is redistributed to the surroundings of the viral factories, probably 
due to a viral mechanism to compartmentalize translation and morphogenesis (Castello et al., 2009b). 
Although speculative, this differential location between g5Rp and eIF4G soon after viral replication, but not a 
later times post infection, could indicate an additional viral mechanism to regulate g5Rp decapping activity. 
In this hypothesis, translation of late viral mRNAs may take place inside the viral factories, where viral 
mRNAs are protected from the decapping activity of g5Rp. At later times post infection, when 
morphogenesis is fully activated, the translation complexes are displaced to the edge of viral factories, 
where viral mRNAs could be targeted by g5Rp. This will be a mechanism used by the virus to maximize the 
energy resources, firstly on translation, and once translation is not required, in morphogenesis. eIF4E is a 
decapping inhibitor able to interact with the cap structure and, consequently, to limit its interaction with the 
decapping enzymes (Schwartz and Parker, 1999; Schwartz and Parker, 2000). Therefore, presence of eIF4E at 
the periphery of viral factories could compete with g5Rp to interact with viral late mRNAs, which could 
explain the slowly decrease of late viral mRNAs.  
In conclusion, the results presented in this Thesis indicate that g5Rp is a RNA-binding protein able to 
interact in vivo with both cellular and viral mRNAs in the context of the infection. Moreover, its 
overexpression leads to a decrease of both cellular and viral mRNAs, and causes a reduction on late viral 
protein synthesis. g5R is an early viral gene that is also important for the proper progression of the infection. 
g5Rp present different subcellular location during ASFV infection: at early times post infection, g5R mainly 
presents an ER pattern and interacts with several components of the cellular translation machinery, while at 
later times, this protein accumulates at the viral factories, where it co-localizes with Dcp1 and the cap 
structure and interacts with the ribosomes and the viral proteins pp220, p10 and p72. Taken together, and 
given that g5Rp possesses decapping activity in vitro (Parrish et al., 2009) these results indicate that g5Rp 
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may acts as a viral regulator of both cellular and viral mRNA metabolism, being involved in impairing cellular 
protein synthesis and in ensuring viral temporal gene expression.  
 
Very little is known about how ASFV manipulates mRNA degradation and decay. To our knowledge 
this is the first experimental approach that tries to explain how this virus achieves this goal. However, 
several issues still remain elusive. Among them, the molecular mechanism used by g5Rp to distinguishes 
among different mRNAs or the possible strategies employed by the virus to regulate its activity. In this 
regard, obtaining an ASFV∆g5R by using new strategies, or, as achieved in vaccinia virus, an ASFV containing 
g5Rp mutated in its catalytic domain would also be interesting.  
The fact that g5R gene seems to be essential to ASFV infection makes it a good candidate in order to 
obtain a vaccine, which has remain elusive, to date. ASFV∆g5R deletion mutant, or an ASFV encoding and 
inactive g5Rp mutant, may be able to trigger a protective host immune response, but will be unable to 
produce productive viral particles. In this regard, it has been described that widespread elimination of 
cellular mRNAs impairs anti-viral immune response, and deletion or inactivation of genes involved in mRNA 
degradation, such as D10 in vaccinia or muSOX in the murine gamma-herpesvirus 68, leads to a attenuation 
of the virulence (Liu et al., 2014; Richner et al., 2011). Interestingly, a recent study has demonstrated that 
the vaccinia double D9 and D10 mutant infection leads to a greater attenuation of the virulence than VACV 
point mutated D10 (Liu et al., 2015). Therefore, and given that g5Rp is the only Nudix enzyme encoded to 
ASFV, a great attenuation of ASFV virulence might be expected if an ASFV mutant lacking active g5Rp could 
be generated in the future. 
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1- During ASFV infection, accumulation of cellular mRNA in the nucleus of infected cells and 
massive degradation of such messengers in the cytoplasm occurs. This phenomenon happens in 
parallel with the expression of viral genes. 
2- ASFV infection causes the relocation of the cellular initiation translation factors eIF4G and 4E, as 
well as ribosomes, to the viral factories, where late mRNAs are also found. 
3- During infection, the components of the cellular decapping machinery Dcp1 and Edc4 undergo 
rearrangement, leading to a decrease of P-Bodies. Furthermore, the infection causes the 
accumulation of the cap structure of mRNA in the cytoplasm of infected cells, especially around 
the viral factories. 
4- ASFV genome encodes for a protein, g5Rp (pD250R in Ba71V strain), which has a Nudix 
hydrolase domain similar to that found in most of the cellular and viral decapping enzymes. g5R 
is an early gene whose transcript is maintained until late times of infection. At early stages of 
infection, g5Rp presents a pattern similar to the endoplasmic reticulum distribution and 
interacts with several components of the translational machinery, such as ribosomes or PABPC, 
while at later times, accumulates around the viral factories and interacts both with ribosomes 
and pp220, p10 and p72 viral proteins. On the periphery of these structures, g5Rp also co-
localizes with Dcp1 and the cap structure. 
5- g5Rp is able to bind polyadenylated RNA in cells stable expressing the protein. This interaction is 
mediated primarily by g5Rp N-terminal domain, which presents a basic channel similar to that 
found in other decapping enzymes. The point mutation of the Nudix domain conserved amino 
acids, although essential for catalysis in vitro, does not affect the g5R ability to bind RNA. 
6- g5R protein interacts with both viral and cellular mRNA in the context of viral infection. 
Furthermore, overexpression of the viral protein causes a decrease in the levels of the two types 
of mRNAs, and affects late viral protein expression. Furthermore, g5R could be an essential gene 
for the proper progress of the infection, since it has not been possible to eliminate it from the 
viral genome by conventional methods. 
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1- Durante la infección del VPPA se produce la acumulación de los ARN mensajeros celulares en el 
núcleo de las células infectadas, y la degradación masiva de dichos mensajeros en el citoplasma. 
Éste fenómeno se produce en paralelo a la expresión de los mensajeros virales. 
2- La infección por VPPA provoca la relocalización de los factores celulares de iniciación de la 
traducción eIF4G y eIF4E, así como de los ribosomas, a las factorías virales, donde también se 
localizan los ARN mensajeros tardíos. 
3- Durante la infección, los componentes de la maquinaria de decapping celular Dcp1 y Edc4 sufren 
una reorganización, lo que produce una dispersión de los cuerpos citoplasmáticos o P-Bodies. 
Asimismo, la infección causa la acumulación de la estructura cap de los ARN mensajeros en el 
citoplasma de las células infectadas, especialmente alrededor de las factorías virales.  
4- El genoma del VPPA codifica para una proteína, g5Rp (pD250R en Ba71V), que posee un dominio 
Núdix hidrolasa similar al encontrado en enzimas de decapping celulares y virales. g5R es un gen 
temprano cuyo ARN mensajero se detecta durante todo el ciclo viral. A tiempos tempranos de la 
infección, g5Rp presenta un patrón de localización similar al del retículo endoplásmico e 
interacciona con distintos componentes de la maquinaria traduccional, como los ribosomas o 
PABPC, mientras que, a tiempos tardíos, se acumula alrededor de las factorías virales e 
interacciona tanto con los ribosomas como con las proteínas virales pp220, p10 y p72. En la 
periferia de éstas estructuras, g5Rp también co-localiza con Dcp1 y con la estructura cap. 
5-  g5Rp es capaz de unir ARN poliadenilado en células que expresan dicha proteína de manera 
estable. Ésta unión está mediada principalmente por el dominio N-terminal, que presenta un 
canal básico similar al encontrado en otras enzimas de decapping. La mutación puntual de los 
aminoácidos conservados en el dominio Núdix, aunque esenciales para la catálisis in vitro, no 
afectan a la capacidad de g5Rp para unir ARN. 
6- La proteína g5R interacciona tanto con ARN mensajeros celulares como virales en el contexto de 
la infección. Asimismo, la sobreexpresión de ésta proteína provoca una disminución en los 
niveles de los dos tipos de ARN mensajeros, y afecta a la expresión de las proteínas virales 
tardías. Además, g5R podría ser un gen esencial para el adecuado progreso de la infección, ya 
que no ha sido posible su eliminación del genoma viral por métodos convencionales.  
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